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A preorganised amino acid derivative containing a cyclopropyl constraint was 
designed to orient an amino acid into its bound conformation. This constrained mimic 
was determined by ITC to be equally potent to the native Phe derivative. It was found 
that a more favorable enthalpy of binding was compensated by an equally unfavorable 
entropy compared to the native ligand. In order to properly ascertain the effects of the 
cyclopropane constraint, a flexible control containing the same number of heavy atoms 
was synthesized and tested, and it was found to be at least 200 fold less potent than the 
constrained analog. However, without structural data of the flexible control, it is difficult 
to infer if the differences in ligand binding affinity arose from the ligand constraint or 
some other unknown complexity to binding.  
We studied the thermodynamic and structural effects of modifying alkyl chains of 
n-alka(e)nol and phenylalka(e)nol binders to MUP-I by both the removal of a rotor via 
deletion of a methylene unit and restriction of a rotor via the installation of an internal 
olefin. In general, we observed that a similar thermodynamic signature accompanies 
modifications for both the n-alka(e)nol and phenylalka(e)nol ligands: A favorable 
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TΔΔSºobs is compensated by an unfavorable TΔΔHºobs such that TΔΔGºobs for both 
removal of a methylene and insertion of an internal olefin are unfavorable and equipotent, 
respectively. The insertion of an internal olefin into an alkyl chain led to  significantly 
more favorable entropies than does methylene removal, yet enthalpy-entropy 
compensation leads to nearly equipotent binding energetics. However, we did find a 
strong correlation between ∆Hobs° and buried apolar Connolly Surface Area (CSA). 
The intrinsic free energies of introducing an internal olefin into the n-alkanols and 
phenylalkanols differ markedly from the observed data. It was observed that intrinsic 
affinities are more favorable than the observable because a favorable TΔΔSºint dominates 
an unfavorable ΔΔHºint. Also, we discovered that the intrinsic entropies of inserting an 
internal olefin are nearly double that of removing a methylene group, suggesting that the 
insertion of an internal olefin results in the restriction of more C-C rotors.  
We have shown through ITC analysis that the added substituents probed in this 
study provided binding increases to our Grb2 SH2 ligands as expected, but that the 
thermodynamic driving force of binding affinities depended greatly upon the specific 
nature and flexible mobility of the ligands in the binding pocket. Through a combination 
of X-ray and ITC studies it was shown that ligands containing rigid and aromatic 
functional groups bound with a higher ∆H° than the more flexible alkyl ligands, and that 
this effect correlates well with more direct vdW contacts made in the pocket. 
Finally, we described a case study where a strict adherence to the Topliss 
operational schemes led to an expedient development of novel MUP-I binding analogs. 
The validity of the schemes was also depicted through the synthesis and testing of ligands 
that were correctly predicted to be weaker/equipotent to the starting ligand. Of important 
 viii 
note is that the degree to which the schemes led to affinity boost depended greatly on the 
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Chapter 1  Strategies of Drug Design: Are they Predictable, Explainable? 
 
1.1   Introduction 
 
Despite the recent advances and improvements to numerous scoring functions and 
programs that are used to predict a protein’s affinity of small molecules, there has yet to 
be developed a reliable computational method for use in drug discovery.i,ii Two of the 
main roadblocks that stand in the way of achieving this goal are: (1) explicitly accounting 
for solvent during the binding process and (2) accurately obtaining the energy minima of 
protein-ligand (solute-solute) interactions necessary to predict the conformation of the 
ligand in the bound structure.i,iiAn alternate route to making early decisions in drug 
desing is the use of high throughput screening (HTS) of synthetic intermediates. This 
technology involves the brute force screening of vast biological assays to identify early 
drug leads. HTS originated as a technique for pharmaceutical companies to screen 
compounds internally. After some tepid growth in the 1980s, its use erupted in the 1990s 
so that by the beginning of the new millennium, weekly throughput capability of HTS 
increased six-fold to 150,000 compounds per week per target.iii,iv  
One of the fundamental reasons that HTS caught on so strongly in the 
pharmaceutical industry is that it fostered easy access to screening of vast libraries of 
compounds for hits rather than relying on human intuition to select candidates, thus 
ensuring that no blockbuster drug was left on a dusty shelf.iv,v Fortuitously, additional 
benefits of this process arose when it was observed that the early screening of drug leads 
correlated with a decline in the attrition of compounds due to bioavailability and 
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pharmacokinetics ( Figure 1.1.1).v Along with HTS came a technology boom in the area 
of practical and user-friendly screening techniques such as time-resolved fluorescence 
spectroscopy techniques that further enhanced its performance making it more useful.vi,vii 
Figure 1.1.1 Attrition rates for drug leads sorted by year and cause.viii 
 
However, as the resources and capital dedicated to HTS have increased, genuine 
discoveries, as measured by investigatory new drug submission (IND), remained 
relatively unchanged.ix It has thus been suggested that drug discovery as an industry 
should go back to the basics of unraveling the science to develop early leads as opposed 
to adhering to brute force methods.ix On this front, many of the fundamental design 
principles and strategies used in drug discovery have come into question.x,xi,xii Thus, a 
better understanding of bimolecular interactions would be beneficial to both drug 
discovery and to the scoring functions aimed at predicting structure-based binding 
affinity. Toward this goal, it is of immediate importance to ask if these fundamental 
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strategies in drug design can be explained rationally by correlating structure with 
thermodynamic parameters. Second, one must also ask if the structural and energetic 
effects of these structural modifications can be accurately predicted. Therefore, we 
pursued a centralized goal of improving the understanding of protein-ligand interactions 
with the hope and goal of improving how they can be implemented in the design of 
therapeutics and predicted in silico.  
This chapter is dedicated to covering in detail some of the known strategies that 
are thought to increase binding affinity and that are used at the early stages of drug 
discovery. Of key significance will be a discussion on if these strategies are well 
explained and predictable. We will focus on significant contributions to this field that 
decompose protein-ligand interactions to provide the entropy and enthalpy of binding and 
to explore for correlating thermodynamics and structural data. We will also examine the 
literature for studies that present a well-designed and systematic experiment that includes 
the use of proper controls. Ultimately, we hope to conclude this chapter with an outline of 
what is lacking in the field and what needs to be accomplished to make fundamental 
discoveries that shall benefit drug development in the pharmaceutical industry.  
1.2   Binding Energetics of Protein Ligand Interactions 
 
Given paucity of knowledge on the basic fundamental properties by which 
protein-ligand interactions are governed, it is important to develop a comprehensive 
approach to understand binding affinity [Ka] in biomolecular interactions.xiii Since the 
ligand binding affinity [Ka] is related to the potency of pharmaceutical compounds, we 
believe that it is first necessary to improve upon the understanding of these interactions 
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before one can accurately predict the protein-ligand binding affinities. As shown by eq 
1.01, Ka is the equilibrium constant between protein (P) and ligand (L) in solution and the 
nascent protein-ligand complex (PL): The larger the value of Ka, then the stronger the 
binding. This value can also be described as Kd, which is simply the reciprical of Ka.  
 
   (eq 1.01) 
                   (eq 1.02)  
The binding affinity (Ka) is proportional to the Gibbs free energy of the binding 
process, ∆G°, given by eq 1.03, which can be further decomposed into its thermodynamic 
components ∆H° and ∆S° (eq. 1.01), which are both of critical importance with studies 
attempting to correlate ligand modifications with individual thermodynamic parameters.  
  ∆G°obs = -RTln(Ka)                          (eq 1.03) 
 ∆Gobs° = ∆Hobs° – T∆S°obs                                                 (eq 1.04) 
Although a complete understanding of biomolecular associations remains a holy 
grail in the field of protein-ligand interactions, generally such processes are understood 
depicted by the Born-Haber cycle (Scheme 1.2.1). xiv  Accordingly, the Born-Haber 
scheme dictates that for binding to occur, both the unbound protein and the ligand in 
solution must first dehydrate. Attractive forces between the protein and ligand lead to the 
solute-solute complex, which is called the intrinsic binding parameter, ∆Gint°. The 
resulting protein-ligand complex is then resolvated to give the observed complex and 
solvent molecules that remain after rehydration are expelled into bulk solvent.  
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Scheme 1.2.1. Born Haber Scheme. 
 
1.3   Intrinsic Analyses 
 
 All energetic consequences of water organization shown in the Born-
Haber cycle are accounted for in the observable energetics that are detected by 
instrumentation. Thus, calculating the intrinsic parameters is a nearly impossible task 
unless one can accurately account for the hydration parameters of the unbound protein, 
the free ligand, and the bound protein-ligand complex (eq 1.05). 
 ΔGºobs = ΔGºint – ΔGºhyd,L+P + ΔGºhyd,C  (eq 1.05) 
 To address this problem, it has been proposed that for a set of two closely related 
compounds 1 and 2, one may make the simplifying assumption that differences in 
ΔGºhyd,L+P and  ΔGºhyd,C are negligible, so they can be removed from the equation when 
calculating the differences in intrinisic parameters (shown in eq 1.06).xv However, the 
main caveat with this assumption is that water molecules in the bound complex are often 
difficult to discern, and therefore, the hydration parameters of the bound complex may 
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not be known with certainty. This technique will be discussed in further detail in Chapter 
2 of this thesis. 
 ∆∆Gºint,2-1 = ΔGºint,2 – ΔGºint,1 = (eq. 1.06) 
 (ΔGºobs,2 – ΔGºobs,1) + (ΔGºhyd,2 – ΔGºhyd,1)  (eq 1.07) 
1.4   Monitoring Protein Ligand Interactions 
 
One of the most common methods for measuring the affinity of an inhibitor for its 
targeted receptor is by measuring its half maximal inhibitory concentration (IC50). The 
IC50 is a measure of how much ligand (or inhibitor) is needed to inhibit a given biological 
process by 50%. Although the IC50 is not a direct measure of the compounds affinity, IC50 
and affinity can be related through the Cheng-Prusoff equation, which can be used to 
calculate Ki from IC50.xvi For receptor inhibition, the equation is: 
   (eq 1.08) 
where Ki is the equilibrium constant, [S] is fixed concentration of substrate and Km 
is the concentration of substrate at which enzyme activity is one-half maximal. However, 
for inhibition constants at  cellular receptors, the equation is given by: 
   (eq 1.09) 
where Ki is again the equilibrium constant, [A] is the agonist concentration, and EC50 is 













In order to obtain the thermodynamic parameters of binding, ∆H° and ∆S°, one 
may use the van’t Hoff equation to obtain values for ∆H° and Ka at different 
temperatures, which can then be used to obtain values of ∆G° and ∆S°. The van’t Hoff 
equation is given by the equation: 
  (eq. 1.10) 
where R is the gas constant. Following a temperature dependent study of the protein 
ligand interactions, one can calculate the enthalpic contributions of binding. 
Alternatively, in the absence of heat capacity changes, one could plot lnk versuses 1/T 
such that the slope is -∆H°/R, or using the equation given by: 
  (eq 1.11) 
 One complicating factor with using the van’t Hoff analysis, however, is 
that it relies on both entropy and enthalpy being temperature independent.xvii Because this 
usually is not the case for protein-ligand interactions, this technique can yield incorrect 
enthalpy and entropy values that are substantially error prone and do not match those 
obtained with calorimetric techniques. Although some reports suggested that accurate 
data can be extrapolated correctly when using the proper techniques and number of trials 
for the analysis,xviii,xix,xx it still remains a challenging method for studying protein-ligand 
interactions because it requires a large number of experiments relative to other known 
methods.   
Isothermal Titration Calorimetry (ITC) is currently the most used and most 
reliable analytical technique to measures the incremental changes in heat released or 












involves a stepwise titration of a protein solution with ligand in a calorimeter so that 
temperature changes during the interaction are detected directly. Accordingly, when each 
injection is plotted relative to the ligand concentration in solution, the resulting isotherm 
of the type shown in Figure 1.4.1 can be extracted to give each of the thermodynamic 
parameters of binding. xxi   Because of the ease and accuracy of extrapolating 
thermodynamic data, ITC has in recent years become a popular technique for determining 
the thermodynamic parameters of many ligand-receptor biological processes.xxii  
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Figure 1.4.1. Typical ITC thermograph.xxiii 
 
 
Extracting useful data from the titration requires modeling a best-fit curve to the 
data points, which is typically done using the Wiseman isotherm.6,xxiv,xxv For the systems 
discussed in this chapter, protein (P) and ligand (L) interact in a 1:1 stoichiometry (eqn. 
1.03.). Therefore, utilizing the ratio of ligand to receptor, the Wiseman isotherm (eq 1.12) 
can be employed to determine the stepwise change in heat of the system with respect to 
moles of ligand added per injection (dQ/d[X]t) relative to the absolute ratio of ligand to 
receptor (Xr = [L]t/[P]t): 
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   (eq 1.12) 
where 
   (eq 1.13) 
 
and Vo is the volume of the cell. It was originally noted by Wiseman et al.6 that the shape 
of the isotherm changes according to the product of the association constant, Ka, and the 
concentration of the selected biological receptor, which in this case is the protein, P. This 
value has been referred to as c, or the Wiseman coefficient, and it has been suggested that 
c values should fall in the range of 10 to 1000 for isotherms that enable the most accurate 
extraction of thermodynamic data from the titration.11 The effect that the c value has on 
the shape of ITC titrations is shown in Figure 1.4.2. For curves exhibiting a c value < 10, 
it is often difficult to extract an accurate ∆H° due to the lack of well defined base and 
saturation levels. Conversely, when the c value > 1000, it is difficult to obtain an accurate 
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1.5   Ligand Preorganization and Conformational Constraints 
 
Flexible molecules bind to a receptor in a defined conformation to optimally align 
its functional groups and nonpolar substituents complimentarily to those in the binding 
pocket.xxviii The entropic penalty arising from a reduction in the accessible rotameric 
degrees of freedom of a ligand upon binding to a protein has long been considered 
avoidable by introducing structural modifications that constrain or decrease the number 
of rotatable bonds in solution. xxix  Provided that these modifications do not cause 
unfavorable interactions within the binding domain, there will theoretically be a smaller 
entropic penalty upon binding of the constrained analog, which should therefore create 
favorable gains in the free energy of the binding (shown in Figure 1.5.1).xxx,xxxi  
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Figure 1.5.1. Proposed Benefits of Ligand Preorganization 
 
 
Indeed, when one expands the Gibbs free energy equation to account for changes 
in the rotational degrees of freedom that are incurred upon binding, as shown in eq 1.14, 
it can be observed that penalties from restricting rotors have adverse effects on the overall 
∆G° of binding. Thus, the notion that these penalties can be avoided by constraining the 
ligand is considered by many to be a viable approach in ligand design.xxxii 









































Pioneering studies by Page and Jenks suggested that the entropy lost upon 
“freezing” a rotor is between 1.1 – 1.5 kcal•mol-1.xxxiii These values were obtained from 
analyzing gas phase entropy differences of cycloaliphatic hydrocarbonsxxxiv between their 
respective flexible alkane isomersxxxv,xxxvi and corresponding constrained alkenes wherein 
a terminal olefin was used to restrict the rotation across a C-C bond (shown in Figure 
1.5.2).xxxiii Jenks then applied a correction factor to account for low-frequency motions in 
the cycloaliphatic hydrocarbons to arrive at ∆S°corr. of  3.7 – 4.9 e.u. per internal rotation. 
This value has since been supported by subsequent analysis from Williams et. al., who 
obtained their assessment by studying the differences in the melting points of a series of 
crystalline alkanes and alkyl carboxylic acids.xxxvii These reported values have since 
garnered considerable attention from the pharmaceutical sciences, since approximating 
the entropies that may be reclaimed upon restricting ligand rotors in biological systems 
has significant implications for drug design.xxxviii,xxxix 
Figure 1.5.2 Jenks study on rotor restriction. 
 
Beyond the proposed entropic benefits of ligand preorganization, there are several 
other suggested reasons to reduce ligand conformational flexibility. First, it is thought 
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that ligand preorganization may increase bioavailability.xl It has been suggested that 
increasing the rigidity of a peptide or peptide-like molecule may disrupt stabilizing 
intermolecular interactions that are thought to cause ligand precipitation. Another 
cooperating benefit of ligand preorganization is a process called peptide mapping, 
wherein detail of the protein binding pocket is surmised via the synthesis of plausible 
constrained intermediates when structural data is not easily obtained.xli  Therefore, since 
peptides and peptide-related biological inhibitors frequently bind in a rigid conformation 
such as a β-turn, β-strand, or an α-helix,xlii several strategies exist for preorganizing a 
ligand to bind in a manner that mimics its bound form.xliii  
Three main strategies to preorganize a ligand are shown below in Figure 1.5.3.xliv 
The first possibility involves the linking of sidechain R1 to sidechain R3, which is shown 
as linkage a. Alternatively, the sidechain may be linked to the backbone atoms as shown 
in path b. Finally, the backbones themselves can be united together forming a 
macrocycle, as shown by path c.  
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To properly determine the effect of ligand preorganization, it is imperative to 
design and synthesize a flexible control lacking the constraint. We believe it is also 
critical that the constrained and flexible molecules have the same number and type of 
heavy atoms, the same functional groups, and the same number of hydrogen-bond donors 
and acceptors.xlv These requirements ensure that differences of activity between the two 
ligands can best be attributed to the constraint itself. Additionally for macrocyclic 
ligands, it is a common to employ a scission control (1.02), which is the formal 
hydrogenolysis of a C-C bond, and an excision control (1.03), which the deletion of a 
carbon to provide two linear chains (Figure 1.5.4).xlix  
Figure 1.5.4 Proper scission and excision controls. 
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1.6   Model Systems for Studying Ligand Preorganization 
 
One of the more challenging aspects of designing a ligand with a 
preorganizational constraint is that one must avoid making unfavorable interactions in the 
binding pocket that could potentially disrupt key protein residues. In a class of Zinc 
peptidase thermolysin inhibitors, for example, it was shown through crystallographic data 
that 1.04 adopts a β turn-like structure in the binding complex (Figure 1.6.1).xlvi This 
finding prompted efforts by Bartlett et. al.  to enforce the preferred conformation of 1.04 
using a chroman ring as a linker moiety between the Cα of the phosphate and the Cα of 
the carboxylate of 1.04.xlvii  Accordingly, Ligands 1.05 and 1.06 were designed and 
synthesized as the respective ligand constraint and flexible control, and the acyclic 
analogue 1.07 was also made to gauge the effect of the chroman linker itself. Following 
the synthesis of the desired analogs, the inihibition constants were determined, and these 
binding studies revealed that macrocycle (1.06) bound with higher affinity than both 








Upon structural investigations into the binding complex of 1.06 and its acyclic 
controls in the binding pocket, several critical differences in the binding modes became 
apparent. First, the substitution of the chroman ring for the carboxylate of 1.06 disrupted 
a critical hydrogen bond that is located in the binding pocket. Second, the chroman ring 
of 1.05 was rotated by 168° away from its binding pose in 1.06, which suggests that it is 
not a proper linker to bridge the two ends of the native inhibitor together. These studies 
indicate that similar molecules may bind to a receptor in completely different 
conformations, which makes it difficult to assign the effects of ligand preorganization 
based solely upon relative binding energetics. Therefore, it is of paramount importance to 
obtain structural data of both the constrained and flexible ligands to interpret the 
energetic effects of ligand preorganization as well as to better guide further 
modifications. 
In other experiments by Bartlett, crystal structures of penicillopsin with 1.08 
showed a configurational turn in the bound state between the P1’ residue and the ϒ-
methyl of the P2 valine (Figure 1.6.2).xlviii  This finding inspired the investigators to 
employ structure-based design to synthesize and test the macrocycle 1.09, which was 
thought to preorganize the ligand in its bound conformation. Ligands 1.10 and 1.11 were 
also synthesized as excision controls to test for the specific effects of ligand 
preorganization. Subsequent binding studies revealed that macrocycle 1.09 exhibited an 
affinity that was 420-fold higher than it acyclic counterpart 1.10 as reflected by Ki.xlix  
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Figure 1.6.2 Bartlett’s pnecilopsin-binding ligands. 
 
The results essentially reaffirmed the major tenant of structure-based design 
wherein the “preorganization” of a ligand into its binding conformation can lead to 
significant affinity enhancements. However, ∆H° and ∆S° were not determined for these 
interactions, so the affinity enhancements cannot be attributed to entropic effects. 
Nonetheless, they analyzed the differences in rotatable bonds in each of the four ligands 
to determine that 1.09 had five rotatable bonds in the core structure whereas the linear 
ligands each had nine. Therefore, both linear ligands bound with different potencies 
despite having the equivalent number of rotatable bonds, which suggests that there were 
one or more other factor(s) that had a significant impact on the changes in binding 
affinity.  In subsequent studies to this report, poor correlations between changes in 
rotatable bonds and binding affinity have also been observed, so there is a question as 
whether there are absolute, “per rotor” additive effects to the binding entropy that 
accompany cyclic constraints.l,li 
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Finally, in a landmark contribution to the field of ligand preorganization in 
protein-ligand interactions, Freidinger et al. targeted a class of luteinizing hormone-
releasing receptors (LH-RH). It was proposed that these molecules bound in the β-turn 
conformation that is shown in Figure 1.6.3.lii In an effort to preorganize the ligand into its 
bound state, they synthesized and tested the lactam derivative 1.13 (Figure 1.6.3) with a 
bond between a sidechain atom and a backbone atom to force the β-turn. They observed a 
nearly ten-fold increase in relative potency of 1.12 compared to 1.13. However, neither 
the testing of a flexible control nor an investigation into the thermodynamics of binding 
were pursued and the number of hydrogen bond donors was not held constant. 
Figure 1.6.3 Freidinger study on LH-RH. 
 
Although these examples support the utility of ligand preorganization in 
biomolecular interactions, there are many cases wherein the expected affinity boost (1.1 – 
1.5 kcal•mol-1) per rotor is not obtained.x,liii ,liv For instance, Spaller et. al. targeted the third 
PDZ domain (PDZ3) of the postsynaptic density-96 kDa (PSD-95) protein as a model 
system for designing and testing the utility of preorganizational constraints.lv They had 
additional interested in this system because the PDZ domains are most commonly 
associated with mediating protein-protein interactions in many eukaryotic cells lvi,lvii The 
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PDZ3 domain was previously shown to bind a nonapeptide such that a four-residue C-
terminal stretch made crucial interactions with a β–sheet of the protein domain.lviii  The 
Spaller group proposed that a macrocyclic constraint would serve as a viable option to 
explore the potential utility of ligand preorganization with this system. After modelling 
studies suggested that the direct linkage of side chains might interfere with the requisite 
protein–ligand interactions, they examined a series of macrocycles to avoid this problem.  
They thus designed constrained ligands 1.14 and 1.15 with varying linker lengths, 
and the flexible controls 1.16 and 1.17 which were the result of a formal hydrolysis of the 
amide bond at the P-1 position (Table 1.6.1) were used as controls.lv The binding 
association constants, enthalpy and entropy were determined for this set of ligands 
utilizing ITC, and the macrocyclic ligands were found to be equipotent to their flexible 
controls. Interestingly, it was observed for constrained/flexible pair (1.15/1.17) where x = 
2, that the constrained macrocycle 1.15 has a more favorable change in entropy than the 
flexible control 1.17, which is as expected under ligand preorganization. However, for the 
ligand pair where x = 1, 1.14/1.16, the opposite trend was observed such that the flexible 
control 1.16 bound with more favorable entropy compared to 1.14. Unfortunately, no 
crystal structures of the bound complexes were obtained to better interpret these results. 
These observations led to two conclusions regarding model systems studying protein 
ligand interactions. First, it is preferable to design flexible controls that do not introduce 
polarizable groups such as the CO2H that are not present in the constraint, as this could 
result in drastically different binding modes and desolvation energies with the protein. 
Second, since small changes in the ligand ring size led to sizeable differences in entropy 
and enthalpy of binding, it was concluded that there are several unknown complexities to 
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ligand preorganization that are not yet fully understood. Given that the investigators were 
not able to crystal structures of the complexes 
Table 1.6.1 Bartlett’s PDZ-binding macrocycles. 
 
 
In a follow up to the previous study, the Spaller group envisioned modifying the 
cyclic constraint of 1.14 and 1.15.  Accordingly, they designed ligands with both 
benzoate and glutamate bridged macrocycles that are shown in Tables 1.6.1 and 1.6.2, 
respectively.  For the glutamate macrocycle, excision of a methylene group would 
provide flexible control 1.21 and scission could be utilized to provide controls 1.22–
1.24.lix The disassociation constants and binding thermodynamics of these ligands were 
obtained and are shown in Table 1.6.2. Surprisingly, the constrained mimic 1.19 bound 
with a slightly higher affinity than the flexible controls 1.17 and 1.18 that was due to a 
favorable change in enthalpy, not entropy. For the glutamate-bridged macrocycles, the 
Ligand 
Ka 







1.14 2.9 ± 0.3 –6.08 ± 0.01 –2.45 ± 0.01 –3.64 ± 0.06 
1.15 2.2 ± 0.2 –5.94 ± 0.07 –1.38 ± 0.07 –4.57 ± 0.2 
1.16 4.5 ± 0.3 –7.29 ± 0.03 –2.29 ± 0.01 –5.01 ± 0.03 
1.17 5.5 ± 0.2 –7.17 ± 0.02 –4.77 ± 0.35 –2.40 ± 0.30 
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constrained ligand 1.20 bound with nearly equipotent affinities compared to both linear 
controls. However, the macrocylic constraint had a more favorable change in entropy of 
binding relative to its linear controls, but this gain was compensated by an unfavorable 
change in enthalpy.  
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1.17 2.3  ± 0.1 –7.3  ± 0.1 –2.6  ± 0.1 –4.7 ± 0.1 
1.18 2.1  ± 1.1 –7.3  ± 0.1 –3.1  ± 0.3 –4.2 ± 0.2 
1.19 2.6  ± 0.1 –7.4  ± 0.1 –1.9  ±0.2 –5.5 ± 0.1 
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Table 1.6.3 Investigation into glutamate-bridged macrocyclic constraints by Spaller 
 
 
Since the various types of macrocylic constraints and the corresponding scission 
and excision flexible controls utilized in this system provided inconsistent results, it was 
concluded that the supposed benefits of ligand preorganization are not fully understood. 
Ligand 
Kd 







1.20 2.4  ± 0.6 –7.3  ± 0.1 –3.9  ± 0.2 –3.4 ± 0.1 
1.21 1.0  ± 0.6 –6.8  ± 0.1 –2.5  ± 0.2 –4.3 ± 0.2 
1.22 1.2  ± 0.6 –7.0  ± 0.1 –2.2  ±0.1 –4.8 ± 0.1 
1.23 1.6  ± 086 –7.1  ± 0.1 –2.4  ±0.1 –4.7 ± 0.1 
1.24 1.8  ± 0.3 –7.1  ± 0.1 –2.6  ±0.1 –4.5 ± 0.1 
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Spaller argues that a significant hindrance to better understanding the effects of ligand 
constraints is that case studies rarely probe the thermodynamics of binding to determine 
the enthalpy and entropy of the binding event. Furthermore, systematic studies with 
structural analysis are not universally performed and the appropriate controls needed to 
test ligand constraints are frequently ignored.  
1.7   Olefins as a rigid constraint 
 
One of the first investigations of using an olefin as a means to restrict rotors was 
investigated by Williams et al. with a series of risotocetin inhibitors.xxxii They found that 
the alkene containing N-furamyl-D-alanine (NFDA, 1.26) bound to its receptor  with an 
affinity nearly ten-fold more than that of the flexible ligand N-succinyl-D-alanine 
(NSDA, 1.25) (Figure 1.7.1). Calculations suggested that these two ligands bound with 
no significant difference in buried surface area, so they concluded that a favorable boost 
in affinity was likely to arise from a favorable entropic component, however, the gains 
were larger than had been predicted by Jenks et. al.xxxiii Thus, it was suggested that there 
were cooperative benefits that arose from restricting adjacent carbons to the C-C double 
bond. However, no thermodynamics of binding or structural information was determined 
for these examples. Thus, there was no direct evidence to correlate the binding affinity 
with any one thermodynamic parameter. 
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Figure 1.7.1. Williams study of risotcetin inhibitors. 
 
Further contributions by Knowles et al. showed that constraining an alkyl linker 
into its proposed biological conformation with an olefin led to significant increases in 
binding affinity of several phosphate-derived metabolites of dehydroquinate synthase.lx 
As shown in Figure 1.7.2, the supposed preferred conformation of 1.27 is aligned such 
that the phosphate group is syn to the atom Ha. This facilitates the enzymatic 
deprotonation of Ha by the enzyme.  It was observed that preorganization of the 
phosphate into such position led to an affinity increase nearly 10-fold that of the parent 
compound 1.27 and substantially more potent than the corresponding E isomer, 1.29. 
That 1.28 processed by dehydroquinate synthase provides circumstantial evidence that 
the internal olefin does preorganize the phosphate into its bound conformation. However, 
thermodynamics of the binding interaction of 1.28 to the enzyme were not determined, so 
change in entropy or enthalpy of the driving force were not known.  
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Figure 1.7.2. Knowles olefin studies. 
 
Verdine and coworkers have recently reported on one of the most extensive and 
systematic studies to date regarding the use of an internal olefin as a conformational 
constraint.  Targeting a new class of peptide mimetics for µ-opiod receptors, they 
investigated constraining a ligand into its putative bound conformation utilizing internal 
olefins as shown in Figure 1.7.3.lxi Interestingly, they found that there was a strong 
preference for the E-olefin such as 1.31 over the relative Z-olefin isomer 1.32. 
Furthermore, they showed that the constrained ligand bound better than the flexible 
control such as 1.33, but they were not able to achieve any peptide mimetics that bound 
with greater affinity than the native ligand 1.30. Although this systematic study supports 
the utility of olefin constraints, there were no thermodynamic or structural studies to 
provide any explanation for the observed affinity boosts. Because of the lack of 
thermodynamic and structural analysis, then the implication of this strategy has no 
compelling thermodynamic or structural rationale.  
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Figure 1.7.3. Verdine olefin studies. 
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1.8   Cyclopropyl Constraints 
 
Since peptides serve as leads in the early stages of many drug design endeavors, 
the Martin group initiated a program nearly 25 years ago to study the effects of ligand 
preorganization utilizing novel cyclopropane-derived peptide mimetics. Initial molecular 
modeling studies suggested that 1,2,3-trisubstituted cylcopropanes might serve as rigid 
and novel replacements for peptides such as 1.34.lxii Peptide mimetic 1.35 was derived 
from a side chain to backbone constraint (Figure 1.8.1, arrow a) wherein the nitrogen 
atom of the amide bond was replaced with a carbon atom. Similarly, 1.36 was derived 
from 1.34 by forming a bond between C (β) of the side chain and the carbonyl carbon 
atom of the backbone (arrow b). Modeling studies of the derived ligands then depicted 
that the trans geometry of the cyclopropane in 1.35 not only restricted the conformation 
of the peptide but also spatially aligned the side chains so that they adopt a χ1-angle of 
gauche (–) (–60°) for the corresponding amino acid residue. Similarly, the backbone in 
1.36 was aligned so that the side chain was aligned in a χ1-angle of anti (180°). These 
model studies on the utility of cyclopropanes paved the road for many future studies on 
the interaction of conformationally constrained peptides to a host protein/receptor.lxiii  
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Figure 1.8.1 Early model of cyclopropyl peptide mimetics. 
 
 
Following a series of cyclopropane-led ventures into a variety of biological 
receptors, we did not quite find the gains of preorganization that we sought out 
after.lxiv,lxv,lxvi For the most part, the combined efforts of designing and testing ligand 
constraints in protein-ligand interactions typically led to constrained ligands that were of 
equipotent binding relative to their flexible counterparts, although there were some 
notable exceptions.lxvii  
Given that in many cases binding affinity enhancements did not accompany 
“supposed” entropic benefits ligand preorganization, we then extended our studies to 
measure the enthalpies and entropies of the protein-ligand association with (ITC). Early 
contributions using the Src SH2 domain revealed for the first time that ligand 
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preorganization in protein-ligand interactions can lead to more favorable entropies of 
binding compared to a flexible control (Table 1.8.1). Unfortunately, an overall increase in 
binding affinity was not realized due to a balancing enthalpic.lxviii ,lxix It was shown through 
crystallography that the constrained ligand 1.38 adopt a conformation similar to native 
1.36 such that the position of their backbone atoms was almost identical. However, 
crystal structures with the flexible control 1.40 did not provide any useful information.lxx 




Table 1.8.1. Src SH2 binding studies.a 
 
aThermodynamic obtained with Src SH2 domain at 25 °C. 
Since crystallographic studies do not provide accurate information regarding the 
movement and fluctuations in the protein-ligand complex, the structural data that was 
obtained did not address the possibility that differences in hydrogen bonding in the 
complex might have contributed to the enthalpic penalty. NMR techniques can reveal 
insights on the effects of protein fluctuation in molecular associations that are not easily 
Ligand 
Ka 







1.36 4.1 x 106 –9.0 –6.1 –2.9 
1.37 6.3 x 106 –9.3 –5.9 –4.3 
1.38 1.4 x 107 –9.7 –6.9 –2.8 
1.39 1.0 x 107 –9.6 –5.9 –3.7 
1.40 1.7 x 107 –9.8 –7.3 –2.5 
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obtained via X-ray. lxxi , lxxii  One such technique is to measure the chemical shift 
perturbations (CSPs) of the domain between its bound and unbound form. CSPs of amide 
bonds can give insight into the hydrogen bond interactions of a protein-ligand complex. 
CSDs  of the pair 1.39 and 1.40 showed that the flexible mimic made stronger hydrogen 
bond interactions with the domain than did 1.39. Additionally, the protein-ligand 
dynamics between the binding of the constrained and flexible mimics and the Src SH2 
domain were studied using NMR relaxation. The results revealed that small, but 
noticeable differences in the hydrogen bonding between the cyclpropane derived mimic 
compared to the native ligand in the binding pocket were postulated to lead to the 
unfavorable enthalpic penalty of binding. Coincidentally, these chemical shift differenced 
were so slight that they could not be observed in the structural data. Since the interactions 
between the protein and the pY+1 ligand residue account for more than 50% of binding 
free energy,lxxiii it was postulated that the use of ligand constraints at binding “hot spots” 
may have adverse effects to the energetics of binding.lxxiv  
To gain further insight into the underlying effects of preorganization utilizing a 
cycolpropane constraint, the project was expanded to include binding of 
phosphotyrosine-derived pseudopeptides to the Grb2-SH2 domain. lxxv  A trans-
cyclopropane containing a tripeptide derivative was found to be slightly more potent than 
a flexible control derived from a succinate, but the more favorable binding was due to an 
enthalpic advantage, not an entropic one (Table 1.8.2). In fact, the ∆S° of binding for the 
cyclopropane-derived ligand was less favorable than the ∆S° of binding of the flexible 
ligand. This was the first example wherein use of a preorganizational constraint led to an 
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enhanced binding affinity relative to a flexible control that was driven by a relatively 
more favorable enthalpy of binding.  











1.41 4.5 x 105 -7.7 -5.4 –2.3 
1.42 2.8 x 106 -8.8 -7.9 –0.9 
1.43 4.0 x 105 -7.7 -5.5 –2.2 
1.44 2.1 x 106 -8.7 -8.3 –0.4 
1.45 1.7 x 105 -7.1 -4.6 –2.5 
1.46 7.1 x 105 -8.0 -6.0 –2.0 
1.47 4.1 X 104 -6.3 -4.2 –2.1 
1.48 2.2 X 105 -7.3 -5.5 –1.8 
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The study was then expanded to include constrained and flexible analogues that 
contained both polar and nonpolar residues at the pTyr+1 position. Those ligands 
containing the polar residues Gln (1.49/1.50), Glu (1.51/1.52), and Lys (1.53/1.54) 
generally bound with unfavorable entropies (Table 1.8.3). However, a more favorable 
enthalpy compensated this overall loss in relative biding entropy and the constrained 
ligands bound with a more favorable affinity than the respective flexible controls due to a 
dominating, more favorable enthalpy change that dominated a less favorable entropy 
change. Further investigations of this system included studies on proton transfer, 
temperature dependence, and enthalpy-entropy compensation, these studies did not reveal 
any significant differences that would provide a reasonable explanation as to the sizeable 
difference in thermodynamic signatures between the constrained and flexible analogues. 
Crystal structures of the protein-ligand complex where R = Val (1.41/1.42), Ile 
(1.43/1.44), and Gln (1.49/1.50) were obtained, and it was shown that constrained ligands 
consistently made more direct polar contacts in the binding pocket of the complex than 
the flexible counterparts. Conversely, the flexible ligands made more nondirect, water 
mediated contacts than the constrained versions.lxxvi  
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Table 1.8.3. Grb2 SH2 expanded ligands.a 
 











1.49 5.6±0.7 -7.8±0.08 -8.7±0.8 0.9±0.4 
1.50 10.2±0.4 -8.3±0.04 -9.8±01.4 1.5±0.2 
1.51 3.0±0.42 -7.5±0.14 -8.8±0.6 1.3±0.7 
1.52 36.0±0.4 -7.6±0.06 -10.3±1.12 2.7±0.3 
1.53 0.98 ±0.05 -6.8±0.03 -7.7±0.7 0.9±0.2 
1.54 5.5±0.3 -7.8±0.04 -9.2±0.6 1.4±0.2 
1.55 5.0±0.05 -7.8±0.02 -6.1±0.2 –1.7±0.1 
1.56 < 1 X 103    
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 Despite these extensive experiments to systematically test the effects of 
preorganization in protein-ligand interactions, it was unclear why the flexible ligands 
bound with more favorable entropy changes than their constrained counterparts. To 
further probe this scientific question, molecular modeling and computer-generated 
simulations were undertaken to study the effects of adding constraints to the Grb2 SH2 
domain tripeptides. Quasiharmonic analysis correctly predicted that the constrained 
ligands would bind with more favorable affinites relative to the flexible controls that was 
driven by a favorable change in enthalpy. Futhermore, upon analyzing the solution 
conformations that were utilized in the calculations, it was discovered that the flexible 
flexible ligand 1.41 adopts a more ordered conformation in the solution state compared to 
the constrained variant (Figure 1.8.2).  
The preferred solution structure arises from a stabilizing hydrogen bond between 
the side chain of the C-terminus and the phosphate group at the pY position.lxxvii It is 
worth reiterating that the purpose of introducing constraints in drug design is to lower the 
conformational entropy of the molecule relative to its more flexible parent compound, 
which is the exact opposite conclusion obtained from using computer-generated 
molecular modeling. Because this discovery calls into great question one of the founding 
and guiding principles of ligand preorganization, one must ask why the constrained 
ligand in this study binds with a higher affinity if not for having a more favorable 
conformation in solution conformations. This study is also one of the first to suggest that 
lowering the conformational entropy of a ligand in a manner that does not mimic the 
bound form may still provide more favorable relative entropies compared to a flexible 
control. 
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Figure 1.8.2. Grouping of population of proposed solution state structures of both constrained 
and flexible ligands. 
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1.9   Studies of Ligand Binding Affinity Increases Driven by Added 
Hydrophobicity. 
 
It is generally accepted in drug design that one may increase drug potency by 
adding nonpolar substituents.xi The rationale for this strategy is based upon the 
hydrophobic effect and the entropically favorable release of water molecules into the 
surrounding solvent during ligand desolvation.lxxviii ,lxxix Previous studies in this regard 
were pursued by Garcia-Echevaira et al. in the search of potent inhibitors of the Grb2 
SH2 domain. lxxx Since it had been shown that target ligands of the variety pYXN, where 
X was any nonpolar residue, bound in a β–turn at the pY+1 position (shown in Figure 
1.9.1), they initially explored the effects of using α,α-disubstituted amino acids to 
preorganize the backbone into its preferred turn.lxxxi When the binding affinity of these 
ligands was analyzed, it was shown that a steady increase in affinity accompanied the 
increase of methylene carbons up until the six membered analog 1.63. To obtain some 
preliminary information as to the cause of this increase, they modeled vdW contacts in 
the pocket, and these correlated well with the increases in binding affinity. This modeling 
study suggests that the hydrophobicity of the α,α-disubstituted residues could be 
correlated to the incremental increase in binding affinity per methylene unit, but no 
structural data were obtained to determine enthalpy and entropy of these associations.  
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The Martin group recently reported on the thermodynamics of binding between a 
series of α,α-cycloaliphatic peptides shown in Figure 1.9.1 and the Grb2 SH2 
domain.lxxxii,10 The ligands were synthesized and their complexes with the Grb2 SH2 
domain was studied with ITC to determine the ∆S° and ∆H° of binding (Table 1.9.1). For 
the pTyr+1 substituted ligands where n = 1 - 5, it was found that the binding affinities of 
ligands 1.59-1.62 increased incrementally with ring size up to a maximal affinity where n 
= 4, which was nearly equipotent to the cycloheptyl analog (n = 5). ITC studies revealed 
that the binding affinity was driven by relatively more favorable changes in enthalpies, 
not entropies, upon the addition of methylene groups which is counter to what would be 
predicted based off of conventional wisdom regarding the thermodynamic effects of 
adding apolar surface area to an inhibitor.xi X-ray crystallographic (X-ray) analysis of 
these ligands complexed with the Grb2-SH2 domain were obtained, and these revealed 
that an incremental increase in van der Waals (vdW) contacts made in the binding pocket 
correlated very well to the favorable changes in ∆H° that were observed per addition of 
each methylene group. lxxxiii  However, the incremental changes in enthalpy did not 
correlate with ∆Cp that was determined for each ligand. This is unexpected considering 
that the temperature-dependent studies of protein-ligand interactions are commonly 
thought to be a barometer of buried apolar surface area. Given the unexpected nature of 
the trends in enthalpy that were obtained with this study along with the failings of ∆Cp to 
reflect the increase in apolar surface area, the authors concluded that there many 



















1.59 –7.1 ± 0.1 –3.3 ± 0.3 –3.8 ± 0.1 4 –116 ± 12 
1.60 –7.7 ± 0.1 –5.4 ± 0.3 –2.3 ± 0.2 5 –185 ± 8 
1.61 –8.5 ± 0.1 –6.3 ± 0.4 –2.2 ± 0.2 9 –141 ± 8 
1.62 –9.3 ± 0.1 –8.5 ± 0.4 –0.8 ± 0.4 13 –181 ± 10 
1.63 –8.9 ± 0.1 –6.8 ± 0.3 –2.1 ± 0.2 14 –173 ± 8 
 
 
The Martin group extended their investigations of hydrophobic effects by 
evaluating Grb2-SH2 binding ligands with linear alkyl substituents at the pY+1 residue. 
The ligands shown in Table 1.9.2 were synthesized and their binding parameters were 
obtained by ITC.lxxxiv Although a favorable increase in binding free energy were observed 
upon adding methylene groups to Ala, subsequent addition of apolar surface area did not 
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provide any significant increases in binding affinity. Any gains that were obtained by a 
more favorable change in enthalpy were compensated by a loss in entropy. It was also 
observed that an increase in vdW contacts made in the binding pocket correlated with 
slight gains in enthalpy upon the addition of apolar surface area, but these parameters 
taken together showed a poor correlation with ∆Cp.° Interestingly structural studies of the 
bound complexes showed that when R = Nva, the alkyl chain adopts a gauche 
conformation in the bound complex which is also observed in ligands 1.61, 1.62 and 
1.63.  Thus, the plateau in observed binding affinity could be arising from the 
unfavorable interaction that the alkyl chains make in the pocket.  
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1.64 –7.3 ± 0.1 –5.1 ± 0.1 –2.2 ± 0.4 4 –123 ± 9 
1.65 –8.1 ± 0.1 –6.8 ± 0.5 –1.3 ± 0.1 9 –170 ± 15 
1.66 –8.0 ± 0.1 –6.7 ± 0.5 –1.3 ± 0.6 12 –173 ± 13 
1.67 –8.1 ± 0.1 –7.3 ± 0.3 –0.8 ± 0.2 14 –138 ± 12 






























Garcia-Echevaria et al. probed the effects of adding nonpolar surface area to the 
pY+3 residue of  tripeptides known to bind to the Grb2 SH2 domain.lxxxv,lxxxvi They 
reasoned that adding such nonpolar substituents at that position would make favorable 
interactions with an extended hydrophobic patch of the Grb2 SH2 domain. Indeed, they 
observed a significant increase in binding affinity when nonpolar substituents were added 
(Figure 1.9.2).  Modeling programs suggested that these gains in ligand binding affinity 
were due to favorable overlap between the apolar R groups and an extended nonpolar 
patch of the binding pocket, but no structural or thermodynamic data was determined to 
confirm this hypothesis.   
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Figure 1.9.2. pY+3 derived ligands. 
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1.10   Studies on the Thermodynamic Nature of Hydrophobic Effects 
Although the Garcia-Echevaria work clearly displays the potential utility of 
exploiting the use of added ligand hydrophobicity at the pY+3 position to achieve gains 
in binding affinity, the fundamental processes that drive such hydrophobic interactions 
are still poorly understood. There are very few cases that study such “entropy-oriented” 
modifications in which entropy and enthalpy of binding are determined, and even fewer 
that correlate the binding thermodynamics with structural changes in the bound complex. 
To address this pressing need, Ladbury and coworkers have developed a database named 
SCORPIO (short for Structure/Calorimetry of Reported Protein Interactions Online) that 
compiles published thermodynamic binding studies for which structural data is also 
available. lxxxvii  Upon searching this database for correlations between binding 
thermodynamics and buried apolar ligand surface area, they found a modest correlation 
(R2 = 0.70) of buried apolar surface area with Gibbs free energy. This study suggests that 
while the increase of ligand hydrophobicity may eventuate into an increase in binding 
affinity, the driving force behind such affinity gains is poorly understood. As such, it 
further brings into question the prevailing thought that such interactions are entropy 
driven. 
There is also a growing body of work showing that hydrophobic effects may also 
have strong enthalpic component.lxxxviii  It was noted by Diederich et al. that several 
benzene derivatives bound to a host cyclophane 1.74 with extraordinarily large 
association constants. When these binding parameters were decomposed to give the 
enthalpy and entropy using a van’t Hoff analysis, it was observed that the binding event 
was strongly enthalpy driven. Furthermore, the binding interactions were severely 
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weakend when the experiment was conducted in CD3OD, yet they still observed that the 
geometry of the complexes in either water or methanol were conserved. Thus, the 
investigators concluded that the favorable enthalpies of binding were largely due to the 
role of water; a finding that was counterintuitive to the generally accepted model of 
hydrophobic effects (Figure 1.10.1). lxxxix  This result gave rise to the term  
“nonclassical“ hydrophobic effect to describe host-receptor interactions in water that are  
enthalpy, not entropy driven. 
 




Indeed, several thermodynamic studies of biological associations between small 
molecules and a host protein have also shown that nonpolar ligands can bind in an 
enthalpy driven process.  For example, Ross discovered that small organic compounds 
 51 
such as indole or proflavin (see Figure 1.10.2) bind to their respective host protein with a 
favorable enthalpy and an unfavorable entropy upon binding.xc Although this result is the 
opposite of what may be expected from hydrophobic effects, he suggests that the 
enthalpy of these interactions stems from stabilizing intermolecular interactions between 
the ligand and receptor that immediately follow ligand desolvation. Ross, citing 
corroborating analyses that support this claim,xci,xcii then postulated that enthalpy-driven 
associations between a host and a receptor represent the norm in biomolecular 
interactions rather than the exception.  
Figure 1.10.2. Ross ligand analysis. 
 
 
Klebe and coworkers have recently studied the effects in the addition of 
methylene groups to cyclic residues in a series of thrombin inhibitors.xciii A key finding 
was that changing an aliphatic substituent from cyclopentyl in 1.79 to cyclohexyl in 1.78 
(Figure 1.10.3) resulted in a much more favorable increase in ∆S° that was compensated 
by an unfavorable change in ∆H°, and thus the overall binding affinity was unaffected by 
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the change in ligand hydrophobicity. That the increase in ligand hydrophobicity led to a 
gain in favorable entropy was interesting, and this prompted structural studies. 
Interestingly, these studies showed that the change in the binding thermodynamics seen 
in 1.79 and 1.78 to the increased flexibility of the cyclohexyl side chain that presumably 
gives an entropic advantage upon binding. Thus, this study demonstrates the importance 
of correlating thermodynamic studies with structural observations to better understand the 
binding interactions.  




In further studies to probe hydrophobic effects in potein-ligand interactions, 
Klebe investigated a class of thermolysin inhibitors.xciv Thermolysin belongs to a family 
of enzymes that can be classified as the M4 family of metalloproteases which can be 
found in bacteria and fungi. It is considered a prototypical model system for studying 
protein-ligand interactions as it is robust and has known procedures to provide readily 
Ligand 
Ka 







1.78 10.2±0.4 -8.3 ±0.04 -2.3±01.4 6.0 ±0.3 
1.79 1.5 x 106 -8.4 ±0.04 -4.4 ±01.4 4.0 ±0.3 
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accesible crystalographic data,xcv and as such, it has been used as model system for other 
pharmaceutically relevant proteases such as the angiotensin converting enzyme (ACE).xcvi 
Klebe explored the effects of adding branched alkyl chains to phosphonamidite-based 
inhibitors of thermolysin shown in Table 1.10.1. In most cases, they observed a favorable 
increase in binding affinity that was driven by a dominating enthalpy upon the addition of 
apolar surface area. This trend was attributed to a relatively dehydrated thermolysin 
binding pocketxcvii  that was able to make favorable dispersive interactions with the 
branched alkyl substituents.   







Further reports of enthalpically driven hydrophobic effects have come from the 
Homans lab in their studies of the incremental addition of methylene groups to pyrazines 
that bind to mouse Major Urinary Protein I (MUP-I). The Homans group studied the 









iPr →   iBu 0.9 1.0 –0.1 
iBu  →   Bn –0.3 1.5 –1.8 
iPr →   Bn 0.5 2.5 –2.0 
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methoxy-3isobutylpyrazine (1.85), which contains one additional methylene group, with 
MUP-I.xcviii Remarkably, they found that the binding affinity increased from 1.84 to 1.85 
upon the addition of a methylene group, but that this increase in affinity was attributed to 
a more favorable change in the enthalpy of binding relative to 1.84 (Table 1.10.2.). 
Structural studies showed that there were no bound water molecules in the complexes of 
1.84 and 1.85, which is not unusual as MUP-I is thought to have an unoptimally hydrated 
binding cavity.xcviii Furthermore, the Stone group also reported on a series of thiazole 
heterocycles that also bound to MUP-I such that favorable changes in enthalpy were 
observed upon the addition of methylene groups.xcix It was noted by both Stone and 
Homans that the observation that addition of methylene groups led to favorable changes 
in enthalpy, not entropy, was perplexing because the burial of apolar surface area was 
considered to grant favorable changes in binding entropy. It was later proposedxii that 
since the binding cavity of MUP-I is “dewetted”, then protein-ligand dispersive 
interactions made in the pocket would not be completely balanced by a corresponding 
loss in protein-solvent interactions prior to binding.cxx. Thus, this phenomenon could 
provide an explanation for the favorable changes in enthalpy observed in both the Stone 
and Homans studies.  
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1.84 -8.1 ± 0.02 -10.6 ± 0.02 2.5 ± 0.8 
1.85 -9.2 ± 0.02 -11.5 ± 0.02 2.2 ± 0.1 
 
 To further study the effects of adding hydrophobicity to MUP-I binding ligands, 
the Homans group extended their study of ligand hydrophobicity to alkyl alkanols. Since 
they previously postulated that the imbalance in dispersive interactions created by 
dehydrated receptorsxcvii such as MUP-I could account for enthalpically driven binding 
interactions, they suggested that the addition of methylene carbons to hexanol would be 
an ideal model system to test this hypothesis. Accordingly, they determined the 
thermodynamics of binding between small hydrophobic alkanols (Table 1.10.3) and 
MUP-I, which showed that the addition of nonpolar surface area was indeed 
accompanied by enthalpically driven gains in affinity.xiv These results further supported 
the hypothesis that the addition of apolar surface area to a protein binding ligand may not 
always lead to more favorable changes in binding entropy, but that enthalpy changes can 
















1.86 1 -5.5 ± 0.02 -9.8 ± 0.02 -4.3 ± 0.8 
1.87 2 -6.8 ± 0.02 -11.4 ± 0.02 -4.6 ± 0.1 
1.88 3 -7.7 ± 0.01 -12.8 ± 0.01 -5.0 ± 0.1 
1.89 4 -8.5 ± 0.02 -13.9 ± 0.02 -5.4 ± 0.1 
1.90 5 -9.3 ± 0.05 -15.2 ± 0.05 -5.9 
 
The Homans studies stand in distinct contrast to investigations by Engberts on the 
addition of methylene groups to Trypsin binders.c They studied the effect of adding 
hydrophobic groups to a set of benzamidinium ligands and determined their binding 
thermodynamics using ITC (Table 1.10.4) It was observed that the addition of methylene 
groups from 1.91 (R = H) to 1.97 (R = nHex) was accompanied by favorable change in 
binding entropy but an unfavorable change in binding enthalpy, such that affinities 
changes were minimal across the series. They also reported a strong correlation to ∆Cp, 
which served as an indicator of the burial of apolar surface area in protein-ligand binding. 
They then why they were not observing significant increase in binding affinity that 
accompanied the burial of hydrophobic surface area. They then conducted binding 
simulations which suggested that there was no significant steric interaction made in the 
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pocket that could account for the compensating unfavorable change in enthalpy. The 
investigators suggested that there are still unknown factors in protein-ligand interactions 
that make it difficult to achieve marked binding affinity increases due to the modification 
of a ligands hydrophobic surface area. 
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1.91 (R = H) 4.5 ± 0.2 -6.4 –4.5 –1.8 –96 ± 5 
1.92 (R = Me) 6.9 ± 0.3 -6.6 –4.4 –2.2 –100 ± 3 
1.93 (R = Et) 2.9 ± 0.3 -6.1 –3.3 –2.8 –166 ± 3 
1.94 (R = nPr) 3.1 ± 0.2 -6.1 –3.0 –3.1 –143 ± 0.5 
1.95 (R = nBu) 3.8 ± 0.2 -6.3 –2.4 –3.9 –174 ± 1 
1.96 (R = nPent) 5.8 ± 0.3 6.5 –2.4 –4.1 –151 ± 2 
1.97 (R = nHex) 13 ± 0.6 7.0 –2.5 –4.5 –203 ± 2 
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It is also worth noting that recent studies question the hypothesis that all water 
molecules surround apolar surface area in a well defined and highly–ordered manner.ci 
During the studies of the hydrophobic interactions between membranes and their 
surrounding proteins, it was discovered that there was a large structural dependence on 
the topology of apolar surface that influenced the hydrogen bond networks formed 
between water molecules. As shown in Figure 1.10.4, a convex surface led to optimal 
hydrogen bonding (shown as vectors) between solvent, whereas a flat or concave surface 
leads to unoptimized hydrogen-bonding networks. The significance of this study is that it 
suggests that water networks are dependent on the classification of ligand surfaces and 
topology. 
Figure 1.10.4. Water binding networks.cii 
 
 
In a structural analysis of ligands bound to HIV-protease, Friere suggested that a 
cavity located in the binding pocket was not optimally filled by 1.98.ciii,civ In attempts to 
explore the effects of filling this cavity with apolar substituents, they found that the 
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substitution of R = H (1.98) with R = F (1.99), Cl (1.100), and Me (1.101) all led to 
increases in binding affinities relative to 1.98 that were driven by increases in favorable 
binding enthalpy, not entropy. It was argued that the boost in enthalpy could be attributed 
to an increase in dispersive interactions arising from the larger vdW radii of the phenyl 
substituents, which also correlated with a more ordered structure in the binding pocket. 
The investigators suggested that the favorable entropies of binding arose from additional 
solvent desolvation that does correlate well with the increase in buried surface area. 
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1.98 H 8.5 ± 0.7 -10.8 ± 0.01 –4.5 ± 0.2 –6.3 ± 0.01 
1.99 F 28.9 ± 0.7 -11.5 ± 0.1 –6.1 ± 0.5 –5.4 ± 0.1 
1.100 Cl 192.3 ± 0.2 -12.7 ± 0.3 –6.4 ± 0.4 –6.2 ± 0.3 
1.101 Me 714 ± 0.4 -13.5 ± 0.2 –6.5 ± 0.7 –7.0 ± 0.2 
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Spaller and coworkers have also studied the effects of introducing halogen 
substitution on an aromatic ring of a PDZ domain agonists in a manner that increases the 
ligand hydrophobic surface area. cv They found that halogen substitution on phenyl rings 
increased binding affinity through an entropically favorable process (Table 1.10.5). This 
effect was attributed to the increase in the vdW radii of the halogens relative to an H 
atom at the para position of a phenyl ring (H: 1.20 Å, F: 1.47 Å, Cl: 1.77 Å).cvi 
Presumably, this would lead to the greater release of ordered water molecules that would 
give rise to favorable entropies. They observed that binding affinity increased upon the 
substituent heteroatoms with larger van der Waal radii in a process that was driven by a 
favorable entropy; however, they did not obtain any structural information of complexes 
in the binding pocket to confirm/support this hypothesis. Thus, although this is an 
interesting study on the binding thermodynamics of substituent effects on phenyl rings, 
the requisite structural data needed to determine the ligand buried surface area and 
possible dispersive interactions made in the binding complex were not obtained.   
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Similarly, the Whitesides group has recently investigated the effects of flouro 
substituted methylene chains in potent binders of human carbonic anhydrase II (HCA 
II). cvii  They observed that fluorinated derivatives bound with more favorable 
enthalpies and entropies relative to the parent alkyl chains. The more favorable 
enthalpy that was observed for the fluorinated derivatives has been proposed by the 
Whitesides group to arise from expulsion of added water in the binding pocket due to the 
larger van der Waal radii of the C-F bonds. It is noted that since the dispersive 
interactions would be weaker in C-F bonds than they are in C-H bonds, then there should 








1.102 4-H -8.0 ± 0.1 -6.9 ± 0.2 1.1 ± 0.2 
1.103 4-F -8.1 ± 0.1 -2.9 ± 0.5 5.2 ± 0.4 
1.104 4-Cl -8.6 ± 0.1 -4.3 ± 0.1 4.3 ± 0.1 
1.105 4-Br -8.5 ± 0.1 -4.4 ± 0.1 4.1 ± 0.2 
1.106 4-I -8.8 ± 0.1 -4.4 ± 0.1 4.4 ± 0.1 
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that the larger radii of the fluoroalkyl group may displace more unoptimally hydrated 
water molecules that would then be hydrated in bulk water. However, their structural data 
did not provide insight regarding differences in hydration of complexes in the binding 
pocket to confirm/support this hypothesis, as accounting for water molecules in the 
binding complex using X-ray crystallography can be unreliable. 
 
1.11   Topliss Operational Schemes. 
 
One of the earlier tactics that was applied to modify potential drug leads screening 
of libraries is the operational schemes of the Topliss decision tree. In this process, a 
whereby a small set of phenyl-substituted analogs are synthesized and their measured 
binding affinities guide the synthesis to a compound with optimized potency, as shown in 
Figure (1.11.1). cviii  These choices in synthesis are guided by considerations of 
hydrophobicity (π values),cix steric effects,cx and electronic factors (σ values)cx of different 
substituents.  
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Figure 1.11.1. Topliss operational schemecxi 
 
In order to apply this strategy, the first step involves the synthesis and testing of 
the initial lead. The selection of the next compound depends up whether or not the analog 
binds with more, equal or less potency. This process is repeated according to the Topliss 
decision tree (Figure 1.11.1). Ideally, one would need to synthesize only two to seven 
compounds in the early stages of drug design using the Topliss operational schemes to 
achieve maximal potency in the series.  However, given today’s resources and brute force 
efforts, many investigators will approach Topliss optimization by synthesizing the 
majority of the substituents shown in the schemes.cxii 
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Interestingly, a literature search revealed that there has been no reported 
systematic study on the Topliss decision tree that reveal the binding thermodynamics 
entropy and enthalpy. There have also been very few studies that correlate changes in 
binding affinity with lipophilicity or the electronic properties of the respective 
substituents.  Even more surprising is that there is no thorough study of the Topliss 
operational scheme that utilizes calorimetric methods to obtain the enthalpy and entropy 
of binding. However, in a study on increasing the potency of inhibitors for the prostate-
specific membrane antigen (PSMA), Berkman et al. determined that ligand potencies 
correlated with the π and σ values of the suggested substituents of the Topliss scheme.cxiii 
As shown in Figure 1.11.2, the π and σ (each shown relative to R = H) are included to 
depict that the highest inhibition was met when both factors were sequentially increased. 
This led the authors to design a second set of inhibitors reflecting the observed trend, 
which guided them to synthesize and test the 4-Cl, 3-CF3; 4-CF3; 2,4-Cl2.  Unfortunately 
the substituents led to no significant increases in PSMA inhibition. This result may be an 
indication that there are more complexities to the schemes than solely relying on π and σ 
values to target gains in binding affinity.  
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Figure 1.11.2. Berkman ligands. 
 
1.12    Conclusions 
Recent advances in calorimetry have allowed for the facile understanding of 
biomolecular interactions between small molecules and their host receptors to provide the 
entropy and enthalpy changes that occur upon a binding event binding event with 
unprecedented accuracy. This advance in technology has brought with it a renewed 
interest in studying many design strategies used in the pharmaceutical industry to develop 
potent and selective inhibitors for medicinally relevant therapeutics. 
 One tactic to optimize affinity is to preorganize a flexible ligand into its bound 
conformation. It is assumed that rigidifying the ligand by reducing the total number of 
rotors will lower its entropy, thereby reducing the entropic penalty associated with 
binding. Although the entropy and enthalpy of binding in many case studies have not 
been determined, there have already been several cases where preorganization of a ligand 
does not grant the anticipated gains in binding affinity driven by a more favorable 
entropy. There is also little scientific evidence of a correlation between the reduction of 
ligand rotatable bonds and binding affinity in biomolecular interactions.  
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It is also believed that increasing the nonpolar surface area of a ligand may lead to 
enhanced binding affinity due to a favorable change in entropy. Such boosts in entropy 
are posited to arise from the release of highly ordered water molecules during ligand 
complexation. Although it has been shown increases in drug potency can be achieved by 
the addition of nonpolar surface area to a ligand, recent thermodynamic and structural 
studies have been reported suggesting that such affinity increase may be the product of 
favorable changes in enthalpy and not entropy driven. Since it is generally thought that 
the driving force hydrophobic effects were favorable changes in entropy, which as we 
have shown is not always observed, we  wondered how these affinity enhancements are 
achieved and if they could be better understood and implemented.   
We also reviewed common strategies for the optimization of drug leads 
containing phenyl substitution. A common motif that is used for optimizing the affinity of 
such ligands is the use of the Topliss decision tree. Although there have been hundreds of 
published studies on drug lead development employing this scheme, there is not a single 
study correlating its thermodynamic effects associated with its implementation in ligand 
optimization. Since such thermodynamic information is lacking in the current application 
of the schemes, we believe that it is imperative to investigate the Topliss decision tree to 
determine if any possible trends can be identified that may lead to a better understanding, 
and possibly implementation, of this optimization process.  
In summary, we reviewed the current literature regarding common strategies and 
motifs employed by big pharma to discover potent drug leads. We dove into this task 
with a keen interest on questioning if the strategies that we encountered were explainable, 
predictable, and most importantly, do they work? Then, we critically examined 
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representative examples of significant strategies in drug design such as (1) ligand 
preorganization, (2) affinity enhancements via the increase of nonpolar surface area, and 
(3) the use of the Topliss decision tree. We found with overwhelming conviction that 
each of these design strategies were poorly understood because each is backed by 
assumptions that have little to no support from thermodynamic or structural evidence. 
Thus, we gathered the questions and observations from our literature review to plan a 
study wherein these design motifs are explored to better understand how and why they 
are effective, so that we could potentially improve how they are employed in the early 
stages of drug discovery. Specifically, does the restriction of ligand rotors in protein-
ligand interactions corresponding to a favorable change in entropy of 1.1–1.5 kcal•mol-1? 
What is the thermodynamic driving fore, if any, that increases affinity when apolar 
surface area is added to a drug lead. And, are there any thermodynamic trends of the 
Topliss decision tree that correlate with favorable gains in ligand potency? 
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Chapter 2 Thermodynamic and Structural Evaluation Preorganizational 
Constraints for MUP-1 Ligands. 
Earlier studies on ligand preorganization with several Grb2 SH2 domain-binding 
peptides revealed that cyclopropane-derived mimetics consistently bound with greater 
potency than their respective flexible controls due to a more favorable enthalpic 
advantage, not an entropic one. cxiv  Since this was the first example wherein a 
preorganizational constraint led to an enthalpically driven increase in binding affinity 
relative to a flexible control, additional studies such as structural characterizationcxv and 
computer-aided simulationcxvi of the binding event were obtained to discern the origin of 
this finding. However, we are still working towards understanding the energetics 
associated with the interactions of binding between peptide ligands and the Grb2 SH2 
domain. Whilst pursuing those studies, we also sought another system where we could 
study the effects of ligand preorganization and hydrophobicity. Accordingly, we 
embarked on a study to further examine this phenomenon by the design, synthesis and 
biological evaluation of ligands that bind to the mouse Major Urinary Protein (MUP-I).  
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2.1   Mouse Major Urinary Protein I (MUP-I). 
Figure 2.1.1 Structure of MUP-I displaying the β barrel binding cavity. 
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The lipocalins are a small family of proteins that adopt an eight-stranded β-barrel 
cavity,cxvii and MUP-I is a member of this family and a pheromone transport protein in 
male rodent urine.cxviii,cxix It forms complexes with pheromones in the male mouse that are 
then excreted in the urine. The active binding site in MUP is enclosed so that there are no 
solvent exposed regions in the pocket (Figure 2.1.1). Interestingly, recent calculations 
have indicated that MUP-I has an unoptimally hydrated binding pocket that is 
dewetted.cxx These studies indicate that unlike a model protein system where water exists 
in the apo structure and is then expelled upon protein ligand binding, MUP-I has regions 
of the binding pocket that are not optimally hydrated by solvent. Thus as shown in Figure 
2.1.2, it is speculated that solute-solute interactions in these dry regions may not be 
accompanied with expulsion of water upon binding to any significant extent. 
 
Figure 2.1.2 Protein-ligand association a ligand and a “dewetted” protein binding domain. (A) 




2.2   Ligand Design 
 
It was disclosed several years ago in a personal communication from the Homans 
group that Phe and Ile derivatives were shown to be modest binders to MUP-I. X-ray 
structural analysis of these compounds were examined, and we queried whether a 
cyclopropane constraint similar to those used in ligands that bound to the Src and the 
Grb2 SH2 domains would preorganize the Phe derivative into its bound state (Figure 
2.2.1). Given that the cyclopropane moiety in 2.08 adds a heavy atom to the ligand 
skeleton relative to 2.06, we designed a suitable flexible control 2.07 that lacked the 
cyclopropane constraint (Figure 2.2.2).  
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Figure 2.2.1 MUP-I ligand design featuring (a) the crystal structure of NHAcPheOMe in the 
protein bound complex and (b) and overlay of this structure with the proposed constrained mimic. 
   
(a).  
   
(b)
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Figure 2.2.2 Ligand design for studies with MUP-I. 
 
2.3   Ligand Synthesis 
 The ligand N-acetyl phenylalanine methyl ester, shown as AcNPheOMe in 
Figure 2.4.2, was prepared by the esterification of phenylalanine using thionyl chloride in 
methanol to provide an amine hydrochloride that was then acylated using pyridine and 
acetic anhydride.cxxi The cyclopropane derived Phe mimic 2.08 was synthesized using a 
known procedure for the synthesis of cyclopropyl lactones.cxxii,cxxiii The synthesis starts 
with a Sonogashira coupling of iodobenzene and propargyl alcohol to give 2.13 (Scheme 
2.3.2), which was then selectively reduced in the presence of P-2 Ni. Treatment with the 
Corey-Meyers acid chloridecxxiv provided the diazoester 2.15 in good yield. For the key 
transformation of this synthesis, the diazoester was treated with Rh2(S-MEPY)4 to 









Scheme 2.3.2 Synthesis of cyclopropane precursor. 
 
 
The known cyclopropyl lactone 2.16 was then opened with 2.17 to provide the 
DMB protected amide 2.19 (Scheme 2.3.3).cxxv Alternatively, 2.16 could be opened under 
mild conditions with 2.17 in the presence of AlMe3 cxxvi . This transformation was 
performed in hopes to increase reaction yield, but the procedure with tBuMgBr 
consistently gave higher yields. The alcohol 2.19 was then oxidized to an intermediate 
aldehyde that was epimerized to give 2.20, which was then oxidized to the acid 2.21. The 
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methyl ester of 2.21 was prepared by reaction with SOCl2 in MeOH, and the N-protecting 
group was removed using TFA to provide the final ligand 2.8.  
 
Scheme 2.3.3 Synthesis of constrained mimic. 
 
 
The flexible mimic 2.07 was prepared by colleague Dr. J. Tian as shown in 
Scheme 2.3.4. Briefly, 2.23 was treated sequentially with pivaloyl chloride and then the 
phenyl derived oxazolidinone 2.24 to give 2.25, which was then treated with pivaloyl 
chloride to provide the intermediate mixed anhydride that was allowed to react with the 
phenyl derived oxazolidinone 2.24 to give 2.25.cxxii Formation of the sodium enolate of 
2.25, followed by addition of 2.26 provided 2.27 as a single diastereomer in 71% yield. 
































































DMB deprotection using TFA afforded 2.29, which was treated with thionyl chloride in 
methanol to give 2.07 in 70% yield.   
 
Scheme 2.3.4 Synthesis of flexible mimic 
 
 
2.4   Thermodynamic Studies  
With the constrained and flexible 2.08 and 2.07 in hand, we then conducted 
binding studies on these ligands with MUP-I (Table 2.4.1). It was found that the 
cyclopropane derived Phe mimic (cPhe) bound with nearly equal affinity to protected 
amino acid 2.06. However, the constrained mimic 2.08 had a more favorable enthalpy of 
binding than the native ligand. Unfortunately, this gain in affinity was compensated by a 
relatively unfavorable entropy changes so that there was no significant change in binding 
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affinity. The flexible mimic 2.07 was then found to bind so weakly that the 
thermodynamics of binding could not be determined Table 2.4.1 because it had a ∆H° of 
binding that was too low for the instrument to detect.  
It shall be noted that the suggested detection limit for the ITC is based off of the 
enthalpy of binding. Thus, it is possible that the flexible mimic could have a binding 
affinity that is driven by a strong entropic force, and such a curve would not be detected 
well by ITC. However, if we assume for this discussion that the binding affinity of 2.07 is 
< 1 x 103 M-1, then this would indicate a preference for the flexible analog that is >200 
fold that of the flexible ligand. To date, this would be the largest affinity boost achieved 
using cyclopropyl constraints to the best of our knowledge. However, without any 
thermodynamic or structural characterization of the binding event with 2.07, then we can 
not make any insightful conclusions that would shed light on preorganizational 
constraints.  
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2.06 2.8 x 105 -7.7 ± 0.1 -11.3 ± 0.7 3.6 ± 0.1 
2.08 2.4 x 105 -7.2 ± 0.1 -12.4 ± 0.7 5.1.3 ± 0.1 
2.07 Did Not Bind (Ka < 1 x 103) 
 
 
2.5   Summary 
 In summary, we have successfully designed, synthesized, and tested a 
preorganized amino acid derivative containing a 1,2,3-trisubstituted cyclopropane that 
was designed to orient the amino acid into its bound conformation. This constrained 
mimic was determined by ITC to be equally potent to a Phe derivative. It was found that 
a more favorable enthalpy of binding was compensated by an equally unfavorable 
entropy compared to the native ligand. In order to properly ascertain the effects of the 
cyclopropane constraint, a flexible control containing the same number of heavy atoms 
was synthesized and tested. The binding enthalpy of the flexible compound was 
decreased by such a large extent that it could not be detected by ITC. Given the known 
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detection limits of the instrument, this indicates that the flexible ligand was at least 200 
fold less potent that the constrained analog. Potency differences of this magnitude have 
never been observed for cyclopropane constraints in protein-ligand interactions. However 
without structural data of the flexible control, it is difficult to infer if the differences in 
ligand binding affinity arose from the ligand constraint or some other unknown 
complexity to binding.  
 
2.6   The Binding Thermodynamics of Phenyl Alkanols  
 
Thermodynamic studies from our investigation of trisubstituted trans cyclopropanes 
that bound to MUP-I showed an unprecedented preference for a constrained analog that 
had a Ka ~200 fold better than the flexible amino acid mimic from which it was derived. 
However, we were left with little thermodynamic and structural information to glean 
from this discovery because no thermodynamic data could be obtained for the flexible 
analog. In order to further our investigation of the effects of ligand preorganization 
constraints on this system, we set out to modify the initial ligand design and to study 
novel binders that would be smaller, less substituted, and more readily available for 
derivative testing.  
Our attention turned back to a class of linear alkanols that were shown to be potent 
MUP-I binders.cxxvii As shown in Section 1.10, the affinity of the n-alkanols for MUP-I 
increased in an enthalpically driven process upon the addition of each methylene group. 
Structural studies revealed that these alkanols adopted an extended conformation in the 
binding pocket until n = 4 (nonanol) at which point the ligands adopted a turned 
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conformation (shown in Figure 2.6.1). This turned structure was maintained for the 
decanol derivative. We were intrigued by this finding and sought to study the effects of 
substituting in a cyclohexyl substituent to enforce its turned posed in the pocket. 
Preliminary studies on the cyclohexyl-substituted ligand 2.32 were somewhat 
disappointing because it was a weaker binder than we anticipated. However, we then 
replaced the cyclohexane moiety with a phenyl ring and found that the analog 2.33 had 
better binding based on preliminary runs.  
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Figure 2.6.1. Above: Binding pose of nonanol (a) and decanol (b) wherein it adopts a 
turned configuration (shown as a dash). Below: cyclohexyl (#) and phenyl (#) alcohols that were 
proposed to mimic the turn. 
  





Based upon these preliminary observations, we opted to pursue a study of the binding 
of a series of phenyl alkanols by studying the effect of increasing nonpolar surface area 
by adding methylene groups. Because it had been shown that the alkanols adopted an 
extended, zig-zag conformation in the binding pocket (up until nonanol), we hoped to 
develop our phenyl alkanol system to study the effects of ligand preorganization using an 
internal olefin. Thus, we set out to study the binding thermodynamics of simple phenyl 
alkanol derivatives utilizing ITC to determine if this system would be beneficial for our 
aforementioned goals. 
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2.7   Developing the ITC protocol 
Our initial attempts at binding studies of phenyl propanol plagued by the inability 
to obtain reproducible values for ∆H° and T∆S°. The difficulties that we faced arose from 
a combination of unforeseen problems attributed to a low c value and inconsistent n 
values. It soon became evident that we needed to revamp our ITC protocols to obtain 
consistent and reproducible ITC data.  
         We first decided to correct the issues with our c value by doing a study 
wherein the concentration of protein and ligand were adjusted. This was carried out by 
using both the Ka from preliminary ITC results and a targeted c value of 500 which can 
then be inserted into eq (1.01) to solve [P]t.  
   (eq 1.01) 
 The ligand concentration then had to be adjusted to obtain good signal to noise ratios 
for our thermograph, and this was done by maintaining a 12-fold equivalence of [L] to 
[P]. We thus identified ligand and protein concentrations that consistently produced 
isotherms having acceptable c values, but our n-values were still significantly different 
from 1.  
It has been suggested that N values that do not reflect the supposed binding 
stoichiometry, or are irreproducible, can be attributed to errors in: (1) the protein 
concentration, (2) ligand concentration or (3) ligand occupancy in the complex during the 
binding event. We opted to address these issues by first assuming that the ratio of ligand 
to protein was 1:1, and this was considered a safe assumption at that time since a number 
of related alkyl alkanols were shown to bind with MUP-I in a 1:1 ratio. This hypothesis 
 85 
was later confirmed by X-ray crystallographic data.  Therefore, we anticipated n values 
that were near 1.0, yet we consistently observed values around 0.7, and they ranged from 
0.5 to 1.4.  As a part of our protocol, the protein concentrations were routinely checked 
by UV-Vis spectroscopy using a known extinction coefficient ε280 = 14,661 M-1cm-1 for 
the protein,cxxvii but the ligand concentration was being measured by weight. Since both 
the ligand and protein had a chromophore, we measured the extinction coefficient of 2.33 
(3-phenylpropanol) in the ITC buffer at pH 7.4 as shown in Figure 2.7.1. We then used 
this extinction coefficient to determine our ligand concentrations and most importantly 
how the UV and weight concentrations compared to each other. If the UV concentration 
matched the weight concentration within 5% error, we opted to proceed with the run 
using the UV corrected ligand concentration. Gratifyingly, this led to achieving isotherms 
that reproducibly provided consistent values for enthalpy and entropy, but our n values 
were still consistently less that 1.0. Since we had confirmed our ligand concentrations 
using UV-Vis spectroscopy and at this time knew that the ratio of protein to ligand in the 
binding pocket was 1:1, we concluded that the low n values were a result of an erroneous 
protein concentration in solution. 
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Since it was previously shown that alkyl alkanols of the form CH3-(CH2)n-OH, where 
n = 4-8, bound to MUP-I in an enthalpically driven binding event, we first determined the 
effects of adding methylene groups to phenyl alcohols of the form Ph-(CH2)n-OH where n 
= 3-5. These ligands (2.33, 2.34 and 2.35) are commercially available and were distilled 
prior to their use in ITC, the thermodynamic parameters of binding for these alcohols 
were collected and are shown in Figure 2.7.2, where the comparison between UV and 
weight for each respective run is also shown. We were gratified to observe that the newly 
discovered series of phenyl alcohols bound to MUP-I with the same trend as the linear 
alcohols. That is to say, the addition of each methylene group led to a favorable increase 
in binding affinity that was driven by ∆H° not ∆S°. Variations in the enthalpy gains and 
entropy losses compared to those observed for the alkyl alkanols were observed and will 




























ligand concentrations for the data of our modified ITC protocol shows that variations in 
our n values did not result in variations of the thermodynamic parameters ∆H° and ∆S°, 
which suggests that variations in n values are due to protein concentrations and thus need 
to be corrected.  
 
Figure 2.7.2. Individual run data analysis of MUP-I ligands at 298 K in PBS buffer at pH 7.4. 
 
 
2.8   The Utility of the Internal Olefin to Restrict Rotors 
 
MUP-I is known as a “promiscuous binder” because it can associate with many 
different types of molecules, albeit they are typically small, hydrophobic ligands. 
Furthermore, typical binding processes are characterized by thermodynamics with a 
strong enthalpic driving force that are postulated to arise from dispersive interactions 
made in the binding complex.cxxvii Given our recently developed series of novel MUP-I 





















































known about MUP-I protein ligand interactions by revisiting our initial approach of 
evaluating the structural and thermodynamic effects of restricting rotors.  
As mentioned in the Section 1.5, restriction of ligand rotors are estimated to provide 
reclaimable entropies between 1.1 – 1.5 kcal•mol-1 per independent rotor restricted, based 
on theory and some notable observations.cxxviii Despite a lack of consistent experimental 
data, the predicted penalties for “freezing” a rotor have an impact upon key decisions in 
early drug development. Many scoring functions apply these values as context-
independent additive per-rotor penaltiescxxix such that these programs disfavor ligands 
with more rotors by simply counting the number of rotatable bonds. This practice of 
applying unbiased per-rotor penalties in computer-assisted ligand screening has recently 
been challenged on the basis that there is no evidence showing how rotatable bonds may 
correlate to losses of configurational entropy upon complex formation.cxxx  
We herein assess the use of these so-called “context-independent” per-rotor penalties 
utilizing a systematic experimental approach. As shown in Figure 2.8.1, we wanted to 
examine the thermodynamic and structural effects of restricting a rotor utilizing an 
internal olefin on simple alkanols and phenylalkanols. We further extended this study by 
examining methylene group deletion on the resultant alka(e)nols. Although “deletion” of 
a CH2 also constitutes as the removal of a heavy atom, the two transformations are seen 
as “equivalent” for many in silico screening programs,cxxix thus we felt that this system 
was well-suited to study this supposed equivalency upon removing rotors.  
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Figure 2.8.1 Proposed restrictor study. 
 
 
The proposed study therefore allows us to explore/ask to significant questions: 
Firstly, does reducing the number of  rotors result in a change to ligand binding entropy 
by an average of 1.1 – 1.5 kcal•mol-1?  Secondly, is there a binding entropy equivalence 
between reducing rotor numbers in an alkyl chain through restriction via introducing 
double bonds or removal through removing methylene groups? To explore this question, 
we collaborated with colleagues from the Homans lab at Leeds University. This granted 
us the ability of examining the variability of the R substituent shown in Figure 2.8.1 to 
include both phenyl and alkyl substituents, which gave us a diverse and larger number of 
substrates. We then synthesized and tested ligands containing an internal C-C double 
bond (2.35), and then removed a methylene group from this scaffold to obtain 2.37, 
which will also be tested. Furthermore, since many of the alkyl alkanols were previously 
shown to bind in a zig-zag conformation, we also opted to test the Z olefin to probe the 
effect of olefin geometry on the entropy of binding.  
Thus, the alkyl and phenyl alkanols shown in Figures 2.8.3 a and b were targeted for 
synthesis and biological testing. The Homans group conducted the ITC and X-ray of all 
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Figure 2.8.3. Saturated and unsaturated n-alka(e)nols (a) and phenylalka(e)nols (b). a  
 
 
(a) aSolid arrows depict introduction of a double bond while dashed arrows depict 
removal of a methylene unit. Abbreviations: “A” = alkanol, “PA” = phenylalkanol. “2Z” = Z-





2.9   Ligand synthesis 
 
 Ligands P6, P5, P4, P3 and PA3(2E) were from commercial sources. The 
syntheses of Z-olefins PA3(2Z), cxxxi  PA4(3Z), cxxxii  PA5(4Z),cxxxii were initiated by 
coupling iodobenzene (2.35) with the requisite acetylides via a Sonogashira coupling to 
afford 2.36-2.38 (Scheme 2.9.1). These acetylides were selectively reduced utilizing P-2 
Nickel, which was generated in situ from Ni(OAc)2 and NaBH4 to afford the requisite Z-
olefins 2.39–2.41 in moderate to good yields. It should be noted that Lindlar conditions 
were also examined for this transformation, but it was often times too slow and despite 
extended reaction time, running without the presence of quinoline, and utilizing a Parr 
Shaker, all attempts at this transformation led to mostly unreacted starting materials.  
 




Phenyl alkenol PA5(3E) was synthesized starting with a Knoevenagel reaction 
wherein hydrocinnamyl aldehyde was treated with malonic acid in the presence of 
piperidine and AcOH to afford the 2.43 acid in 30% yield (Scheme 2.9.2).cxxxiii Treatment 
of this acid with LAH afforded the alcohol 2.44 in 40% yield. The remaining E-olefins 
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were made through reduction of their commercially available acid precursors. 
Accordingly, 2.45 and 2.46 were reduced using LAH to provide the alcohols 
PA4(3E)cxxxiv (2.47) and PA5(4E) (2.48) in 65% and 47% yields, respectively (Scheme 
2.9.3). 
Scheme 2.9.2. Synthesis of phenyl alkenol 2.44 
 
 




2.10   Thermodynamic Binding Studies of Alkyl and Phenyl Alka(e)nols 
 
 The observed thermodynamic parameters of binding, ΔGºobs, ΔHºobs, and 
TΔSºobs, were measured by ITC at 298 K for the n-alka(e)nol and phenylalka(e)nols, and 
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these results are shown in tables 2.10.1 and 2.10.2, respectively. Dr. Richard Malham 
(R.M.) at Leeds University preformed all ITC work for the alkyl alkanols and we 
performed all of the binding studies for the phenyl alka(e)nols. We obtained the ITC data 
for the phenyl alkanols using the established protocol where the protein concentration is 
normalized based on ligand concentration.  
The thermodynamics of binding for ligands A6, A7, and A8 were previously 
reported by the Homans group,cxxvii and they are shown here with their respective alkenols 
which were previously unknown. Accordingly, we observed for both the alkyl and phenyl 
alka(e)nols that the binding affinity correlated well with the number of methylene groups 
in the alkyl chain. Therefore, ligands A7, A72E and A73E have a similar affinity for 
MUP-I that is different from the respective six and eight carbon analogues.  The phenyl 
alkanols show the same trend, such that the ligands ligands PA3, PA3(2E) and PA3(2Z) 
all have similar binding affinities within error. 
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Table 2.10.1. ITC binding studies alkylalkanols with MUP, at 298 K in PBS buffer, pH 7.4, 










A6  –6.2 ± 0.07 –11.7 ± 0.3 5.0 ± 0.3 
A6(2E)  –6.5 ± 0.02 –10.6 ± 0.4 4.1 ± 0.4 
A6(2Z)  –6.2 ± 0.02 –9.7 ± 0.8 3.5 ± 0.8 
A6(3E)  –6.3 ± 0.02 –9.4 ± 0.07 3.1 ± 0.4 
A6(3Z)  –6.2 ± 0.02 –9.3 ± 0.3 3.1 ± 0.3 
A6(5)  –6.1 ± 0.02 –10.9 ± 0.02 4.8 ± 0.02 
A7  –7.9 ± 0.05 –13.4 ± 0.4 5.5 ± 0.4 
A7(2E)  –8.2 ± 0.5 –12.7 ± 0.9 4.5 ± 0.5 
A7(3Z)  –7.2 ± 0.02 –10.0 ± 0.05 2.8 ± 0.07 
A8  –8.8 ± 0.1 –14.5 ± 0.5 5.6 ± 0.2 
A8(2E)  –8.5 ± 0.05 –12.6 ± 0.3 4.1 ± 0.5 
A8(3Z)  –8.1 ± 0.02 –11.8 ± 0.1 3.8 ± 0.1 
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PA3 0.71 –6.9 ± 0.02 –12.2 ± 0.02 5.3 ± 0.02 
PA3(2E) 0.50 –6.8 ± 0.02 –11.4 ± 0.4 4.6 ± 0.1 
PA3(2Z) 0.80 –6.7 ± 0.02 –8.4 ± 0.5 1.7 ± 0.1 
PA4 0.66 –7.4 ± 0.02 –13.8 ± 0.7 6.4 ± 0.07 
PA4(3E) 0.75 –7.2 ± 0.02 –12.0 ± 0.02 4.8 ± 0.02 
PA4(3Z) 0.75 –7.3 ± 0.02 –11.0 ± 0.6 3.7 ± 0.07 
PA5 0.71 –8.3 ± 0.02 –16.5 ± 0.05 8.2 ± 0.05 
PA5(3E) 0.85 –7.9 ± 0.5 –12.7 ± 0.4 4.8 ± 0.5 
PA5(4E) 0.84 – 8.3± 0.02 –13.4 ± 0.5 5.2 ± 0.07 
PA5(4Z) 0.85 –7.7 ± 0.02 –13.1 ± 0.7 5.4 ± 0.02 
a n-values were normalized to upon adjusting the protein concentration to the known ligand 
concentration 
 
Observed Thermodynamics of Binding: Methylene Removal. The difference in the 
observed thermodynamic parameters of binding, ΔΔGºobs, ΔΔHºobs, and TΔΔSºobs, 
between each member of the n-alka(e)nol and phenylalka(e)nol series and each analogous 
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member that possesses one fewer methylene groups, which are the energetic 
consequences of methylene removal, are given in Tables 2.10.3 and 2.10.4, respectively. 
For the alkyl alkanols, we observed that a removal of a methylene group on average 
eventuates in a slightly favorable change in TΔΔSºobs  of 0.2 kcal•mol-1 that is dominated 
by an unfavorable ΔΔHºobs of 1.2 kcal•mol-1 such that ΔΔGºobs for the alchemical 
modification is unfavorable by 1.0 kcal•mol-1. Similarly, we observed for the 
phenylalka(e)nols that the removal of a methylene group across the series eventuates in 
favorable binding entropies that are more than compensated by unfavorable binding 
enthalpies such that ΔΔGºobs is 0.6 kcal•mol-1. 
Next, we compared the two data sets of phenyl and alkylalka(e)nols. We found that 
on average the ΔΔGºobs for the removal of a methylene group from the n-alka(e)nol series 
is more unfavorable by 0.4 kcal•mol-1 than for the phenyl alka(e)nols because the average 
TΔΔSºobs of the former is less favorable by a statistically significant 0.9 kcal•mol-1 than 
that for the latter. The average ΔΔHºobs for removing a methylene from the n-alka(e)nols 
is less unfavorable than that for the phenylalka(e)nols, but these values are not 
significantly different as their error ranges overlap. That TΔΔSºobs for the removal of a 
methylene group from the n-alka(e)nols is significantly less favorable than for the phenyl 
alka(e)nols may reflect differences in the energetics of ligand desolvation, which will be 
further discussed in a following section. Lastly, we observed that the binding free 
energies of the ligand pairs A6/PA3, A7/PA4, and A8/PA5 are similar, suggesting that a 
phenyl ring is the approximate equivalent of a trimethylene group with regard to binding 
affinity for this biological system. 
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A8→A7 0.9 ± 0.1 1.0 ± 0.1 –0.1 ± 0.2 
A7→A6 1.1 ± 0.4 1.6 ± 0.3 –0.5 ± 0.3 
A8(2E)→A7(2E) 0.3 ± 0.5 -0.1 ± 4.1 0.4 ± 0.5 
A7(2E)→A6(2E) 1.7 ± 0.5 2.1 ± 4.3 –0.4 ± 0.7 
A8(3Z)→A7(3Z) 0.9 ± 0.05 1.8 ± 0.7 –0.9 ± 0.2 
A7(3Z)→A6(3Z) 1.0 ± 0.05 0.7 ± 1.3 0.3 ± 0.3 















PA5→PA4 0.9 ± 0.07 2.7 ± 1.0 –1.8 ± 1.3 
PA4→PA3 0.6 ± 0.02 1.6 ± 0.8 –1.1 ± 0.4 
PA5(4E)→PA4(3E) 1.0 ± 0.02 1.4 ± 0.9 –0.4 ± 0.4 
PA4(3E)→PA3(2E) 0.4 ± 0.05 0.7 ± 0.8 –0.3 ± 0.1 
PA5(4Z)→PA4(3Z) 0.4 ± 0.02 2.1 ± 0.9 –1.7 ± 0.07 
PA4(3Z)→PA3(2Z) 0.7 ± 0.02 2.7 ± 3.2 –2.0 ± 0.1 
Average 0.6 ± 0.02 1.8 ± 1.4 –1.2 ± 0.07 
  
 
In summary, we observed for the phenylalka(e)nols and alkylalka(e)nols that 
methylene group removal is accompanied by a dominating penalty in binding enthalpy 
that is slightly offset by an enhanced entropy. This is presumably due to the occurrence of 
a dewetted, hydrophobic binding pocket where nonpolar, nondirectional dispersive 
interactions dominate the binding process.cxxvii, cxxxv  Similar trends in binding 
thermodynamics were reported by Stone and coworkers upon the addition of methylene 
groups to thiazole derivatives which bind to MUP-I.xcix They also observe that a favorable 
change in binding entropy is dominated by an unfavorable change in binding enthalpy 
such that the overall process is unfavorable for methylene group removal. 
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However, these results stand in contrast to several systems in which the 
removal/addition of methylene groups were studied. For example, Engberts et. al. 
previously studied the effect of incremental removal of methylene units to 
benzamidinium chloride inhibitors on the thermodynamics of their binding to trypsin. 
They found that such removal of methylene groups to benzamidinium chloride inhibitors 
to trypsin led to a decrease in affinity that was accompanied by an unfavorable 
entropy.cxxxvi It is also worth noting Whitesides’ studies on carbonic anhydrase II binders 
that also varied in the number of methylene groups.cxxxvii Therein, it was determined that 
the removal of methylene groups to benzenesulfonamide derivatives resulted in losses in 
both binding entropy and enthalpy such that the overall binding affinity decreased.  
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2.11   Observed Thermodynamics of Binding: Insertion of Internal Olefin. 
Table 2.11.1 Difference in observed ITC for the insertion of a C-C double bond into 










A6→A6(2E) 0.3 ± 0.1 1.2 ± 0.1 –0.8 ± 0.2 
A6→A6(2Z) 0.8 ± 0.4 2.4 ± 0.07 –1.5 ± 0.3 
A6→A6(3E) 0.5 ± 0.5 2.4 ± 1.0 –1.9 ± 0.5 
A6→A6(3Z) 0.6 ± 0.5 2.4 ± 1.0 –1.8 ± 0.6 
A6→A6(5) 0.7 ± 0.05 0.9 ± 0.7 –0.2 ± 0.2 
A7→A7(2E) -0.3 ± 0.05 0.8 ± 0.3 –1.1 ± 0.3 
A7→A7(3Z) 0.7 ± 0.1 3.4 ± 0.2 –2.7 ± 0.2 
A8→A8(2E) 0.3 ± 0.1 1.9 ± 0.3 –1.6 ± 0.4 
A8→A8(3Z) 0.7 ± 0.1 2.6 ± 0.2 –1.9 ± 0.2 
Average* 0.5 ± 0.07 2.1 ± 0.1 –1.7 ± 0.1 
(E) 0.2 ± 0.1 1.6 ± 1.2 –1.3 ± 0.2 
(Z) 0.7 ± 0.05 2.7 ± 0.1 –2.0 ± 0.1 
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Table 2.11.2 Difference in observed ITC for the insertion of a C-C double bond 










PA3→PA3(2E) 0.0 ± 0.2 0.7 ± 0.6 –0.7 ± 0.1 
PA3→PA3(2Z) 0.2 ± 0.02 3.9 ± 0.7 –3.6 ± 0.1 
PA4→PA4(3E) 0.2 ± 0.02 1.7 ± 1.0 –1.6 ± 0.1 
PA4→PA4(3Z) 0.1 ± 0.02 2.7 ± 0.9 –2.7 ± 0.1 
PA5→PA5(3E) 0.4 ± 0.1 3.8 ± 0.8 –3.4 ± 0.6 
PA5→PA5(4E) 0.02 ± 0.07 3.1 ± 0.9 –3.0 ± 0.3 
PA5→PA5(4Z) 0.6 ± 0.07 3.4 ± 1.0 –2.7 ± 0.3 
Average 0.2 ± 0.05 2.8 ± 0.3 –2.6 ± 0.5 
(E) 0.2 ± 0.05 2.4 ± 0.4 –2.2 ± 0.2 
(Z) 0.3 ± 0.02 3.3 ± 0.5 –3.0 ± 0.1 
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The difference in the observed thermodynamic parameters accompanying 
the introduction of an internal olefin between the n-alkanol and phenylalkanol 
series and each analogous member of the n-alkenol and phenylalkenol series are 
given in Tables 2.11.1 and 2.11.2, respectively. Accordingly, we observed that for 
the n-alkanols, a favorable TΔΔSºobs of 1.7 kcal•mol-1 is compensated by an 
unfavorable ΔΔHºobs of 2.1 kcal•mol-1 but to a weaker extent than was observed 
for methylene removal, such that the resulting alkenols are equipotent. Hence, we 
do observe a favorable change in the entropy of binding upon the insertion of a C-
C double bond, which is in agreement with what is expected for the lowering of 
ligand conformational entropy, this benefit in entropy is wiped out by a penalty in 
binding enthalpy that presumably arises from entropy/enthalpy compensation.  
Similarly for the phenylalkanols, a favorable change in binding entropy of 2.6 
kcal•mol-1 accompanies the insertion of an internal olefin that is also compensated 
by an unfavorable change in enthalpy of 2.8 kcal•mol-1 such that the resulting 
phenylalkenols are equipotent. Again, we observe that although unfavorable 
changes in ∆∆H° compensate favorable changes in entropy, but to a weaker extent 
than was observed for the removal of a methylene. The average values are also 
given in Tables 2.11.1 and 2.11.2.  
The ΔΔGºobs for the introduction of Z-olefins into the n-alkanols and 
phenylalkanols is 0.5 and 0.1 kcal•mol-1 more unfavorable, respectively, than that 
for the introduction of E-olefins, which for all intents and purposes is a rather 
insignificant difference. That larger differences in the free energies of binding 
between Z- and E-olefins are not observed suggests the lack of any 
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configurational preference by the protein. Interestingly, we observed that 
TΔΔSºobs for the introduction of the terminal olefin is on average more favorable 
than the modification of methylene removal, which is interesting. One notable 
exception to this trend is that the modification of A6 to A6(5) is only +0.9 
kcal•mol-1, which is similar to what was observed for the removal of a methylene 
group. These changes in thermodynamic parameters upon binding to MUP-I for 
the insertion of an internal olefin into the phenyl and alkylalka(e)nols depict that 
there is a larger entropic benefit upon binding for modifying the ligand with an 
internal olefin than for methylene removal.  
There have been few systematic studies on the utility of the introduction of an 
internal C–C double bond as a means to preorganize a protein-binding ligand into 
a constrained conformation,cxxxviii,cxxxix and to the best of our knowledge there has 
been no known evaluation of this class of rotor restriction that includes ITC 
analysis. In a rather encompassing study of µ-opiod receptors (MOR), Verdine 
and coworkers inserted both E– and Z–olefins into methyl linkers of several 
closely related, flexible mimics of a known high-affinity binder. cxl  It was 
discovered that the ligands containing E–olefins generally bound better than the 
flexible mimics, which subsequently bound better than the ligands restricted with 
Z–olefins in the methylene linker. That this trend is not observed in our system is 
not all that surprising given the directional interactions that are required for 
favorable binding interactions to MORs, which is not the case for MUP-I since its 
binding interactions are dominated by non-directional vdW interactions.  
Intrinsic Analysis: 
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Water plays a significant role in the thermodynamics of protein-ligand 
interactions, but quantifying its role is difficult. While displacing a bound water 
molecule during complex formation is generally regarded as having an 
entropically favorable consequence, cxli  predicting the contribution of solvent 
reorganization to binding thermodynamics is a formidable task because it depends 
upon relative changes in the dispersive interactions arising from protein and 
ligand desolvationcxlii and upon the surface topology of the protein binding domain 
and the ligand.cxliii Protein-ligand binding can be decomposed by way of a Born-
Haber cycle (see Section 1.2) to obtain the thermodynamic parameters arising 
from complex formation in the absence of solvent, herein referred to as the 
‘intrinsic’ thermodynamic parameters. Accordingly, a protein-ligand interaction in 
water may be described as follows:  
 
 
where L, P, and C denote ligand, protein, and complex, respectively, and the 
number of water molecules hydrating each is given by x, y, and z. The observed 
free energy of complexation ΔGºobs is then given by the expression: 
ΔGºobs = ΔGºint – ΔGºhyd,L+P + ΔGºhyd,C                                                                 (2.3) 
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where ΔGºint is the intrinsic free energy for complex formation, ΔGºhyd,L+P is the 
sum of the free energies of hydration of unbound ligand and apo protein, and 
ΔGºhyd,C is the free energy of hydration of the protein-ligand complex. If one 
makes the simplifying assumption that the free energy change associated with 
hydration of the complex, ΔGºhyd,C, is the same for two closely related ligands L1 
and L2 interacting with the same protein, then the difference in the intrinsic free 
energies of complex formation between ligands L1 and L2, ΔΔGºint,2-1, is given by 
the expression: 
∆∆Gºint,2-1 = ΔGºint,2 – ΔGºint,1 = 
(ΔGºobs,2 – ΔGºobs,1) + (ΔGºhyd,2 – ΔGºhyd,1)                                                          (2.4) 
 
Given the structural simplicity of the ligands employed in this study, it is 
possible to estimate their hydration free energies, ∆Ghyd,L, and enthalpies, ∆Hhyd.L, 
using group contributions that are based on compilations of experimentally 
determined values for hydrocarbons and monohydric alcohols at 298 K.cxliv With 
these values, differences in the intrinsic thermodynamic parameters of binding, 
ΔΔGºint, ΔΔHºint, and TΔΔSºint, for methylene group removal and the introduction 
of an internal olefin were calculated. 
We observed that the differences in the intrinsic thermodynamic values 
accompanying the removal of methylene groups for the alkyl alka(e)nols are 
similar to differences in the observed values. Namely, the individual 
modifications are characterized by a favorable TΔΔSºint that is dominated by an 
unfavorable ΔΔHºint with the result ΔΔGºint for each is unfavorable. For the 
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phenyl alka(e)nols we see this same trend such that favorable gains in binding 
entropy are negated by unfavorable changes in binding enthalpy.  The average 
values over the set of n-alka(e)nols and phenylalka(e)nols are given in Tables 
2.11.3 and 2.11.4 respectively.  
When we compare the phenyl and alka(e)nols, we find that the average ΔΔGºint 
for the removal of a methylene group from the n-alka(e)nols is more unfavorable 
by 0.4 kcal•mol-1 than for the phenyl alka(e)nols because the average TΔΔSºint of 
the former is less favorable by a statistically significant 1.5 kcal•mol-1 than that of 
the latter. The average ΔΔHºint for the n-alka(e)nols is less favorable than that for 
the phenylalka(e)nols is evident, but the difference is not statistically significant. 
Because the observed and intrinsic thermodynamic values accompanying the 
removal of methylene groups for the two series of ligands exhibit a similar trend, 
our analysis suggests that differences between the two series do not arise from 
solvent reorganization accompanying binding. Rather, they are more likely the 
result of dissimilarities in dispersive or vdW interactions in the different protein-
ligand complexes. We consider this a significant discovery for the utility of 
intrinsic analysis, as our results have revealed important details regarding specific 
protein-ligand interactions that were before unforeseen.  
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Table 2.11.3 Intrinsic difference in observed ITC for the removal of a methylene group in 












A8→A7 0.7 ± 0.9 1.9 ± 0.6 –1.2 ± 0.6 
A7→A6 0.9 ± 0.7 2.5 ± 0.6 –1.6 ± 0.7 
A8(2E)→A7(2E) 0.1 ± 2.2 0.8 ± 1.1 –0.7 ± 0.8 
A7(2E)→A6(2E) 1.5 ± 2.2 3.0 ± 1.1 –1.5 ± 0.9 
A8(3Z)→A7(3Z) 0.7 ± 0.1 2.7 ± 0.5 –2.0 ± 0.6 
A7(3Z)→A6(3Z) 0.8 ± 0.1 1.6 ± 0.6 –0.8 ± 0.7 
Average 0.8 ± 0.1 2.1 ± 0.3 –1.3 ± 0.3 
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PA5→PA4 0.7 ± 0.3 3.5 ± 4.2 –2.9 ± 0.3 
PA4→PA3 0.4 ± 0.2 2.5 ± 3.6 –2.2 ± 0.1 
PA5(4E)→PA4(3E) 0.8 ± 0.2 2.2 ± 3.6 –1.4 ± 0.2 
PA4(3E)→PA3(2E) 0.2 ± 0.2 1.5 ± 3.5 –1.3 ± 0.2 
PA5(4Z)→PA4(3Z) 0.2 ± 0.2 2.9 ± 3.9 –2.8 ± 0.2 
PA4(3Z)→PA3(2Z) 0.2 ± 0.2 1.5 ± 3.5 –1.3 ± 0.2 
Average 0.1 ± 0.2 3.6 ± 3.3 –3.1 ± 0.2 
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Intrinsic Thermodynamics of Binding: Insertion of Internal Olefin The 
average values over the set of n-alkanols (collected by Richard Malham) and 
phenylalkanols are given in Tables 2.11.5 and 2.11.6. Differences in the intrinsic 
thermodynamic values resulting from the introduction of an internal olefin do not 
follow the same trend as the observed values. Whereas ΔΔGºobs is relatively 
equipotent for most of the individual modifications where an internal olefin is 
introduced because a favorable TΔΔSºobs is compensated by an unfavorable 
ΔΔHºobs, ΔΔGºint is favorable for all modifications because a favorable TΔΔSºi 
dominates an unfavorable ΔΔHºint.  Furthermore, the effect of solvent on enthalpy 
is minimal in that ΔΔHºint is only slightly more favorable than ΔΔHºobs for the 
insertions of an internal olefin. It is the effect of solvent on entropy that dictates 
the sign of the free energy differences associated with introducing an internal 
olefin. For the individual modifications, TΔΔSºint is more favorable than TΔΔSºobs 
by ~ 1.2 kcal•mol-1 because the entropy associated with desolvation of the 
saturated ligands is more favorable than that for the unsaturated analogs. 
The average ΔΔGºint for the introduction of an internal olefin into the n-
alkanols is 0.2 kcal•mol-1 less favorable than that for phenylalkanols because the 
average TΔΔSºint for the former is less favorable by a statistically significant 0.9 
kcal•mol-1 than the latter. Hence, the data suggests that the phenylalkanols benefit 
from the introduction of an internal olefin to a slightly greater extent than the n-
alkanols due to a more favorable entropic component that may be the result of 
reduced conformational entropy in the unbound state.  However, this benefit is 
negated by an enthalpic penalty.   
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Table 2.11.5 Intrinsic difference in intrinsic ITC for the insertion of a C–C double bond 










A6→A6(2E) –0.6 ± 0.2 1.4 ± 0.7 –2.0 ± 0.8 
A6→A6(2Z) –0.3 ± 0.2 2.3 ± 0.6 –2.6 ± 0.6 
A6→A6(3E) –0.4 ± 0.2 2.5 ± 0.6 –3.0 ± 0.5 
A6→A6(3Z) –0.3 ± 0.2 2.6 ± 0.6 –2.9 ± 0.7 
A6→A6(5) 0.02 ± 0.2 1.1 ± 0.5 –1.1 ± 0.7 
A7→A7(2E) –1.2 ± 0.5 0.9 ± 1.1 –2.2 ± 0.6 
A7→A7(3Z) –0.2 ± 0.1 3.6 ± 0.6 –3.8 ± 0.7 
A8→A8(2E) –0.6 ± 0.3 2.1 ± 0.6 –2.7 ± 0.6 
A8→A8(3Z) –0.2 ± 0.3 2.8 ± 0.6 –3.0 ± 0.6 
Average* –0.5 ± 0.07 2.3 ± 0.07 –2.8 ± 0.2 
(E) –0.3 ± 0.1 1.7 ± 0.4 –2.4 ± 0.4 
(Z) –0.2 ± 0.4 2.8 ± 0.3 –3.1 ± 0.3 
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Table 2.11.6. Intrinsic difference in intrinsic ITC for the insertion of a C–C double bond 










PA3→PA3(2E) –0.9 ± 0.2 1.0 ± 0.8 –1.9 ± 0.5 
PA3→PA3(2Z) –0.7 ± 0.2 4.0 ± 0.8 –4.7 ± 0.5 
PA4→PA4(3E) –0.7 ± 0.2 2.0 ± 1.2 –2.7 ± 0.5 
PA4→PA4(3Z) –0.8 ± 0.2 3.0 ± 1.1 –3.8 ± 0.5 
PA5→PA5(3E) –0.5 ± 0.3 4.0 ± 1.0 –4.5 ± 0.8 
PA5→PA5(4E) –0.9 ± 0.2 3.2 ± 1.1 –4.1 ± 0.6 
PA5→PA5(4Z) –0.3 ± 0.2 3.6 ± 1.1 –3.9 ± 0.6 
Average –0.7 ± 0.07 3.0 ± 0.4 –3.7 ± 0.2 
(E) –0.8 ± 0.1 2.6 ± 0.5 –3.3 ± 0.3 
(Z) –0.6 ± 0.1 3.5 ± 0.6 –4.1 ± 0.2 
 
 113 
We noticed that the introduction of an internal olefin into the n-alkanols 
and phenylalkanols gave intrinsic entropies that were consistently two-fold larger 
in magnitude than those observed for the removal of a methylene unit. It should 
be mentioned that this result, taken together with the previously discussed result 
of inserting a terminal olefin into A6 suggests that an internal olefin yields more 
favorable intrinsic entropies than either introducing a terminal olefin or removal 
of a methylene group.  
It should be stated that the solvation parameters for calculating the 
intrinsic values do not depend on location or geometry of the olefin.  In general, 
we found that ΔΔGºint for the introduction of E-olefins into both the n-alkanol and 
phenylalkanol series is 0.5 and 0.2 kcal•mol-1 more favorable, respectively, than 
that for the introduction of Z-olefins because ΔΔHºint for the introduction of Z-
olefins is less unfavorable. Since larger differences in the free energies of binding 
between Z- and E-olefins are not observed, there appears to be no configurational 
preference by the protein. 
2.12   Crystal Structures 
Crystallographic Analysis. X-ray crystal structures of MUP-I in complex with 
alkyl alcohols A6, A6(3Z), A6(2E), A7, A7(3Z), A7(2E), A8, A8(3Z), and 
A8(2E) were obtained to a resolution of <1.5 Å by C. Lee at Leeds University. 
The structures of the complexes with aryl alcohols PA3, PA3(2E), PA4, PA4(3E), 
PA5, and PA5(3E), were obtained to a resolution of <2.0 Å research scientist Dr. 
John Clements. Backbone atoms belonging to the protein in the complexes of the 
n-alka(e)nols align closely, with pair wise RMSDs <0.2 Å. However, the position 
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and conformation of the bound ligands in the pocket vary considerably from one 
complex to another. For example, while A6 and A7 both bind such that their 
hydroxyl oxygen atoms make direct polar contacts with the hydroxyl oxygen 
atom of Tyr120, the alkyl chains belonging to these ligands extend in different 
directions within the pocket, and their terminal methyl carbon atoms of the 
terminal methyl groups occupy positions that are >9 Å from one another in 
aligned complexes. This is not an unusual observation given that the lipophilic 
molecule 2-sec-butyl-4,5-dihydroxythiazole was found via X-ray crystallography 
to bind to MUP-I in different poses.cxlv Moreover, it was previously shown by the 
Homans groups that 1-pentanol bound to MUP-I with different binding modes, 
each having partial occupancy. 
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Figure 2.12.1 Complexes of MUP-I with the n-alka(e)nols obtained at Leeds University. Oxygen and 
nitrogen atoms are colored red and blue, respectively.a 
                                        
 
(a)                                                           (b)    
                                   
(c)            (d) 
 
aCarbon atoms belonging to the protein (line, cartoon) are colored green while those 
belonging to the ligands (sticks) are colored cyan or magenta, the latter shown for 
complexes in which the bound ligands occupy more than one pose. Protein-ligand direct 
contacts and those mediated by water molecules (red spheres) are indicated with dashed, 
black lines. (a) Complex with A6. (b) Complex with A6(2E). (c) Complex with A6(2Z). (d) 




Figure 2.12.2 Complexes of MUP-I with the n-alka(e)nols.a 
                                    
(a)                                         (b)     
                                   
            (c)                                         (d)     
                                 
(e)                                                                                                      (f) 
aOxygen and nitrogen atoms are colored red and blue, respectively. Carbon atoms 
belonging to the protein (line, cartoon) are colored green while those belonging to the 
ligands (sticks) are colored cyan or magenta, the latter shown for complexes in which 
the bound ligands occupy more than one pose. Protein-ligand direct contacts and those 
mediated by water molecules (red spheres) are indicated with dashed, black lines. (a) 
Complex with PA3. (b) Complex with PA3(2E). (c) Complex with PA4. (d) Complex with 






Figure 2.12.3 Complexes of MUP-I with the n-alka(e)nols.a 
                         
(a) (b) 
                         
(f)                                                                                         (g) 
aOxygen and nitrogen atoms are colored red and blue, respectively. Carbon atoms 
belonging to the protein (line, cartoon) are colored green while those belonging to 
the ligands (sticks) are colored cyan or magenta, the latter shown for complexes in 
which the bound ligands occupy more than one pose. Protein-ligand direct contacts 
and those mediated by water molecules (red spheres) are indicated with dashed, 
black lines. (e) Complex with A7(2E). (f) Complex with A7(3Z). (g) Complex with 




While some of the ligands in the complexes participate in direct and/or water- 
mediated polar contacts to MUP-I, others do not (Figure 2.13.2-2.13.4), suggesting 
that maintaining a conserved protein-ligand polar contact network is not a 
prerequisite for the binding of ligands to this protein. For example, n-alkenols 
A6(2E) and A6(3Z) make no direct or water-mediated contacts to the protein in their 
respective complexes (Figure 2.13.2). It is clear that certain residues belonging to the 
protein do recur frequently when analyzing polar networks in the different 
complexes, and these are Phe38, Leu40, and Tyr120 (Figure 2.13.1 a), which have 
polar interactions with the ligands either directly or through water-mediated contacts 
in several of the complexes, the former two via their backbone carbonyl oxygen 
atoms. 
In those complexes for which ligands bind in two different poses (Figure 2.13.2 d, 
g and Figure 2.13.3 a, b, g), the OH group of the ligand in one pose makes more 
polar contacts with Tyr120, but in the other pose the ligand makes no such contacts. 
Inspection of the images also leads us to conclude that longer n-alka(e)nols tend to 
make more polar contacts with Tyr120 and water networks than shorter ones due to 
more extensive H2O networks. This observation would seem to run counter to the 
previous assumption that complexes of related ligands have similar thermodynamic 
parameters of hydration; However, upon examining closely related ligands, e g. 
those differing by a single methylene unit or internal double bond (Figure 2.12.3 a 
and g), the assumption appears to still be valid.  
As observed in Figure 2.12.3 c, polar protein networks with PA4 involving direct 
and water-mediated contacts to Phe38, Leu40, and Tyr120 of MUP-I were also 
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observed for the phenylalka(e)nols. Once again, in the complexes for which ligands 
bind in two different poses, the ligand in one makes more polar contacts with the 
protein, but in the other pose it does not. Unlike the n-alka(e)nols, however, the 
networks of polar contacts do not appear to be dependent on the size of the ligand d 
(Figure 2.13.4), and similar contact networks were observed for all ligands in the 
phenylalka(e)nol series. Given the size of MUP-I binding pocket, it is interesting 
that, with the exception of A6, no more than two crystallographic water molecules 
were observed in the pocket of the complexes with n-alka(e)nols, phenylalka(e)nols, 
or the apo structure,cxlvb supporting the hypothesis that the pocket may be 
dewetted.cxlvi  
Assessing the assumption that hydration differences of protein complexes for two 
comparable ligands are minimal. It was crucial for us to scrutinize the role of water, 
because assuming solvation of the protein complex is the same for different ligands 
is necessary to calculate our intrinsic binding data. Accordingly, the number of 
crystallographic water molecules observed in the binding pocket of the complexes 
were tallied and differences in this number were recorded for ligands based upon 
methylene group removal and introduction of an internal olefin (Table 2.12.1). For 
both the n-alka(e)nols and the phenylalka(e)nols, methylene group removal is 
accompanied by an average increase of 0.50 crystallographic water molecules, 
whereas the introduction of an internal olefin is accompanied by an average 
decrease of 0.22 water molecules (Table 2.12.2). The variations in hydration of the 
protein are thus evident, but these are rather small. Larger ligands tend to displace a 
greater number of water molecules, but there is no correlation between differences in 
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the number of crystallographic water molecules in the pocket and differences in 
ligand Connolly surface area.cxlvii  
We also examined average all-atom B factors, which are thought to be a 
barometer of relative protein dynamics.cxlviii It is postulated that larger B-factors are 
an indication of greater thermal motion in the complexes for a series of varying 
proein-ligand bound structures. However, it has been questioned whether B-factors 
can be accurately correlated with thermodynamic parameters such as entropy and 
enthalpy. Specifically, in a series of Grb2 SH2 bound ligands wherein the B-factors 
were tallied, it was found that the B-factors were generally smaller for the ligands 
that bound with more favorable entropies compared to a set of constrained ligands 
that bound with more favorable enthalpies.lxxvi For this current work, we investigated 
All-Atom B-factors and found no significant correlations between the 
thermodynamic parameters of the phenyl and alkylalka(e)nols. (table 2.12.1).  
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Table 2.12.1. Structural features of the complexes.a 
 
Average All-Atom B-factor  
(Å2)[a] 
Complex 








A6 25.0 17.2 31.8 3 143.3 
A6(2E) 20.2 14.8 37.6 2 137.7 
A6(3Z) 18.7 14.7 24.2 2 136.4 
A7 22.8 14.7 34.8 3 158.1 
A7(2E) 
 










A8 24.5 17.6 30.9 1 176.4 
A8(2E) 
 









PA3 22.4 17.1 29.3 2 158.0 
PA3(2E) 22.4 16.6 39.0 2 153.1 




PA4(3E) 22.1 15.1 34.6 1 196.9 
PA5 21.4 16.1 22.2 1 196.9 




[a] Average all-atom B-factor data were adjusted according to the method 
recommended by Ringe et al.cxlix for comparing data obtained from different crystals [b]. 
Residues comprising the binding pocket were defined as those that make at least one 
contact to the ligands in at least one of the complexes. These are Leu24, Phe38, Leu40, 
Leu42, Ile45, Leu54, Phe56, Phe90, Ile92, Leu101, Leu105, Leu116, and Tyr120. [c] In 
the case of multiple binding modes, average all-atom B-factor and CSA data are reported 
for each ligand pose. [d] Number of crystallographic water molecules found in the 




Table 2.12.2. Change in number of bound waters averaged per modification. 
 
Modification 




∆ No. bound 
H2O 
A6→A6(2E) -1 A8→A7 2 
A6→A6(3Z) -1 A8(3Z)→ A7(3Z) 0 
A7→A7(2E) -1 A8(2E)→ A7(3E) 1 
A7→A7(3Z) -1 A7→A6 0 
A8→A8(2E) 0 A7(3Z)→A6(3Z) 0 
A8→A8(3Z) 1 A7(2E)→A6(2E) 0 
PA3→PA3(2E) 0 PA5→PA4 1 
PA4→PA4(3E) 1 PA5(3E)→PA4(3E) 0 
PA5→PA5(3E) 0 PA4→PA3 0 
Average -0.22 PA4(3E)→PA3(2E) 1 
  Average 0.50 
 
 
We do observe that CSA correlates strongly with ΔHºobs for the Homans n-
alkanols A6 A7, and A8 (R2 = 0.96) and our phenylalkanols PA3, PA4 and PA5 (R2 
= 0.98) with slopes of -0.08 and -0.11 kcal•mol-1Å-2, respectively (graph 2.12.1). 
These values closely match those obtained for the correlation of non-polar CSA and 
ΔHºobs for the binding of pYXN tripeptides to Grb2 SH2 (-0.11 kcal•mol-1Å-2).cli We 
also observed a correlation, albeit weaker, between the number of protein-ligand 
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vdW contacts and ΔHºobs for the phenylalkanols PA3, PA4 and PA5 (R2 = 0.62)  and 
phenylalkenols PA3(2E), PA4(3E) and PA5(3E) (R2 = 0.72). Since there is a 
correlation between the burial of ∆CSA with an increase in tallied vdW contacts in 
the binding pocket, one may assume in this case that the binding is driven in part by 
the propensity of the ligand to make favorable vdW interactions. Since the binding 
pocket of the apo structure is dewetted,cxxxv  then the amount of dispersive 
interactions gained during the protein-ligand association over-compensate for 
interactions that are lost between the protein and solvent.  
Lastly, in an effort to elucidate the effect of changes in the number of bound water 
molecules on the thermodynamics of binding, the crystallographic datasets were 
examined for each modification type (across both observed and intrinsic data) and 
separated such that the individual modifications (i.e. rotor removal and rotor 
restriction) in which changes in the hydration of the bound complex were observed 
upon the testing the modified ligand (that is to say, methylene removed or olefin 
inserted) were placed in one subset while the individual modifications for which no 
changes in hydration of the bound complex were observed were placed in another 
subset. The two sets were compared and the average observed thermodynamic 
parameters associated with each were not found to be statistically different, 
suggesting that there are no significant differences in solvation parameters of the 
protein complexes over a set of closely related  molecules.  
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Graph 2.12.1. Graph depicting the relationship between Ligand CSA and ∆Hobs° 
  
 
2.13   Summary and Conclusion 
 
We studied the thermodynamic and structural effects of modifying alkyl 
chains of  phenylalka(e)nols that bind to MUP-I by removing a rotor via deletion 
of a methylene unit and restriction of a rotor via the installation of an internal 
olefin. Our collaborators from the Homans group at Leeds University did the 
analogous studies on a series of n-alka(e)nols.  
We addressed several critical questions regarding protein-ligand interactions. 
These included: (1) a systematic analysis of the thermodynamic effects of 
restricting a rotor by introducing an internal olefin, (2) unveiling the “solvent 
y = -109.77x + 5200.2 
























Ligand CSA (A^2) 
∆CSA correlation of P3 through P5 to ∆Hobs 
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free” or intrinsic binding analysis to ascertain pertinent solute-solute interactions, 
(3) studying the “equivalence” of rotor removal by comparing results of 
restricting rotors via an internal olefin vs. methylene deletion, and (4) structure-
thermodynamic between thermodynamic parameters of binding such as entropy 
and enthalpy, and structural characteristics in the pocket such as dispersive 
interactions and buried Connolly surface area..  
In general, we observed that for the n-alka(e)nols the insertion of an internal 
olefin gives significantly more favorable binding entropies than does methylene 
removal, yet enthalpy-entropy compensation leads to nearly equipotent binding 
energetics for the observable data. Similar thermodynamic trends were observed 
for the phenylalka(e)nols such that a favorable TΔΔSºobs is offset by an 
unfavorable ΔΔHºobs so that there are no significant gains in ΔΔGºobs for either 
removal of a methylene and insertion of an internal olefin. No significant 
thermodynamic distinction was observed between the introduction of E- and Z-
olefins, implying that the MUP-I binding pocket has no preference for one over 
the other. 
 To develop a clearer understanding of the differences that we observed 
between the thermodynamics of binding of the phenylalkanols and alkylalkanols, 
we calculated the “solvent free” or intrinsic thermodynamics of binding to 
determine if differences arose from the solvent or from dispersive interactions. We 
employed an intrinsic analysis approach to this protein system to decompose 
ligand binding, which was possible because all hydration parameters of these 
ligands could be calculated. The results of these calculations indicated that the 
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intrinsic energetics associated with methylene group removal do not differ 
markedly from the observed, suggesting that the thermodynamic signature arises 
from dispersive interactions between the protein and the ligands and not solvent 
reorganization. 
In contrast, the intrinsic free energies of introducing an internal olefin into the 
n-alkanols and phenylalkanols differ markedly from the observed data. The 
intrinsic affinities are more favorable than the observed affinities because a 
favorable TΔΔSºint dominates an unfavorable ΔΔHºint. There is little difference 
between the observed and intrinsic enthalpies, so it suggests that the effect of 
solvent reorganization on the entropic component likely accounts for the 
difference. We can thus deduce from these calculations that the enthalpy/entropy 
compensation that we observe in the thermodynamic data is in part due to solvent 
reorganization. Since the origin of enthalpy/entropy compensation has long been 
sought after, our observation that solvent reorganization plays a role in this 
phenomenon is a significant discovery that may lead to the better understanding 
of solvent reorganization in protein-ligand interactions.  
Furthermore, using our intrinsic analysis we also discovered that the 
intrinsic entropies of inserting an internal olefin are nearly double that of 
removing a methylene groups. This latter discovery is a potentially significant 
development for scoring functions that are utilized in the prediction of ligand 
binding affinities. These scoring functions currently assign equal and unbiased 
entropic penalties per rotor restricted, yet our results suggest that there is at least a 
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correlation with how a ligand’s conformation is constrained and the binding 
entropy gained from rotor restriction.  
Analysis of the X-ray crystallographic structures of complexes with the n-
alka(e)nols and phenylalka(e)nols maintained any conserved polar and/or water-
mediated networks, and ligands were frequently shown to bind in multiple poses. 
Different ligands may adopt different binding poses relative to the pocket, and the 
same ligand may adopt different poses. For both the n-alka(e)nols and the 
phenylalka(e)nols, methylene group removal is generally accompanied by an 
increase in the number of interfacial crystallographic water molecules whereas the 
introduction of an internal olefin is accompanied by a decrease in the number of 
such water molecules. However, no meaningful correlations could be found between 
differences in the number of crystallographic water molecules in the pocket with 
differences in our structural and thermodynamic parameters. Yet, we did find a 
strong correlation between ∆Gobs° and ligand CSA. Thus, this finding further 
supports the thought that MUP-I binding events are driven by favorable dispersive 
interactions made between the ligand and the protein in the binding pocket. 
For future studies, it would be important to test more examples where a terminal 
alkene is bound to MUP-I to further probe the trend that we observed where upon 
the terminal olefin bound with significant less favorable binding entropy than the 
other corresponding phenyl and alkylalka(e)nols of the data set. This dataset alone 
could shed more light onto the favorable binding entropies that were observed upon 
the insertion of an internal olefin in to these MUP-I binding alkanols. 
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Chapter 3 Studies of Increasing Ligand Hydrophobicity to a Known Protein 
Binder 
 
3.1   Introduction 
 
It is generally accepted in drug design that one may increase potency by adding 
nonpolar substituents to a drug lead.xi The rationale for this strategy is based upon a belief 
that the release of water molecules into the surrounding solvent during ligand desolvation 
is entropically favorable, in accord with the hydrophobic effect.clii,cliii  However, there are 
few studies of such “entropy-oriented” modifications where entropy and enthalpy of 
binding are determined, and even fewer that correlate the binding thermodynamics with 
structural changes in the bound complex.cliv,clv Therefore, as part of our longstanding 
interest in correlating structure with binding thermodynamics of protein-ligand 
interactions, we became interested in the effects of adding nonpolar substituents to 
protein-binding ligands. One potential model system that looked intriguing to us was a 
class of peptidic inhibitors of the Grb2 SH2 domain that were previously pursued by the 
Novartis research group as potential anti-cancer therapeutics.clvi,clvii  
3.2   Grb2 Adaptor Protein 
Growth receptor bound protein (Grb2) is a 25,000 KDa protein whose purpose in 
the mammalian cell is to function as an adaptor protein by coupling signaling receptors 
with effector proteins.clviii ,clix Grb2 consists of one SH2 domain flanked by two SH3 
domains as shown in Figure 3.2.1 bound to a peptide. This SH2 domain is known to have 
 129 
a high affinity for phosphotyrosyl peptides with the sequence pYXN, where X is usually 
an apolar side chain. The SH3 domains are responsible for forming a cellular complex 
with the proline rich region of the Son of sevenless (Sos) effector protein.  
Figure 3.2.1 X-ray of the Grb2 SH2 domain bound to a heptapeptide.  
 
 
Grb2 plays a significant role in many cellular functions, one of which is cellular 
proliferation. When a signaling receptor is activated by an external growth factor, it 
induces transphosphorylation of intracellular domains, which have a high affinity for the 
SH2 domain Grb2. Once the Grb2 SH2 domain has bound to the phosphorylated 
sequences, it relocates Sos to a position where it converts the inactive GDP-bound form 
of RAS  to its GTP-bound form. This activation then initiates the kinase cascade that is 
crucial for cellular growth (Figure 3.2.2).clx,clxi Because of this important role that Grb2 
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SH2 domains have in stimulating cellular growth, selective and potent inhibitors of this 
domain have been proposed as viable strategy for developing anti cancer therapeutics.clxii 
Figure 3.2.2 Biological role of Grb2. 
 
3.3   Experiment Design 
Significant increases in ligand potency were previously observed for the pY+3 
derived ligands relative to the corresponding analogs having a free C-termini shown in 
Figure 3.3.1. The Novartis group designed these peptides so that they could target an 
extended hydrophobic patch of the Grb2 SH2 domain. They postulated that they might be 
able to increase the potency of their initial ligands by attaching lipophilic groups to the 
pY+3 residue of various tripeptides, Although this strategy was shown to be successful, 
as a variety of the pY+3 ligands shown in figure 3.3.1 are more potent than the parent 
compound lacking the hydrophobic group (1.74), it was supported only by modeling 
studies (Figure 3.3.2) and neither X-ray analysis nor thermodynamic data were 
obtained.clvii  
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Figure 3.3.2 Known model of pY+3 susbtituents interacting with an extended hydrophobic patch 




Accordingly, we sought to design and synthesize ligands inspired by the established 
precedent shown in Figure 3.2.1 so that we could study the thermodynamic and structural 
effects of adding hydrophobicty in protein-ligand interactions utilizing ITC and X-ray 
crystallography. Given the importance of nonpolar interactions in drug discovery, we 
were interested in uncovering the origins of this phenomenon so that we could develop 
the fundamental knowledge to understand how this motif in drug design effects protein-
ligand interactions. The ligands were derived from the tripeptide framework pYXN 
(where X is a non polar residue) containing apolar substituents that were linked to the 
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pY+3 position with a three carbon chain. The framework of these ligands is shown in 
Figure 3.3.3. 
Figure 3.3.3 Ligand framework for studies on hydrophobicity. 
 
3.4   Investigation of an Appropriate Carbon Linker 
Before we initiated our studies, we first had to synthesize and test ligands to 
determine the optimal number of methylene groups to use as a linker with the terminal 
groups at the pY+3 site. Although previous studies used molecular modeling to determine 
that n = 3 is the optimal number of methylene groups to achieve favorable interactions (as 
shown in Figure 3.3.2),clvii it was imperative to determine this experimentally since so 
much of our design depended on making favorable vdW interactions with the binding 
pocket. Therefore, ligands of the type shown in Figure 3.4.1 where n was varied from one 
to five and where R = phenyl 3.06–3.09 and indolyl 3.10-3.13 were first synthesized and 
tested. Dr. Bo Cheng synthesized and tested the indolyl ligands 3.10–3.13. 
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3.4 Ligand Synthesis 
For the synthesis of ligands 3.06-3.13, we envisioned a convergent route that 
features a disconnection at the pY+2 position to provide fragments A and B (Scheme 
3.4.1).  The advantage of this approach is that it would allow use of fragment A as a 
common intermediate, that may be coupled with the N-alkyl asparagine derivative 
(fragment B) to provide the final ligands in only one step. Since the residue at the pY+1 
position is achiral, there is no risk of racemising the center upon a standard peptide 
coupling.  
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scheme 3.4.1 Retrosynthesis of desired tripeptides. 
 
Commercially available 1-amino cyclohexyl carboxylic acid (Ac6c) was first 
converted into the known benzyl ester 3.18.  After coupling 3.15 with Cbz-Tyr, the 
dipeptide 3.19 thus formed was deprotected to give 3.20 in 95% yield (Scheme 3.4.2). 
The dipeptide was then acylated using acetic anhydride in dioxane-H2O (1:1) to provide 
3.21.  Using a known procedure for the phosphorylation of tyrosine derivatives, the 
benzyl protected phosphorylated dipeptide 3.22 was obtained in 70% yield.  Overall, this 
route provided large amounts of a common intermediate to provide rapid access to all of 
the ligands needed for this study.  Indeed, the ability to stock decagram quantities of 3.22 
was useful in providing rapid and convergent access to our desired compounds. 
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scheme 3.4.2 Synthesis of Fragment A 
 
 
The Asn derivatives that would make up Fragment B were synthesized via the 
coupling Cbz-protected Asn to amines 3.23–3.30 using carbodiimide, followed by 
deprotection conditions and then deprotected to give the Asn derivatives 3.27-3.34 that 
were coupled with dipeptide 3.19 to give 3.31–3.38 in moderate yields. Global 
deprotection with H2 and 10% Pd/C provided the ligands 3.06-3.13 in 22–83%  yields.   
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scheme 3.4.3 Synthesis of desired peptides for the linker studies. 
 
 
3.5   Isothermal Titration Calorimetry 
Having ligands 3.06-3.13 now in hand, the binding energetics for the Grb2 SH2 
domain were conducted. As shown in Table 3.5.1, these ITC studies indicated a clear 
preference in ligand binding affinity for ligands having a three carbon methylene linker in 
both the phenyl and indolyl series. Namely, there is a maximum in both Ka and ∆H° at n = 
3 for the phenyl substituted ligands, and for the indolyl series, there is a maximum in 
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affinity for n = 3.  This result supports the previous hypothesis based on molecular 
docking studies that a trimethylene unit provided optimal binding affinities for the pY+3 
derivatives. We were also intrigued by the observation that the peak in binding affinity at 
n = 3 (R = Ph) correlated very well with an increase in favorable ∆H° that decreased 
when n > 3. Thus, the peak in enthalpy of binding shown in Graph 3.5.1 provided 
preliminary evidence of a plausible increase in vdW interactions between the ligand and 
the protein.  























Table 3.5.1 ITC binding studies with Grb2 SH2, at 298 K in HEPES buffer, pH 7.5. aITC 






















3.10 3.11 3.12 3.13
Ligand 
Ka 







3.06 1.5 ± 0.2 –9.8 ± 0.1 –7.7 ± 0.3 –2.1 ± 0.8 
3.07 2.6 ± 0.2 -9.8 ± 0.2 –7.7 ± 0.3 –2.1 ± 0.6 
3.08 6.0 ± 0.7 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 
3.09 4.2 ± 0.2 –9.8 ± 0.1 –7.7 ± 0.4 –2.0 ± 0.5 
3.10 2.8 ± 0.1 –10.2 ± 0.1 –7.9 ± 0.3 –2.3 ± 0.3 
3.11a 1.1 ± 0.2  –9.6 ± 0.1 –6.7 ± 0.2 –2.9 ± 0.3 
3.12a 2.4 ± 0.1 –10.1 ± 0.1 –8.1 ± 0.2 –2.0 ± 0.2 
3.13a 4.9 ± 0.1 –10.4 ± 0.1 –10.2 ± 0.2 –0.2 ± 0.3 
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3.6   Structural Studies of the pY+3 ligands of Varying Linker Length n 
Since one of the initial goals of the study was to examine how changes in binding affinity 
accompany the addition of nonpolar surface area to a ligand, the thermodynamic studies 
of varying the linker length n generated a great amount of curiosity.  Accordingly, to 
better understand our previous ITC data in a fashion that would shed light onto the source 
of the ∆H° values, we obtained crystal structures of complexes of 3.07 and 3.08 with the 
Grb2 SH2 domain. All X-ray data was collected by Dr. John Clements. These structures 
were obtained to a resolution of <2.0 Å, and backbone atoms belonging to the protein in 
the complexes of the ligands align closely, with pair wise RMSDs <0.2 Å. The two 
structures are shown below in 
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Figure 3.6.1 overlaid with complex 3.04 where R = H for a comparison. Interestingly, the 
peptide backbone of 3.07 and 3.08 are aligned closely to one another, but the phenyl 
substituent at the pY+3 position of 3.07 binds in two poses, one of which positions the 
phenyl ring away from the protein relative to the other. The phenyl substituent of 3.08 
also binds in two poses, however, in both of these the phenyl rings are localized to the 
non polar residues of the extended “hydrophobic patch” of the domain. This result can be 
rationalized such that the three-carbon linker allows for better spatial position of the 
phenyl substituent to make favorable vdW contacts with the binding pocket.
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Figure 3.6.1 Cocrystal of the Grb2 SH2 domain (surface).[a] 
 
[a] The binding site of the Grb2 SH2 domain. Ligand 3.07 is in green and 3.08  in cyan and ligand 3.04 is 
in magenta (shown in sticks). Only carbon atoms are shown. 
The vdW contacts made between the protein and the pY+3 substituents for both 
3.07 and 3.08 were tallied ( between the distances of 3.4 and 4.2 Åclxiii) and are shown in 
Table 3.6.1. In one pose, 3.07 (n = 2) makes 13 contacts with the pocket while the other 
pose makes only four. On the other hand, 3.08 (n = 3) makes eight contacts with the 
binding pocket in both poses. These values suggest that there may be less variability in 
the position of the phenyl ring at the pY+3 substituent of 3.08 than for 3.07 in their 
respective isoenergetic posses.  
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3.7   Summary 
 We examined effects upon binding affinity of varying the number of 
methylene groups linking the C-terminus of Grb2 SH2 domain binders with nonpolar 
substituents. We determined that a methylene linker of three carbon atoms was needed to 
provide optimal interactions between an apolar substituent R and an apolar patch of the 
Grb2 SH2 domain. We also obtained X-ray data suggesting that the methylene linker 
where n = 3 provided the best spatial position of the aryl substituent to make optimal 
interactions with the hydrophobic patch. We would thus use a linker of n = 3 in our 









vdW contacts  
made 
3.07 -9.8 ± 0.2 –7.7 ± 0.3 –2.1 ± 0.6 13,4 
3.08 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 8,8 
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3.8   Substituent Effects at the pY+3 Derived Tripeptides. 
With the linker length known, we proceeded to study the thermodynamic and 
structural effects of varying that nature of nonpolar substituents at the pY+3 position of 
Grb2 SH2 binding ligands. The synthesis of all ligands studied are presented in one 
section even though each of the ligands shown in Figure 3.8.1 was selected to ask 
specific questions that will be discussed in due course. In general, these ligands contain 
substituents that vary in their aromatic (where R = phenyl, naphthyl, indolyl), and 
aliphatic (where R = cyclohexyl, isopropyl and, isobutyl) substituents. The substitution 
patterns on the phenyl ring were also varied to compare the effects associated with 
electron withdrawing and donating functionality. Furthermore, known ligand 3.04 (where 
R = H) was used as a benchmark to judge the effects of adding apolar surface area. 
 145 
Figure 3.8.1 pY+3 substituents where R is varied on a three carbon linker. 
 
Ligands in Figure 3.3.3 were synthesized in the same manner as the previous 
section. In particular, the asparagine derivatives were synthesized in the same manner as 
in Scheme 3.2.3 and coupled with dipeptide 3.15 in moderate yields (scheme 3.3.4), and 
then deprotected with H2 and 10% Pd/C  in MeOH to provide the debenzylated ligands 
3.39-3.48.  
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Scheme 3.8.1 Peptide Synthesis.a Dr. Bo Cheng.b Dr. J. Tian. 
  
3.9   Thermodynamic studies 
Binding energetics for ligands 3.39-3.41 with the Grb2 SH2 domain were 
determined by ITC (Table 3.9.1). When R is phenyl, the ligand binds with more 


















































3.60: R = Naphthyl, (80%, 2 steps)
3.61a: R = 1H-indol-1-yl, (54%, 2 steps)
3.62a: R = 1-H-indol-3-yl(70%, 2 steps)
3.63: R = Cyclohexyl (72%, 2 steps)
3.64: R = isobutyl (67%, 2 steps)
3.65: R = isoPropyl (99%)
3.66b: R = 4-Cl-phenyl (70%, 2 steps)
3.67b: R = 4-Me-phenyl (39%, 2 steps)
3.68: R = 4-CF3-Phenyl (65%, 2 steps)
3.69: R = 4-OMe-Phenylyl (99%, 2 steps)
R
R
3.39: R = Naphthyl, (75%, 2 steps)
3.40a: R = 1H-indol-1-yl, (78%, 2 steps)
3.41a: R = 1-H-indol-3-yl(55%, 2 steps)
3.42: R = Cyclohexyl (75%, 2 steps)
3.43: R = isoPropyl (22%, 2 steps)
3.44: R = isoButyl (87%, 2 steps)
3.45b: R = 4-Me-phenyl (30%, 2 steps)
3.46b: R = 4-Cl-phenyl (32%, 2 steps)
3.47: R = 4-CF3-Phenyl (94%, 2 steps)
3.48: R = 4-OMe-Phenylyl (20%, 2 steps)
3.50: R = Naphthyl
3.51a: R = 1H-indol-1-yl
3.52a: R = 1-H-indol-3-yl
3.53: R = Cyclohexyl 
3.54: R = isobutyl 
3.55: R = isoPropyl 
3.56b: R = 4-Cl-phenyl 
3.57b: R = 4-Me-phenyl 
3.58: R = 4-CF3-Phenyl
3.59: R = 4-Ome_Phenylyl
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These findings indicate that the addition of apolar surface area leads to an enthalpically 
driven affinity enhancement, which is counterintuitive to the hydrophobic effect, which 
would suggest that the increase of apolar surface area would lead to potency increases 
that were are driven by a favorable entropy. There is also a more favorable binding 
entropy for this event as well. The napthyl and indolyl derived ligands 3.28 and 3.13, 
respectively, bound with a more favorable change in enthalpy relative to 3.08, but there 
were no significant differences in entropy changes observed. Thus, the increase in apolar 
surface area from R = Ph (3.08) to R = Np (3.28) led to favorable changes in binding 
enthalpy that resulted in an overall increase in binding affinity. Furthermore, relative to 
our benchmark 3.04, we also observe with 3.28 that the affinity increases due to a more 
favorable binding enthalpy, but to a greater extent, which correlates well with the 
addition of the larger surface of 3.28 relative to 3.08.  
The indolyl ligands 3.29 and 3.30 had a slightly less favorable enthalpy of binding 
relative to 3.08. We made numerous attempts to obtain a crystal structure of this 
complex, but all attempts have thus far failed.  
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Table 3.9.1 ITC binding studies with Grb2 SH2, at 298 K in HEPES buffer, pH 7.5.  
 
aPerformed by Dr. Bo Cheng. TC experiments were conducted at 25 °C in HEPES buffer at pH 











3.04 0.7 ± 12 -9.3 ± 0.1 -8.5 ± 0.4 –0.8 ± 0.4 
3.08 6.0 ± 0.7 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 
3.39 6.0 ± 0.3 -10.6 ± 0.1 -9.6 ± 0.4 –1.2 ± 0.5 
3.13 a 4.9 ± 0.1 –10.4 ± 0.1 –10.2 ± 0.2 –0.2 ± 0.3 
3.40 a 2.7 ± 0.2 -10.2 ± 0.3 -9.1 ± 0.8 –1.1 ± 0.8 
3.41a 3.5 ± 0.2 -10.3 ± 0.1 -9.1 ± 0.3 –1.2 ± 0.6 
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At this point in our studies, it was clear that we were observing enthalpically 
driven hydrophobic effects upon the addition of aromatic surface area to the test ligand 
3.04, but an explanation as to where the enthalpy originated was lacking. It was 
conceivable that the enhanced change in binding entropy arose from favorable dispersive 
interactions with C-terminal substituents, but there was little support for this hypothesis 
at that time. Moreover, we were seeing more favorable gains in both entropy and 
enthalpy relative to benchmark 3.04 for the binding event. These observations lead us to 
believe that there was not just one contributing factor at play, and thus we modified our 
studies to include structural and thermodynamic analysis of the alkyl ligands 3.42–3.44. 
Since cyclohexane has been postulated to have a more entropically favorable dehydration 
in water than benzene,clxiv we reasoned that studying R = cyclohexane for R = benzene 
might lead to added hydrophobic effects that may help us better discern the effects of 
added apolar surface area.  
Accordingly, with the alkyl ligands 3.42–3.44 series in hand, the ITC data was 
collected for their binding to the Grb2 SH2 domain (Table 3.9.2). For these ligands, it 
was observed that they bind with more favorable ∆∆S° compared to 3.08, but this is 
wiped out by a less favorable binding ∆∆H° such that 3.42-3.44 so that ∆∆G° relative to 
3.08 is unfavorable. The addition of apolar surface area still led to binding affinity 
increases relative to 3.04. However, it was remarkable that whereas the aromatic ligands 
bound with more favorable enthalpy relative 3.04, the alkyl ligands bound with more 
favorable entropy. This indicated that the difference in the dehydration of the alkyl verse 
aromatic pY+3 substituents may have an effect on the binding enthalpy and entropy, but 
further experiments were needed to explore that hypothesis. Once such experiment would 
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be to compare the temperature dependent thermodynamics, or ∆Cp°, of the alkyl and 
aromatic ligands. In biological systems, ∆Cp is frequently used as a barometer of 
hydrophobic effects.clxv A negative value of ∆Cp is associated with the burial of nonpolar 
surface area and a positive number with the burial of polar surface area.  Thus, this 
analysis could provide additional data to discern if the alkyl substituents were burying 
more apolar surface area compared to 3.08.  The analyses of this experiment is discussed 
in the following section. 
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Table 3.9.2 ITC binding studies with Grb2 SH2. 
 
a 
ITC experiments were conducted at 25 °C in HEPES buffer at pH 7.45 ± 0.05. Errors based on 5% 











3.04 0.7 ± 12 -9.3 ± 0.1 -8.5 ± 0.4 –0.8 ± 0.4 
3.08 6.0 ± 0.7 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 
3.39 6.0 ± 0.3 -10.6 ± 0.1 -9.6 ± 0.4 –1.2 ± 0.5 
3.43 1.7 ± 0.2 -9.8 ± 0.1 -7.8 ± 0.4 –2.1 ± 0.3 
3.44 1.7 ± 0.2 -9.8 ± 0.2 -7.8 ± 0.2 –2.1 ± 0.2 
3.42 1.9 ± 0.2 -9.8 ± 0.1 -8.0 ± 0.4 –1.9  ± 0.2 
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3.10   Temperature Dependent Studies 
The ∆Cp values of the aromatic ligands 3.08, 3.28, and 3.13 are shown in figure 
3.10.1-4. The ∆Cp for 3.04 is also shown on each respective ∆Cp trace for comparison.  




 Measurements were performed in 50 mM HEPES buffer containing 150 mM NaCl at pH 7.5.  ∆Cp values 
for the binding of each ligand were obtained from the slope of the plots and the error in ∆Cp was taken as 






























Measurements were performed in 50 mM HEPES buffer containing 150 mM NaCl at pH 7.5.  ∆Cp values 
for the binding of each ligand were obtained from the slope of the plots and the error in ∆Cp was taken as 
the standard error in the slope. All runs for 3.04 were done by Dr. James Myslinski. 
 
Figure 3.10.3 ∆Hº of binding to the Grb2 SH2 domain as a function of temperature for 3.28 
 
Measurements were performed in 50 mM HEPES buffer containing 150 mM NaCl at pH 7.5.  ∆Cp values 
for the binding of each ligand were obtained from the slope of the plots and the error in ∆Cp was taken as 




















































Figure 3.10.4 ∆Hº of binding to the Grb2 SH2 domain as a function of temperature for 3.13 
 
Measurements were performed in 50 mM HEPES buffer containing 150 mM NaCl at pH 7.5 by Dr. Bo 
Cheng.  ∆Cp values for the binding of each ligand were obtained from the slope of the plots and the error in 
∆Cp was taken as the standard error in the slope. All runs for 3.04 were done by Dr. James Myslinski. 
 
These experiments show that when R is aromatic, the ∆Cp values for 3.08, 3.39, 
and 3.13 become more negative upon addition of the aromatic substituent, which 
correlates well with the increase in binding affinity as extra nonpolar surface is added to 
3.04, Table 3.10.1. These are in agreement with what one may expect from targeting 
classical hydrophobic effects to enhance to potency of a drug lead; however, the burial of 
nonpolar surface area correlates with a favorable change in ∆H° and not ∆S° (Table 
3.10.1), which indicates a hydrophobic effect driven by enthalpy. Since hydrophobic 
effects are supposed to increase binding affinity due to a more favorable entropic 
component, this is counter to what is expected. 
Because the ∆Cp data of 3.08, 3.28, and 3.13 confirmed that the addition of 
nonpolar surface area correlated well with more favorable changes in binding enthalpy of 



























where R is aliphatic to determine if it trended similarly.  Thus, the ∆Cp for 3.42 was 
determined and is also shown  with 3.04 included as a comparison.  We observed that 
3.42, similar to ligands 3.08, 3.28, and 3.13 has a ∆Cp that is more negative than the 
benchmark 3.04.  The value for the ∆Cp of 3.42 suggests that we are observing a 
hydrophobic effect upon the addition of apolar surface area to 3.04, which is expected 
given what is known for hydrophobic effects.  
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(x 107 M-1) 
∆G° 
(kcal•mol-1) ∆Cp° 
3.04 0.7 ± 12 -9.3 ± 0.1 -179 ± 10 
3.08 6.0 ± 0.7 –10.2 ± 0.2 -209 ± 12 
3.39 6.0 ± 0.3 -10.6 ± 0.1 -217 ± 8 
3.13 4.9 ± 0.1 –10.4 ± 0.1 -210 ± 10 
3.42 1.9 ± 0.2 -9.8 ± 0.1 -196 ± 8 
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3.11    Structural Studies. 
Unfortunately, we were not able to obtain an X-ray structure for 3.42 (R = 
Cy), which provides the most appropriate comparison to 3.08 because they have 
the same number of carbon atoms. However, we were able to obtain a crystal 
structures of  3.43 (R = iPr) complexed with Grb2 SH2 domain, and it is shown in 
Figure 3.11.1 overlayed with 3.08 as a reference. The structure was obtained to a 
resolution of <2.0 Å and backbone atoms belonging to the protein in the 
complexes of 3.43 and 3.04 align closely, with pairwise RMSDs <0.2 Å. Analysis 
of the X-ray data shows that the orientation of the iPr substituent at the pY+3 
position 3.43 varies drastically, and the iPr group in two different poses. In both 
of these, the iPr group is directed away from the hydrophobic patch of Grb2. An 
analysis of the van der Waals contacts made at the pY + 3 position (using the 
distance criteria of 3.4-4.2 Å for nonbonded atoms) is shown in Table 3.11.1 in 
addition to the contacts made by 3.08 as a reference.  As previously discussed in 
Section 3.6, the phenyl substituent in 3.08 binds in an orientation so that it makes 
eight favorable contacts (in each pose) with the domain. However, 3.43 binds 
with fewer vdW contacts with three contact in one pose and two in the other pose.  
There was more variation in the orientation of the iPr group in 3.43 than 
the Ph group in 3.08, and we noticed this trend correlates well with the differences 
in binding entropy observed for the alkyl ligands. Furthermore, there is also an 
apparent structural correlation between the eight vdW contacts made in 3.08 and 
its binding enthalpy relative to our benchmark. Thus, the data suggests that the 
flat, more rigid aromatic substituent may better suited to make more favorable 
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vdW contacts than the alkyl substituents, at least one of which (3.43) has been 
shown through structural analysis to have varying position in the binding 
complex. This is in agreement with our observation that the alkyl ligands bind 
with an unfavorable ∆∆H° between 1.0–1.8 kcal•mol-1 relative to the aromatic 
series. Thus, we reasoned that the more rigid, aromatic substituents of 3.08, 3.39, 
and 3.13 interact with the domain with more dominating and favorable binding 
enthalpies relative to the alkyl ligands (3.42, 3.43, 3.44) due to the ability of the 
aromatic substituent to make more favorable dispersive interactions in the binding 
pocket.  
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Figure 3.11.1 Cocrystal of the Grb2 SH2 domain (surface).[a] 
 
[a] The binding site of the Grb2 SH2 domain. Ligand 3.43 is in green and 3.08 is in cyan. Only 




Table 3.11.1 Tabulated vdW contacts. 
 
 
3.12    Phenyl Substituent effects 
We were also interested in probing the effects of altering the electrostatic 
nature of the phenyl group of 3.08, and towards this end 3.45 – 3.48 were 
designed. As our inspiration for selecting these ligands, we chose phenyl 
substituents from the Topliss operational schemesclxvi whereby a small set of 
phenyl-substituted analogs are synthesized and their measured binding affinities 
guide the synthesis to a compound with optimized potency. These choices in 
synthesis are guided by considerations of hydrophobicity,clxvii steric effects,clxviii  
and electrostaticscx of different substituents. We hoped that by applying these 
schemes to 3.08 that we might obtain trends in the substituent effects that might 










3.08 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 8, 8 
3.43 -9.8 ± 0.1 -7.8 ± 0.4 –2.1 ± 0.3 3, 2 
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These ligands 3.34–3.37 were synthesized (Section 3.8) and ITC data in 
the presence of the Grb2 SH2 domain were collected and is shown in Table 
3.12.1. Examination of these results reveal that modifying the substitution on the 
phenyl ring has little effect on the ligand binding affinity. However, out of the 
group of “Topliss” ligands that were tested, the 4-CF3 derived 3.34 had the most 
favorable entropy of binding. This finding is in agreement with previous 
reportsclxix suggesting that increasing the van der Waal radii of phenyl substituents 
can lead to a more favorable entropy of binding relative to the unsubstituted or 
starting phenyl-derived ligand. This effect has been attributed to a more favorable 
entropy of ligand desolvation due to the larger substituent on the phenyl ring. 
Although this does not help us better discern the binding interactions of this 
system, it is at least a noteworthy observation. 
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Table 3.12.1 ITC binding studies with Grb2 SH2, at 298 K in PBS buffer, pH 7.5. 
aSynthesized and tested by Dr. J. Tian. 
 
ITC experiments were conducted at 25 °C in HEPES buffer at pH 7.45 ± 0.05. Errors based on 5% 
error in ligand concentration plus standard deviations. aPerformed by Dr. J Tian. 
3.13   Exploring Leveling Effects 
What remained puzzling to us after our phenyl substitution studies is that 
we were still observing enthalpy-entropy compensation rather than a significant 
Ligand 
Ka 







3.08 6.0 ± 0.7 –10.2 ± 0.2 –8.8 ± 0.3 –1.4 ± 0.6 
3.46 4.7 ± 0.5 -10.3 ± 0.1 -9.2 ± 0.6 –1.2 ± 0.7 
3.48 a 5.1 ± 0.4 -10.5 0.1 -9.5 ± 0.4 –1.0 ± 0.6 
3.47 3.0 ± 0.7 -10.1 ± 0.1 -8.4 ± 0.2 –1.7 ± 0.4 
3.45a 4.7 ± 0.4 -10.3 ± 0.1 -9.0 ± 0.4 –1.3 ± 0.4 
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change in binding affinity. We wondered if this was because we had reached an 
affinity plateau for this protein-ligand system such that no further affinity gains 
could be achieved.clxx In an effort to circumvent this problem, we decided to 
change the pY+1 residue of our ligand framework from Ac6c to Ile, which would 
give us 3.76 (Table 3.13.1) as a less potent starting benchmark. Thus, we 
postulated that since this would give us a lower affinity starting point for 
optimization that we may not hit the supposed affinity plateau that we 
encountered in our studies. Therefore, we decided to synthesize and test a 
derivative of 3.76 that was modified with a cyclohexyl substituent to provide 3.75 
(table 3.13.1).  
Accordingly, 3.40 was coupled with NHBocIle under carbodiimide 
coupling conditions to give an intermediate Boc-protected dipeptide that was 
deprotected with TFA to give 3.71. The following TFA salt was similarly coupled 
to BocTyr and deprotected to give 3.72. The tripeptide was then acylated and 
phosphorylated to give 3.74, which was then easily debenzylated under 
hydrogenolysis conditions to provide the desired ligand 3.75 (Scheme 3.13.1) 
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scheme 3.13.1 pY+3 leveling effect Ligand Synthesis. 
 
With this ligand in hand, we obtained ITC data fir binding with Grb2-SH2 
and they were compared to 3.76 which had already been tested by colleague Dr. 
James Myslinski (table 3.13.1). Interestingly, we found that 3.38 did not have a 
significant affinity increase compared to 3.37, which is a puzzling result. We 
initially decided to make and synthesize more derivatives, but it was shown by 
Dr, James Myslinski on somewhat related work at the pY-1 position that showed 
that the substituent effects were additive and thus we did not proceed with making 
the other analogues. clxxi 
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Table 3.13.1 ITC analysis with Grb2 SH2 domain in HEPES at pH 7.5. Ligands made 















3.76a 0.1 ± 0.04 -8.2 ± 0.02 -7.4 ± 0.2 0.8 ± 120.2 
3.75 0.2 ± 0.04 -8.3 ± 0.1 -6.5 ± 0.4 1.8 ± 0.3 
3.04a 0.7 ± 12 -9.3 ± 0.1 -8.5 ± 0.4 –0.8 ± 0.4 
3.42 1.9 ± 0.2 -9.8 ± 0.1 -8.0 ± 0.4 –1.9  ± 0.2 
 166 
3.14    Conclusions  
We have shown that the added substituents probed in this study provided 
binding increases to our Grb2 SH2 ligands, but the thermodynamic driving force 
(∆H° or ∆S°) of binding affinities depended greatly upon the topical surface of the 
apolar substituent. Through a combination of X-ray and ITC studies it was shown 
that ligands containing aromatic and planar functional groups bound with a higher 
∆H° than the more flexible alkyl ligands, and that this effect is consistent with 
more direct vdW contacts made in the pocket, based off of our limited structural 
analysis. We also observed that when the phenyl ring in 3.08 was replaced by 
more nonpolar surface area such as a napthyl (3.39) or indolyl (3.13) substituent, 
that further affinity increases were driven by more favorable changes in enthalpy. 
Interestingly, this increase in binding affinity was also accompanied by a 
synergistic benefit in entropy that may be attributed to the release of ordered 
water molecules, although no crystallographic data was obtained to support or 
refute this hypothesis.  
However, when we applied a similar tactic to our benchmark 2.04 by 
substituting with less planar, alkyl substiuents, affinity boosts were observed but 
in this case they were driven by entropy, and they were not as large in magnitude 
as with the aromatic ligands. Based upon our X-ray structural analysis, the 
binding entropy correlated with the alkyl substituents having more flexibility in 
the binding pocket as well as having fewer contacts made in the binding pocket. 
The alkyl ligand examined was in two drastically different poses that we observed 
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by X-ray. Furthermore, the binding entropy also correlates with the alkyl 
substituents having a more favorable desolvation entropy. 
 Temperature dependent studies (∆Cp) on 3.42, a representative alkyl 
ligand,  suggests that more apolar surface area was buried upon complexation of 
3.42 to the Grb2–SH2 domain than our benchmark ligand 3.04.  This suggested 
that the favorable entropy observed upon binding arose from entropy driven 
hydrophobic effects.  
Several studies have surfaced recently disputing the claim that addition of 
apolar surface area leads to affinity enhancements in protein ligand interactions 
that are driven by enthalpy not entropy.6,9 Thus, coming into this study we asked 
the question: How will adding apolar surface area to ligands affect the binding 
thermodynamics of protein-ligand complexation? Our findings presented herein 
do confirm that addition of ligand apolar surface area can be accompanied by a 
favorable change in enthalpy, but we also offer a revision: Although we have 
confirmed that the addition of apolar surface area to known Grb2 binders led to 
enthalpically driven binding increases, we have shown that this effect may 
dependent upon the surface topology lipohilic group. Hence, the more rigid, 
aromatic substituents 3.08, 3.13 and 3.39 that bound to Grb2–SH2 domain  
consistently bound with more favorable binding enthalpies relative to both the 
alkyl ligands (3.42–3.44) and a common benchmark (3.04).  Presumably this is 
due to more favorable vdW contacts that the aromatic ligands make in the binding 
pocket, although we were only able to obtain limited structural data to support this 
hypothesis. Therefore, our study does suggests that the increase of lipophilicity of 
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a ligand can increase the ligand potency through favorable binding enthalpies, but 
this process can also be driven by entropy depending on the ligand surface 
topology. This indicates that there still may be unknown components to increasing 
the hydrophobicity of protein-binding ligands that are worthy of further 
investigation 
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Chapter 4 Topliss Approach to the Binding Affinity Enhancement of 
MUP-I Binders. 
4.1   Introduction 
 
One of the underlying challenges in the discovery of new medicinal drugs is 
the design and synthesis of small organic molecules that bind tightly to biological 
receptors. Despite many recent advances in the area of in silico drug 
design,clxxii ,clxxiii ,clxxiv,clxxv,clxxvi computer scoring functions are still not capable of 
reliably calculating binding affinity from molecular structure. As a result, several 
strategies have been developed to optimize binding affinity of ligands. One of the 
earlier methods that aims to streamline the traditional optimization of drug leads 
are the operational schemes of the Topliss decision tree, whereby a small set of 
initial analogs are synthesized, and their measured binding affinities then guide 
the synthesis of an optimal compound.clxxvii,clxxviii These choices in ligand structure 
are dictated by considerations of hydrophobicity, steric effects, and electrostatic 
factors of differing substituents.  
Although the Topliss operational schemes were originally published in 
1972, they are frequently employed in contemporary drug design and 
discovery.clxxvii,clxxviii As of the submission of this dissertation, at least 40 unique 
drug discovery projects in both the private and public sector have employed these 
schemes within the past five years.clxxix However, there has yet to be a single study 
that examined the detailed thermodynamic effects associated with applying the 
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Topliss tree. This is very surprising considering the fact that the Topliss schemes 
are intended first and foremost to identify useful trends for the synthesis of potent 
drug leads.clxxx Thus, we hoped that in analyzing the thermodynamic trends 
associated with the Topliss operational schemes, we could discover ways in which 
they could be used more efficiently. 
4.2   Experimental Design 
We identified a set of phenyl alkanols ranging from 3-phenylpropanol to 6-
phenylhexanol that bound to MUP-I with moderate to very good binding affinities 
(Table 4.1).clxxxi It was observed that the ligand affinity increased steadily upon the 
addition of methylene groups from n = 1 until n = 3, at which point the affinity 
reached its zenith. For the six carbon analog (n = 4), binding affinity decreased 
slightly. This was attributed to an unfavorable syn-pentane interaction that the 
ligand adopts in the binding pocket that is visible in the crystal structure 6-
phenylhexanol 4.00 complexed with MUP-I (figure 4.1).  
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1 1.1 ± 0.03 -6.9 ± 0.01 -12.2 ± 0.47 5.3 ± 0.1 
2 3.0 ± 0.03 -7.4 ± 0.02 -13.9 ± 0.69 6.4 ± 0.1 
3 11.1 ± 0.04 -8.3 ± 0.07 -16.5 ± 0.71 8.2 ± 0.3 
4 10.0 ± 0.05 -8.2 ± 0.2 -13.3 ± 0.60 5.1 ± 0.6 
 aITC experiments were conducted at 25 °C in PBS buffer at pH 7.45 ± 0.05. Errors based 
on 5% error in ligand concentration plus standard deviations. 
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Figure 4.2.1 Pose of 6-phenylhexanol (4.00)  (Table 4.1, n = 4) in the binding complex 
of MUP-I 
  
Several features of the phenyl alkanol that we had investigated in Chapter 2 
immediately intrigued us. First, since these ligands contained an unsubstituted 
phenyl ring, we quickly envisioned the utility of this carbon platform skeleton as a 
model system for studies utilizing the Topliss decision tree. Second, because we 
had previously discovered that the binding affinity of these ligands was effected 
by the addition/subtraction of methylene groups, we were also hopeful that we 
would be able to obtain differences in the ligand binding affinity that were not 
severely compromised from enthalpy-entropy compensation.clxxxii  Lastly, we felt 
that MUP-I would serve as an appropriate model system for our Topliss studies 
because its binding associations with small molecules are postulated to be driven 
by nondirectional van der Waals (vdW) contacts,clxxxiii and as such there are no 
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obvious polar networks that we would need to maintain. Thus, we initiated our 
studies with phenyl butanol since it showed the median bioactivity of the four 
ligands shown in Table 4.2.1. Using phenyl butanol as a starting point seemed likely 
it to maximize our chances of observing affinity enhancements, and it would also 
provide us the opportunity to apply the schemes to ligands that were nearly an 
order of magnitude more or less potent.  
 Shown in Figure 4.2.2 is the classic Topliss decision tree that was reported in 
the original publication.11 The strategy requires one to first synthesize a 4-Cl 
derivative of an initial compound and then test its bioactivity. The chart then 
guides one to the next compound based on whether or not the analog binds with 
more, equal or less potency than the previous iteration. This process is repeated 
until the potency of the initial hit increases. 
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Figure 4.2.2 Topliss decision tree from an unsubstituted phenyl ring of a known drug 
lead 
 
4.3   Ligand Synthesis 
All of the alcohols that were targeted in this study were readily synthesized 
via a Sonogashira coupling from the related aryl iodides. Accordingly, the 
reaction of aryl halides 4.01-4.07 with alkyne 4.08 in the presence of PdCl2 and 
CuI provided the requisite alkynes in 42 – 91% yields. To obtain the saturated 
alcohols 4.18-4.22, the alkyne was reduced by palladium-catalyzed 
hydrogenation. Because these conditions led to dehalogenation of ligands 4.16 
and 4.17, the ligands were prepared by reduction using PtO2, which is known to 
be less likely to hydrogenolyze C-X bonds (scheme 4.3.1). For the discussions of 
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the binding and thermodynamic properties of 4.16-4.22, we developed a code 
system based on their substitution pattern such that 4.18 is written as C4pCF3 
such methylene carbons are coded as “C” followed by the number of methylene 
groups in the ligand, followed by the phenyl substitution pattern.  
 
scheme 4.3.1 Ligand synthesis of desired Topliss derived alkanols. 
 
 
We determined the binding energetics of these protein-ligand interactions 
using ITC. To our delight, the affinity of the initial analog C4pH to MUP-I was 
expediently optimized following strict adherence to the Topliss operational 
schemes (Figure 4.3.1). In the manner that the charts are meant to reveal the 



















4.16:n = 2, R = 4-Cl (86%)
4.17:n = 2, R = 3,4-Cl2, (62%)
4.18:n = 2, R = 4-CF3, (53%)
4.19:n = 2, R = 4-Me, (99%)
4.20:n = 2, R = 4-OMe, (84%)
4.21:n = 1, R = 4-CF3, (62%)
4.22:n = 1, R = 4-Me, (58%)
PdCl2, PPh3
CuI, TEA
4.09:n = 2, R = 4-Cl (78%)
4.10:n = 2, R = 3,4-Cl2 (41%)
4.11:n = 2, R = 4-CF3, (99%)
4.12:n = 2, R = 4-Me, (74%)
4.13:n = 2, R = 4-OMe, (48%)
4.14:n = 1, R = 4-CF3, (92%)
4.15:n = 1, R = 4-Me, (70%)
4.01:R = 4-Cl.






n = 1: 4.23
n = 2: 4.24
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changes in the substituents led to both increased and decreased ligand potency. 
For example, the notable increase in the binding affinity with the 4-Cl substitution 
that was not observed with the 4-OMe indicates that there may be a preference in 
this system for electron withdrawing over electron donating substituents. 
Furthermore, a slight increase in binding affinity was observed when the electron 
donating capabilities of the ligand were reduced as evident by comparing 4-OMe 
C4pOMe to the 4-Me analog C4pMe. This increase in potency may also be 
attributed to the removal of a polar atom from the ligand. The drop in binding 
affinity for the 3,4-Cl2 C4p,mCl2 was initially attributed to added steric 
encumbrance in the pocket, but no structural data could be obtained to support 
this hypothesis. 
Finally, the schemes correctly led us to the 4-CF3 substituted ligand C4pCF3 
the most potent analog. That both the 4-OMe and 4-Me derivatives did not 
provide significant affinity enhancements validates the utility of these schemes for 
this system because they were not predicted provide affinity boosts based off of 
our testing of the initial 4-Cl analog. 
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Figure 4.3.1. Topliss Analysis. 
 
 
We next analyzed the thermodynamics of substituent effects that led to 
affinity enhancement (Table 4.3.1). In general, we found that all the substituents 
that led to an increase in binding affinity had a more favorable entropy of binding 
than the starting unsubstituted ligand (shown in Graph 4.1). Therefore, the general 
trend in binding entropy that we observe between the Topliss derivatives and the 
parent analog also correlates well with the increase in the Hansch-π valuesclxxxiv 
becoming more positive (R2 = 0.96, Graph 4.3.2). 
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C4pH 3.0 ± 0.03  -7.4 ± 0.02 -13.9•± 0.7 6.4 ± 0.1 0 
C4pOMe 4.3 ± 0.01  -7.7 ± 0.01 -14.4 ± 0.6 6.7 ± 0.3 -0.02 
C4pCl 16.0 ± 0.1  -8.4 ± 0.01 -12.2  ± 0.5 3.8 ± 0.2 0.71 
C4pMe 8.4 ± 0.02  -8.2 ± 0.01 -11.4 ± 0.5 3.2 ± 0.3 0.56 
C4pCF3 28.0 ± 0.2  -8.8 ± 0.05 -14.0 ± 0.4 5.2 ± 0.2 0.88 
C4p,mCl2 Did not Bind (Ka < 1 x 104) 1.25 
aITC experiments were conducted at 25 °C in PBS buffer at pH 7.45 ± 0.05. Errors based 
on 5% error in ligand concentration plus standard deviations. Ligands are referred to by their 
phenyl substituent and alkyl linker length,  such that 4-(4-(trifluoromethyl)phenyl)butanol (4.18) is 
listed as C4pCF3.  
 
Comparing the binding energetics for the pair C4pH and C4pCl was 
reveals that C4pCl binds with a more favorable affinity because of an increase in 
binding entropy of 2.6 kcal•mol-1. There is a small increase in affinity from 
C4pCl to C4pCF3 which is due to a favorable ∆∆H° of 1.8 kcal•mol-1that is 
compensated by an unfavorable T∆∆S° of 1.4 kcal•mol-1. Conversely, for the 
ligand pair C4pCl and C4pOMe, the binding energetics reveal C4pOMe binds 
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with a less favorable affinity because of a less favorable ∆∆S° of 2.9 kcal•mol-1 
that dominates a favorable ∆∆H° of 2.2 kcal•mol-1. Lastly, for the ligand pair 
C4pCl to C4pOMe, we observe that C4pOMe binds with a lower affinity 
because an unfavorable ∆∆H° of 2.9 kcal•mol-1 dominates a favorable ∆∆H° 2.2 
kcal•mol-1. The substitution to the 3,4-Cl2 analog led to a large decrease in binding 
enthalpy such that it could not be detected by our instrumentation. Typically, 
ligands that bind to a protein with an enthalpy so unfavorable that accurate 
thermographs cannot be obtained are thought to have a Ka < 1 x 103 M-1 as 
indicated in Table 4.3.1. 
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Graph 4.3.1 Bar graph showing thermodynamic parameters of binding of C4pH, C4pMe, and 
C4pCl and C4pCF3 to MUP-I. 
 
 
Graph 4.3.2 Graph of π value correlation to T∆S° 
 
It was also notable that the effect of replacing a methyl group with a trifluoro group 
was accompanied by a favorable change in relative binding that was partially offset by an 
unfavorable change in  relative binding entropy of 2.0 kcal•mol-1 that led to an increase in 






























affinity of 0.7 kcal•mol-1. It is worth noting that this is observation is not consistent with 
the conventional view that C-H atom pair allows for better dispersive interactions in the 
binding pocket than the respective C-X atom pair. However, in a recent report by 
Whitesides,cxxxvii it was shown that ligands having C-F bonds consistently bound with 
higher enthalpy and affinity than in the respective C-H analogs. It is also worth noting 
that he also observed a favorable change in entropy with this ligand modification, which 
is not observed our system. 
4.4   Effect of Flourination of Alkyl Bonds. 
It has been previously shown that adding methylene groups to a ligand is a viable 
strategy to enhance binding affinity in select MUP-I binders.clxxxv,clxxxviclxxxvii During the 
course of our own studies with the phenyl alkanols, we observed a very similar 
phenomenon whereupon added apolar surface area in the form of a methylene group led 
to enthalpy driven affinity enhancements (Chapter 2). Since we had already observed 
pronounced affinity boosts upon the addition of apolar surface area to the phenyl 
alkanols, we decided to probe the effects that we observed upon the introduction of C-F 
bonds on different derivatives of these binders (Table 4.2.1) wherein the length of the 
methylene linker was varied accordingly. This strategy allows us to investigate two 
significant scientific questions regarding protein-ligand interactions: (1) is there any 
dependence on the initial affinity of the starting analog that effects the Topliss-derived 
affinity boosts? And (2), since both methylene addition and Topliss substituent effects 
are shown to grant affinity increases in this system, can we combine these two 
modifications to obtain synergistic, additive affinity gains?clxxxviii ,clxxxix,cxc  
 182 
Inspired by the high affinity obtained by 4-CF3 substitution, we first synthesized 
and tested the C5pCF3 analog of our initial study, only to find that the affinity of this 
ligand for MUP-I was below the detection limit of 1 x 103 M-1 of the instrument (Table 
4.4.1). The decline in binding affinity was not surprising because extending the 
methylene linker of our phenyl alcohols eventually led to deleterious effects in binding 
affinity (Table 4.2.1). Following this result, we next synthesized derivatives of our phenyl 
alkanols wherein n = 1 (Table 4.4.1). As in the case where n = 2, The increase in affinity 
of C3pMe to C3pCF3 was again accompanied by a very favorable enthalpy of 1.6 
kcal•mol-1 that compensated an unfavorable change entropy of 0.8 kcal•mol-1 such that 
binding affinity was more favorable by 0.7 kcal•mol-1. in which correlates very well to 
the trend that we observed for the phenylbutanol system. 
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C3pH 1.1 ± 0.03 –6.9 ± 0.01 –12.2 ± 0.5 5.3 ± 0.1 
C3pMe 8.8 ± 0.03 –8.2 ± 0.01 –13.7 ± 0.5 5.6 ± 0.1 
C3pCF3 34.1 ± 0.3 –8.9 ± 0.04 –15.3 ± 0.4 6.4 ± 0.2 
C5pCF3 Did not Bind (Ka < 1 x 104) 
aITC experiments were conducted at 25 °C in PBS buffer at pH 7.45 ± 0.05. Errors based on 5% 
error in ligand concentration plus standard deviations. Ligands are referred to by their phenyl substituent 
and alkyl linker length,  such that 3-(4-(trifluoromethyl)phenyl)propan-1-oll (4.21) is listed as C3pCF3.  
 
4.5   Structural Characterization 
X-ray crystal structures of MUP-I complexed with ligands C4pH, C4pMe, and 
C4pCF3 were obtained by Dr. John Clements to a resolution of <2.0 Å (Figure 4.5.1). The 
number of crystallographic water molecules and total number of vdW contacts in the 
binding pocket of the complexes were tallied. Backbone atoms belonging to the protein in 
the complexes align closely (RMSD < 0.2 Å). However, the position and conformation of 
the bound ligands in the pocket vary considerably from one complex to another. For 
example, C4pH binds to MUP-I in two different poses, such that in one pose the 
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hydroxyl group on the ligand makes seven direct polar contacts with the phenolic oxygen 
atom of Tyr120 and the other it makes two. Polar protein-ligand networks involving 
direct and water-mediated contacts to protein residues Phe38, Leu40, and Tyr120 were 
also observed for the analogs bound to MUP-I (Figure 4.5.1). For ligand complexes with 
C4pH and C4pMe, there are two bound water molecules in the complex. However, for 
the ligand complex of C4pCF3, there is only one bound molecule in the water complex. 
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Figure 4.5.1 Structural complexes of MUP-I with the Topliss derived analogs C4pH, 
C4pMe, and C4pCF3 were obtained to a resolution of <2.0 Å research by researcher Dr. 





                              (c)  
a Oxygen and nitrogen atoms are colored red and blue, respectively. Carbon atoms 
belonging to the protein (line) are colored green while those belonging to the ligands 
(sticks) are colored magenta or cyan, the latter shown for complexes in which the bound 
ligands occupy more than one pose. Protein-ligand direct contacts and those mediated by 
water molecules (red spheres) are indicated with dashed, black lines. (a) Complex with 
C4pH. (b) Complex with C4pMe. (c) Complex with C4pCF3 
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The vdW contacts made in the binding complex were tallied and are shown in Table 
4.5.1 As previously noted, the C4pH analog binds in two different poses in the binding 
pocket, with one making 49 vdW contacts in one pose and 33 in the other. This 
observation highlights one of the difficulties with drawing conclusions from counting 
vdW contacts, because two isoenergetic protein-ligand complexes show some variation. 
However, the number of vdW contacts observed for C4pMe and C4pCF3 show less 
variation: C4pMe makes 42 contacts and C4pCF3 makes 50 contacts. Since this falls 
within the range that we observed for C4pH, it is difficult to assign the significance of 
any differences in the number of contacts to ∆∆G°, ∆∆H°, or T∆∆S°. Thus, there are no 
correlations of thermodynamics parameters with the number of vdW contacts.  
Table 4.5.1 Structural characteristic that were observed from the protein bound 












Buried ∆ CSA 
(Å2) 
C4pH -7.4 ± 0.02 -13.9 ± 0.7 6.4 ± 0.1 49,33 153.6, 154.7 
C4pMe -8.2 ± 0.01 -11.4 ± 0.5 3.2 ± 0.3 42 165.3 
C4pCF3 -8.8 ± 0.05 -14.0 ± 0.4 15.2 ± 0.2 50 174.6 
 
We then compared the differences in ∆Go with ligand Connolly surface areacxci 
(∆CSA) that occurred upon binding for the three ligands for which we had obtained 
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cyrtallographic data. The ∆CSA correlates strongly with ΔGºobs for these ligands (R2 = 
0.99) with a slope of -68 cal/molÅ-2 (Graph 4.5.1). That the burial of nonpolar surface 
area is consistent with more favorable entropies of binding relative to C4pH is 
suggestive of an entropically driven hydrophobic effect; however, the correlations to ∆H° 
and T∆S° are not very strong.  
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That the optimization of phenylbutanol using the Topliss approach led to favorable 
increases in entropy was intriguing. Typically with MUP-I binders, affinity is increased 
through the addition of nonpolar surface area that imparts more favorable binding 
enthalpy changes.clxxxv,clxxxvi However, increases in entropy were observed as the dominant 
driving force in the Topliss studies shown in Figure 4.3.1. Furthermore, the crystal data 
indicated that the increases in binding affinity of our initial ligand correlated very well 
with ∆CSA. Such entropically driven increases in binding affinity are considered to arise 
from hydrophobic effects.  
Spaller and coworkers recently studied the effects of introducing halogen atoms on the 
aromatic an aromatic ring of compounds that bind to the PDZ domain.cxcii They also 
found that halogen substitution on phenyl rings increased binding affinity through an 
entropically favorable process. This change in entropy was attributed to the increase in 
the vdW radii of the halogens relative to an H atom at the para position of a phenyl ring 
(H: 1.20 Å, F: 1.47 Å, Cl: 1.77 Å).cxciii This trend is a similar to what we observed upon 














favorable entropic gains arise from ligand desolvation, however, we observe a very poor 
correlation between ∆CSA and ∆S°. It is likely that other components are at play. 
A similar observation by the Whitesides group in a study on carbonic anhydrase II 
(HCA II) binder was postulated to arise from differences in dehydration of the binding 
pocket between the C-H and C-F groups, since the dispersive interactions in the complex 
would be weaker for C-F bonds than they are in C-H groups.Error! Bookmark not defined. It was 
speculated that the larger radii of the fluoroalkyl group may displace more unoptimally 
hydrated water molecules that would then be hydrated in bulk water. It is thought that one 
face of the active site in HCA II is a hydrophobic “wall” and therefore may contain 
unoptimally hydrated water molecules.cxciv Upon obtaining crystal structures of ligands 
C4pMe and C4pCF3, we observed that there was one less water molecule in the ligand 
complex of C4pCF3. However, one must be careful when extrapolating meaningful 
correlations from crystallographic data, but it is at least noteworthy that the displacement 
of a water molecule does correlate with a favorable change in enthalpy that we observe 
upon modifying alkyl groups to fluoroalkyl groups, which arises from the water molecule 
making more enthalpically favorable hydrogen bond networks in bulk solvent. 
4.6   A possible dependence of the Topliss schemes on initial analog potency. 
Based off of the results from expanding the effects of the fluorine groups to 
phenyl alkanols of different initial potency, we became interested in studying if there was 
an effect of the affinity gained by the Topliss-derived modifications and the starting 
potency of the initial lead compound. To analyze this concept further, we decided to rank 
our Topliss derived ligands such that their affinity boost is calculated relative to their 
initial potency. Therefore, if we are to assume for this study that the ligand panel that was 
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shown in Table 4.2.1 represents the spectrum of binding for MUP binders, then 
phenylpentanol would represent the theoretical ceiling for potency, and phenylpropanol 
would represent the optimization floor. For the sake of this model system shown in  
Figure 4.2.1, the difference in affinity of these two ligands can be referred to as the 
optimization index. Any optimization of a weak ligand could be observed relative to the 
optimization index to ascertain the magnitude of affinity enhancement that is being 
gained (or lost) by the chemical transformation on a starting ligand, this may be called the 
relative percent increase (RPI) of the newly tested analog (eq. 4.1).  For example, the RPI 
of an analog (C) of starting ligand A, could be calculated as follows:  
                                           (eq. 4.1) 
When we look at the RPI of the C4pMe and C4pCF3 analogs used in the Topliss 
decision tree (Figure 4.3.1), it is observed that there is a greater affinity boost in all cases 
where the structural modification was applied to the weakest of the phenyl alcohols in the 
original panel (Figure 4.6.1Table 4.2.1 ). Therefore, although the Topliss tree did provide 
direction towards a higher affinity binder, which was one of our goals, we observed that 
it was more effective when applied to weaker ligands and that its efficacy tapered down 
as it was applied to more potent binders. This analysis suggests that the Topliss schemes 
may be less effective for advanced intermediates that bind with greater affinity. However, 
further ligands would be necessary to bulk up this claim. Therefore, future studies would 
be to synthesize C3pCl, C3pOMe and C3pCl2 and test their binding affinities. 
Furthermore, one could also envision extending this study out even further to 
phenylehtnaol, which was shown in our labs to have a binding affinity that was slightly 
 192 
less than instrumentation limit of Ka = 1 x 103 M-1, which is to say that there was evidence 
that it bound to MUP-I, but unfortunately the ∆H° was too weak to obtain reproducible 
data.   
Figure 4.6.1 Increase in the binding affinity of each analog relative to the known optimal 
increase at the onset of study. Herein called the relative percent increase or RPI. 
   
Conclusion 
We have described a case study where application of the Topliss operational schemes 
led to an expedient development of novel MUP-I binding analogs. We used ITC to 
measure the binding affinities for the Topliss-derived analogues and then followed the 
suggested path of the Topliss decision tree to obtain significant affinity enhancements of 
our lead compound. These analogs were then further decomposed by studying the 
thermodynamics and structural properties of binding.  It was discovered that the Topliss-
derived analogs in general bound with more favorable entropy of binding relative to the 









“lead” C4pH.  Although no consistent correlations were observed between ∆G° and 
T∆S°, we did observed a rather strong correlation between the T∆∆S° and the relative π 
values that correspond to the ligand’s phenyl substitution. Furthermore, we also found a 
very strong correlation with ∆G0 and ∆CSA for the ligands for which we obtained crystal 
structures.  
Analysis of the Topliss-derived ligands also led us to discover and explain in thorough 
detail a trend regarding the binding differential between fluoroalkyl and alkyl 
substituents. It was observed in two different cases that analogs with C-F bonds bound 
with more favorable changes in binding enthalpies. This is a significant discovery 
considering that many medicinally relevant molecules are fluorinated. It has been 
proposed by Whitesides that the driving force of this event is the displacement of 
unoptimally hydrated water molecules in the binding pocket due to the larger radii of the 
fluorine atom. Indeed, it was observed in our studies that the structural data that the 
ligand-bound complex of the fluorinated analog contained one less water molecule in the 
binding pocket than our “lead” C4pH. Although this is an intriguing result, we have 
herein observed two cases where fluoroalkyl ligands show more pronounced changes in 
binding enthalpy relative to their corresponding alkyl variant. Upon attempting to study 
this effect on C5pH, the ligand binding event was no longer detectable by our 
instrumentation, which based off of our previous studies with the phenylalkanols may  be 
due to added steric encumbrance in the binding pocket. Unfortunately, no structural data 
was obtained to confirm this hypothesis. Thus, our analysis suggests that further studies 
on a modified ligand model systems could be designed to further probe the binding 
thermodynamics of fluoroalkyl chains with MUP-I. 
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Chapter 5 Experimental 
 
5.1   General 
Tetrahydrofuran and diethyl ether were dried by filtration through two columns of 
activated, neutral alumina according to the procedure described by Grubbs.cxcv Methanol 
(MeOH), acetonitrile (MeCN), and dimethylformamide (DMF) were dried by filtration 
through two columns of activated molecular sieves, and toluene was dried by filtration 
through one column of activated, neutral alumina followed by one column of Q5 reactant.  
These solvents were determined to have less than 50 ppm H2O by Karl Fischer 
coulometric moisture analysis. Benzene, methylene chloride (CH2Cl2), diisopropylamine 
(i-Pr2NH), triethylamine (Et3N), diisopropylethylamine (i-Pr2Net), and pyridine were 
distilled from calcium hydride immediately prior to use. All reagents were reagent grade 
and used without purification unless otherwise noted, and air or moisture sensitive 
reagents were weighed in a glove box. All reactions involving air or moisture sensitive 
reagents or intermediates were performed under an inert atmosphere of nitrogen or argon 
in glassware that was flame or oven dried. Solutions were degassed using three freeze-
pump-thaw cycles under vacuum. Reaction temperatures refer to the temperature of the 
cooling/heating bath. Volatile solvents were removed under reduced pressure using a 
Büchi rotary evaporator at 25–30 °C (bath temperature).  Thin layer chromatography was 
run on pre-coated plates of silica gel with a 0.25 mm thickness containing 60F-254 
indicator (EMD Millipore).  Chromatography was performed using forced flow (flash 
chromatography) and the indicated solvent system on 230-400 mesh silica gel (Silicycle 
flash F60) according to the method of Still,cxcvi unless otherwise noted. 
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Infrared (IR) spectra were obtained either neat on sodium chloride or as solutions 
in the solvent indicated and reported as wavenumbers (cm-1).  Proton nuclear magnetic 
resonance (1H NMR) and carbon nuclear magnetic resonance (13C NMR) spectra were 
obtained at the indicated field as solutions in CDCl3 unless otherwise indicated.  
Chemical shifts are referenced to the deuterated solvent (e.g., for CDCl3, δ = 7.26 ppm 
and 77.0 ppm for 1H and 13C NMR, respectively) and are reported in parts per million 
(ppm, δ) relative to tetramethylsilane (TMS, δ = 0.00 ppm).  Coupling constants (J) are 
reported in Hz and the splitting abbreviations used are: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; comp, overlapping multiplets of magnetically nonequivalent 
protons; br, broad; app, apparent. 
5.2   Procedures  
 
[1-R-(1α-2α-3α)]-2-(4-Phenyl)-3-hydroxymethylcyclopropanecarboxylic 
acid-(2,4-dimethoxy-benzyl)-methylamide (2.19). A freshly prepared solution of tert-
BuMgCl in ether (2.0 M, 2.95 ml, 5.90 mmol) was added dropwise over 30 min to a 
solution of 2.16 (171 mg, 0.982 mmol) and 2.17 (485 mg, 2.95 mmol) in THF (2.1 mL) at 
–20 °C.  After stirring the mixture for 1 h at –20 ºC, the cooling bath was removed, and a 
saturated aqueous solution of NH4Cl (5 mL) was added slowly with stirring. The mixture 
was extracted with Et2O (3 x 10 mL), dried (Na2SO4), filtered and concentrated under 























with EtOAc:Hex (2:1) to yield 273 mg (78%) of the title product as a colorless oil.  1H 
NMR (400 MHz, CDCl3) (rotamers 1:1) δ 7.22 (d, J = 8.5 Hz, 0.5 H), 7.13 (t, J = 11.3 
Hz, 1 H), 7.03 (br s, 0.5 H), 6.94 (d, J = 7.9 Hz, 0.25 H), 6.47-6.45 (comp, 2 H), 5.12 (d, 
J = 8.2 Hz, 0.5 H), 4.61 (comp, 1 H), 4.11 (d, J = 7.18 Hz, 1 H), 3.83-3.78 (comp, 7 H), 
3.67-3.63 (comp, 1 H), 3.32 (br s, 1 H), 3.06 (s, 1.5 H), 2.96 (s, 1.5 H), 2.63 (app t, J = 
9.6 Hz, 1 H),  2.27 (app t, J = 9.2 Hz, 0.6 H), 1.91 (m, H); 13C NMR (100 MHz, CDCl3) δ 
171.4, 170.9, 160.9, 160.6, 158.8, 158.5, 136.3, 136.2, 131.6, 126.7, 126.5, 117.5, 116.4, 
104.5, 104.3, 98.8, 98.4, 60.5, 59.3, 55.6, 55.5, 55.4, 49.3, 45.3, 35.8, 33.5, 31.1, 27.4, 
27.1, 25.4, 25.3, 25.1, 24.1 21.2; IR (DCM) 3400, 1613, 1456, 1415 cm-1 mass spectrum 
(CI) m/z 356.1861 [C21H25NO4 (M+1) requires 356.1860]. 
NMR Assignments: Rotamers (1:1) 1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 
8.5 Hz, 0.5 H, C13-H), 7.13 (t, J = 11.3 Hz, 1 H, C8-H), 7.03 (br s, 0.5H, C6-H), 6.94 (d, 
J = 7.9 Hz, 0.25 H, C7-H), 6.46-6.45 (comp, 2H, C15-H & C14-H), 5.1 (d, J = 8.2 Hz, 
0.47 H, C11-H), 4.61 (comp, 1.0 H, C11-H), 3.83-3.78 (comp, 7 H, C18-H & C17-H  & 
C1-H), 3.32 (br s, 1 H, C1-OH), 3.06 (s, 1.5H, C10-H), 2.63 (app t, J = 9.6 Hz, 1 H, C3-
H), 2.27 (app t, J = 9.23 Hz, 0.6 H, C4-H ), 1.91 (m, 1 H, C2-H); 13C NMR (100 MHz, 
CDCl3) δ 171.4 (C9), 170.9 (C9), 160.9 (C15 or C19), 160.6 (C15 or C19), 158.8 (C15 or 
C19), 158.5 (C15 or C19), 136.3 (C5), 136.2 (C5), 131.6 (C6), 126.7 (C7 or C8), 126.5 
(C7 or C8), 117.5 (C7 or C8), 116.4 (C7 or C8), 104.5 (C13 or C16), 104.3 (C13 or C16), 
98.8 (C13 or C16), 98.4, 60.5 (C1), 59.3 (C17 or C18), 59.3 (C17 or C18), 55.6 (C11 or 
C10), 55.5 (C17 or C18), 55.4, 49.3, 45.3, 35.8 (C2 or C4), 33.5 (C2 or C4), 31.1, 27.4 







phenylcyclopropanecarboxamide (2.26). Tetrapropylammonium-perruthenate (TPAP) 
(5.1 mg, 0.014 mmol) was added to a suspension of N-methylmorpholine-N-oxide (128 
mg, 1.10 mmol), 2.19 (312 mg, 0.730 mmol), and powdered, activated 4 A-molecular 
sieves (730 mg) in CH2Cl2 (7.3 mL). The reaction mixture was stirred at room 
temperature for 8 h.  The black suspension was then filtered through a plug of silica gel 
(3cm x 5cm), and the plug was washed with CH2Cl2, dried (Na2SO4), filtered and 
concentrated under reduced pressure. The crude material was purified by flash 
chromatography eluting with EtOAc:Hex (1:1) to yield 216 mg (70%) of the titled 
compound as a clear oil.  1H NMR (400 MHz, CDCl3) (rotamers 6:4) δ 9.48 (d, J = 7.5 
Hz, 0.4 H), 9.44 (d, J = 7.5 Hz, 0.4 H), 7.23-7.07 (comp, 5 H), 6.95 (d, J = 8.5 Hz, 0.5 
H), 6.39 (d, J = 8.5 Hz, 1.25 H), 6.35 (dt, J = 8.5, 2.1 Hz, 0.5 H),  4.95 (d, J = 16.4 Hz, 
0.5 H), 4.58 (d, J = 16.4 Hz, 0.5 H), 4.39 (d, J = 11.6 Hz, 0.4 H), 4.37 (d, J = 11.6 Hz, 0.4 
H), 4.35 (d, J = 11.6 Hz, 0.4 H), 3.71 (s, 6 H), 3.11 (s, 1.1 H), 2.97 (q, J = 8.6 Hz, 1 H), 
2.87 (s, 1.4 H), 2.82-2.77 (comp, 0.6 H), 2.67 (t, J = 8.6 Hz, 0.4 H), 2.13-2.05 (m, 0.9 H); 
13C NMR (100 MHz, CDCl3) δ 177.0, 168.48, 167.1, 166.7, 160.7, 159.9, 158.3, 158.2, 























104.4, 103.9, 98.8, 98.0, 55.4, 48.4, 45.0, 34.8, 34.1, 33.33, 33.1 32.9, 32.7, 32.4, 32.2,  
30.9, 30.8, 25.8, 25.1, 21.5; IR (neat) 2936 (br), 1723, 1696, 1611 cm-1 ; mass spectrum 
(CI) m/z 354.1706  [C21H24NO4 (M+1) requires 354.1705]. 
NMR Assignments: Rotamers (60/40) 1H NMR (400 MHz, CDCl3) δ 9.48 (d, J = 
7.5 Hz, 0.4 H, C1-H), 9.44 (d, J = 7.5 Hz, 0.4 H, C1-H), 7.23-7.07 (comp, 5 H, C6-H & 
C7-H & C8-H & C15-H), 6.95 (d, J = 8.5 Hz, 0.5 H, C7-H), 6.35 (dt, J = 8.5, 2.1 Hz, 0.5 
H, C14-H), 4.95 (d, J = 16.4 Hz, 0.5 H, C11-H), 4.58 (d, J = 16.4 Hz, 0.4 H, C11-H), 
4.37 (d, J = 11.6 Hz, 0.4 H, C11-H), 4.35 (d, J = 11.6 Hz, 0.4 H), 3.71 (s, 6 H, C17-H & 
C18-H), 3.11 (s, 1.1 H, C10 H), 2.97 (m, 1H, C3-H), 2.87 (s, 1.4 H, C10-H), 2.82-2.77 
(comp, 0.6 H, C2-H), 2.67 (t, J = 8.89 Hz, 0.4 H, C2-H), 2.13-2.05 (m, 1 H, C4-H). 13C 
NMR (100 MHz, CDCl3) δ 177.0 (C1), 168.5 (C9), 167.1, 166.7, 160.7, 159.9 (C16, C17, 
or C15), 158.3 (C16, C17, or C15), 158.2 (C16, C17, or C15), 134.9 (C5), 134.5, 133.2 
(C6, C7, or C8), 129.5 (C6, C7, or C8), 129.0 (C6, C7, or C8), 128.7 (C6, C7, or C8), 
128.6, 128.4 (C6, C7, or C8), 128.2, 127.9, 127.1, 116.9 (C18 or C19), 116.2 (C11), 
104.4, 103.9, 98.8, 98.0, 55.4 (C18 or C19), 48.4 (C18 or C19), 45.0 (C11), 34.8 ( C4, or 
C10), 34.1 (C4, C10), 33.33 (C10 or C4), 33.16, 32.9 (C10 or C4), 32.7, 32.4, 32.2 (C2, 







carbamoyl]-cyclopropanecarboxylic acid (2.19). A solution of the aldehyde 2.20 in 
MeOH (5.1 mL) containing Et3N (1.31 g, 10.2 mmol) was heated under reflux for 20 h.  
The solution was then cooled to room temperature whereupon the solvents were removed 
under reduced pressure. The residue was then dissolved in acetone (9.2 mL), whereupon 
8 N Jones Reagent (230 µL, 1.84 mmol) was added dropwise.  After stirring the mixture 
for 45 min, a saturated aqueous solution of NaCl (5 mL) was added slowly. The mixture 
was extracted with EtOAc (5 mL), dried (Na2SO4), filtered and concentrated under 
reduced pressure. The crude material was then dissolved in EtOAc (5 mL) and passed 
through a filter frit, whereupon the mother liqueur was concentrated under reduced 
pressure.  The crude material was purified by silica gel chromatography eluting with 
EtOAc (1% AcOH) to yield 197 mg (97%) of the title product as an amber-colored oil. 
1H NMR (400 MHz CDCl3) (rotamers 6:4) δ 7.32-7.22 (comp, 8 H), 7.21-7.18 (comp, 
6H) 6.82 (d, J = 8.5 Hz, 0.5 H), 6.50-6.44 (comp, 1.5 H), 6.40 (d, J = 2.4 Hz, 0.25 H), 
6.38 (d, J = 2.4 Hz, 0.25 H), 6.35 (d, J = 2.4 Hz, 0.50 H), 6.16 (dd, J = 7.7, 2.4 Hz, 0.5 H 
),  4.91 (d, J = 15.0 Hz, 0.5 H), 4.54 (d, J = 15.0 Hz, 0.5 H) 4.21 (d, J = 15.0 Hz, 0.5 H), 
4.03 (d, J = 15.0 Hz, 0.5), 3.80 (s), 3.76 (s), 3.71 (s),  3.15-2.95 (comp, 5.5 H), 2.86-2.78 
(m, 1 H), 2.71 (s, 1.5 H), 2.35 (s, 2.9H); 13C NMR (100 MHz, CDCl3) δ 177.0, 176.8, 
























129.0, 128.7, 128.6, 128.4, 128.3, 128.2, 127.9, 127.5, 127.1, 125.3, 116.9, 116.2, 104.4, 
104.0, 98.8, 98.6, 98.3, 98.0, 55.4, 55.3, 55.2, 48.4, 45.1, 34.8, 34.1, 33.3, 33.2, 32.9, 
32.7, 32.4, 32.2, 30.9, 30.7, 25.8, 25.1, 21.5. mass spectrum (CI) m/z 370.1651 
[C21H24NO5 (M+1) requires 370.1654]. 
NMR Assignments: 1H NMR (400 MHz, CDCl3) (rotamers 60:40) δ 7.32-7.22 
(comp, 8 H, C6-H & C8-H), 7.21-7.18 (comp, 6H, C7-H), 6.82 (d, J = 8.5 Hz, 0.5H, C13-
H), 6.50-6.44 (comp, 1.5 H, C16-H), 6.25 (d, J = 8.5 Hz, C14-H), 6.16 (dd, J = 7.7, 2.4 
Hz, C13-H, 0.5 H), 2.71 (s, 1.5-H, C10-H); 13C NMR (100 MHz, CDCl3) δ 177.0 (C1 or 
C9), 176.8 (C1 or C9), 168.5 (C17 or C15), 167.1 (C17 or C15), 166.7 (C17 or C15), 
160.7 (C17 or C15), 159.9 (C17 or C15), 158.3, 158.25 (C16 or C13), 134.9 (C5 or C8), 
134.5 (C5 or C8), 133.3(C5 or C8), 129.5 (C6 or C7), 129.4 (C6 or C7), 129.0 (C6 or 
C7), 128.7 (C6 or C7), 128.6, 128.4 (C6 or C7), 128.3, 128.2, 127.9 (C19 or C13), 127.5 
(C19 or C13) 127.1, 125.3 (C19 or C13), 116.9, 116.2 (C19 or C13), 104.4, 104.0, 98.8, 
98.6, 98.3, 98.0, 55.4 (C18 or C17), 55.3 (C18 or C17), 55.2 (C18 or C17), 48.4  (C11 or 
C10), 45.1 (C11 or C10), 34.8 (C11 or C10), 34.1, (C11 or C10), 33.3 (C2, C3, C4), 33.2, 







cyclopropanecarboxylic acid (2.20). SOCl2 (12.6 mg, 0.293 mmol) was added to a 
solution of 2.21 (90.0 mg, 0.244 mmol) in MeOH (1.0 mL). The reaction mixture was 
stirred at 0 ºC for 30 min and then at room temperature for 6 h.  The solution was 
concentrated under reduced pressure, and the crude material was purified by silica gel 
chromatography eluting with CH2Cl2 (1% MeOH) to yield 32 mg (34%) of the title 
product as a clear oil. 1H NMR (400 MHz, CDCl3) (rotamers 6:4) δ 7.32-7.22 (comp, 8 
H), 7.21-7.18 (comp, 6 H) 6.76 (d, J = 8.5 Hz, 0.5 H), 6.44-6.42 (comp, 1.5 H), 6.37-6.31 
(comp, 2.5 H), 6.17 (dd, J = 7.7 Hz, 2.4 Hz, 2 H), 4.93 (d, J = 15.4 Hz, 1 H), 4.51 (d, J = 
15.4 Hz, 1 H) 4.21 (d, J = 15.4 Hz, 1 H), 4.03 (d, J = 16.1 Hz, 1H), 3.80 (s, 7 H), 3.76 (s, 
7 H), 3.71 (s),  3.15-2.95 (comp, 4 H), 2.86-2.78 (comp, 6 H), 2.71 (s, 1.5 H), 2.35 (s, 3 
H);  13C (100 MHz, CDCl3) δ 183.1, 173.5, 166.5, 160.8, 160.0, 158.5, 155.6, 153.1, 
143.0, 135.3, 134.9, 129.5, 128.9, 128.9, 128.6, 128.5, 128.2, 127.3, 127.2, 104.6, 104.1, 
55.6, 52.4, 48.4, 45.1, 35.0, 33.5, 33.1, 33.1, 32.9, 32.7, 32.2, 29.9, 26.0, 25.2. IR 
(CDCl3) 2951, 2360, 1729, 1644, 1613, 1507, 1456 cm-1. mass spectrum (CI) m/z 
384.1812 [C22H26NO5 (M+1) requires 384.1811]. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) (rotamers 6:4) δ 7.32-7.22 

























6.37-6.31 (comp, 2.5 H), 6.17 (dd, J = 7.7, 2.4 Hz, 2 H),  4.93 (d, J = 15.4 Hz, 1 H), 4.51 
(d, J = 15.4 Hz, 1 H) 4.21 (d, J = 15.4 Hz, 1 H), 4.03 (d, J = 16.1 Hz, 1H), 3.80 (s, 7 H), 
3.76 (s, 7 H), 3.71 (s),  3.15-2.95 (m, 4 H), 2.86-2.78 (m, 6.5 H), 2.71 (s, 1.6 H), 2.35 (s, 
2.9H) 13C (100 MHz, CDCl3) δ 183.1 (C1 or C9), 173.5 (C1 or C9), 166.5 (C17 or C15), 
160.8  (C17 or C15), 160.0  (C17 or C15), 158.5 (C16 or C14), 155.6 (C16 or C14), 
153.1 (C16 or C14), 143.0 (C16 or C14), 135.3, 134.9, 129.5 (C8, C7, C6 or C5), 128.9 
(C8, C7, C6 or C5), 128.9 (C8, C7, C6 or C5), 128.6 (C8, C7, C6 or C5), 128.5 (C8, C7, 
C6 or C5), 128.2 (C8, C7, C6 or C5), 127.3 (C8, C7, C6 or C5), 127.2 (C8, C7, C6 or 
C5), 104.6 (C12), 104.1 (C12), 55.6 (C18 or C19), 52.4 (C8, C7, C6 or C5) 48.4 (C10 or 
C11), 45.1 (C10 or C11), 35.0 (C2, C3, C4), 33.5 (C2, C3, C4), 33.1 (C2, C3, or C4), 





acid-(2,4-dimethoxybenzyl)methylamide (2.8). A solution of the methyl ester (0.084 
M) in CH2Cl2 (835 µL) containing TFA (590 mg) was stirred at room temperature for 3h, 
whereupon the solution was concentrated under reduced pressure.  The crude product was 
diluted with MeOH and filtered though a frit, and then concentrated under reduced 
pressure to yield 19 mg (100%) of the tilted product as a clear oil. 1H NMR (400 MHz, 
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CDCl3) δ 7.26-7.18 (comp, 5 H), 3.75 (s, 3 H), 2.92 (d, J = 5.5 Hz, 1 H), 2.80 (t, J = 5.5 
Hz, 1 H), 2.57 (s, 3 H), 2.55-2.51 (m, 1 H); 13C NMR (150 MHz, CD3OD), δ 174.2, 
169.8, 136.2, 129.8, 129.2, 128.0, 52.8, 33.1, 32.4, 26.5, 25.6. mass spectrum (ESI) m/z 
278.1676 [C13H15NO3 (M+1) requires 278.1673]. 
NMR Assignments: 1H NMR (400 MHz, CD3OD) δ 7.26-7.18 (comp, 5 H, C6-H 
& C7-H & C8-H), 3.75 (s, 3H, C11-H), 2.92 (d, J = 5.5 Hz, 1 H, C4-H), 2.80 (t, J = 5.5 
Hz, 1 H, C2-H), 2.57 (s, 3 H, C10-H), 2.55-2.51 (m, 1 H, C3-H); 13C (150 MHz, CD3OD) 
δ 174.2 (C1), 169.8 (C9), 136.2 (C5), 129.8 (C7), 129.2 (C6), 128.0 (C8), 52.8 (C11), 





(E)-5-Phenylpent-4-en-1-ol (2.48). A solution of 2.46 (0.18 g, 0.75 mmol) in 
THF (4 mL) was slowly added to a solution of LAH (0.029 g, 0.75 mmol) in THF (4 mL) 
at 0 oC.  After gas evolution had subsided, the cooling bath was removed, and stirring was 
continued for 2 h.  The mixture was recooled to 0 °C, whereupon sat. Na2SO4 was slowly 
added until the formation of a white precipitant had subsided. The mixture was then 
filtered through a frit funnel, eluting with Et2O.  The combined filtrate and washings were 
concentrated under reduced pressure.  The crude residue was then purified by flash 
chromatography, eluting with CH2Cl2 to afford 46 mg (35%) the title compound as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 7.39-7.19 (comp, 5 H), 6.42 (d, J = 15.7 Hz, 1 H), 
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6.27-6.25 (comp, 1 H), 3.67-3.64 (comp, 2 H), 2.77-2.28 (comp, 2 H), 1.79-1.72 (comp, 2 
H), 1.23-1.21 (m, 1 H); 13C (150 MHz) 137.6, 130.4, 130.0, 128.5, 126.9, 125.9, 62.4, 
32.2, 29.3; IR (neat):, 3331.5 (br), 2918.9, 2359.3, cm-1;  mass spectrum (ESI) m/z 
162.1044 [C16H15O2 requires 162.1045]. 
 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.39-7.19 (comp, 4 H, C7–H, 
C8–H, C9–H), 6.42 (d, J = 15.7 Hz, 1 H, C5–H), 6.27-6.25 (comp, 1H, C4–H), 3.67-3.64 
(m, 2 H, C1–H), 2.77-2.28 (m, 2 H, C3–H), 1.79-1.72 (comp, 2 H, C2–H), 1.23-1.21 (m, 
1 H); 13C (150 MHz) 137.6 (C6), 130.4 (C8), 130.0 (C9), 128.5 (C7), 126.9 (C5), 125.9 
(C4), 62.4 (C1), 32.2 (C2), 29.3 (C3). 
General procedures for the coupling of amino acids and peptides. 
Method A: N-Methylmorpholine (NMM) (602 mg, 5.04 mmol) was added to a 
solution of N-protected amino acid and C–protected amino acid (5.4 mmol) in DMF (17 
mL) and stirred at –10 ºC.  The reaction mixture was stirred for 10 min at 0 °C, 
whereupon 1–hydroxybenzotriazole hydrate (HOBt) (514 mg, 3.36 mmol) and 1–(3–
Dimethylamino)propyl]-3-ehtylcarbodiimide hydrochloride (EDCI) (355 mg, 1.85 mmol) 
were added.  The ice bath was removed, and stirring was maintained for 14 h at room 
temperature.  The mixture was concentrated to dryness under reduced pressure. Saturated 
aq. NaHCO3 (10 mL) was added, and the solid was isolated by filtration and washed with 
1.0 M HCl (3 x 15 mL) and H2O (15 mL). If the crude product was found not to be > 95% 
pure by 1H NMR, the crude product was purified by flash chromatography, 
recrystallization, or RP-HPLC using a binary grade of solvents, A and B (given). 
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Method B: N-Methylmorpholine (NMM) (602 mg, 5.04 mmol) was added to a 
solution of N-protected amino acid and C–protected amino acid (5.4 mmol) in DMF (17 
mL) and stirred at –10 ºC.  The reaction mixture was stirred for 10 min at 0 °C, 
whereupon HOBt (514 mg, 3.36 mmol) and EDCI (355 mg, 1.85 mmol) were added.  
The ice bath was removed, and stirring was maintained for 14 h at room temperature. The 
mixture was concentrated to dryness under reduced pressure. Saturated aq. NaHCO3 (10 
mL) was added and aqueous phase was extracted with EtOAc (3 x 20 mL). The combined 
organic layers were washed with 1.0 M HCl (3 x 15 mL) and H2O (15 mL), dried 
(Na2SO4), and concentrated to dryness under reduced pressure. If the crude product was 
found not to be > 95% pure by 1H NMR, the crude product was purified using flash 




propanamido) cyclohexanecarboxylate (3.19). Prepared from 3.18 and Cbz-Asn 
according to the general method B.  The crude product was purified by silica gel 
chromatography eluting with CH2Cl2/MeOH (99:1) to yield 570 mg (64%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (comp, 10 H), 7.00 (d, 
J = 7.6 Hz, 2 H), 6.70 (d, J = 7.6 Hz, 2 H), 6.20 (br s, 1 H), 6.05 (br s, 1H), 5.41 (br s, 1 
H), 5.16-5.03 (comp, 4 H), 4.33 (d, J = 6.4 Hz, 1 H), 2.95 (dd, J = 13.6, 5.6 Hz, 1 H), 
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2.85 (dd, J = 13.6, 5.6 Hz, 1 H), 1.90 (d, J = 13.2 Hz, 2 H), 1.76 (t, J = 11.6 Hz, 2 H), 
1.58-1.42 (comp, 3 H), 1.28-1.05 (comp, 3 H); 13C NMR (100 MHz, CDCl3): δ 173.6, 
170.2, 155.0, 135.8, 130.5, 128.5, 128.5, 128.2, 128.0, 115.6, 67.0, 58.9, 56.1, 37.2, 32.2, 
31.9, 24.9, 21.2, 21.0.; mass spectrum (CI) m/z 531.2490 [C31H35N2O6 (M+1) requires 
531.2495]. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (comp, 10 H, C8-H, 
C9-H, C10-H. C21-H, C22-H, C23-H), 7.00 (d, J = 7.6 Hz, 2 H, C13-H), 6.70 (d, J = 7.6 
Hz, 2 H, C14-H), 5.41 (br s, 1 H, OH), 5.16-5.03 (comp, 4 H, C6-H and C19-H), 4.33 (d, 
J = 6.4 Hz, 1 H, C4-H), 2.95 (dd, J = 13.6, 5.6 Hz, 1 H, C11-H), 2.85 (dd, J = 13.6, 5.6 
Hz, 1 H, C11-H), 1.90 (d, J = 13.2 Hz, 2 H, C16-H or C16’-H), 1.76 (app t, J = 11.6 Hz, 
2 H, C16-H or C16’-H), 1.58-1.42 (comp, 3 H, C17-H or C17’-H or C18-H), 1.28-1.05 
(comp, 3 H, C17-H or C17’-H or C18-H); 13C NMR (100 MHz, CDCl3): δ 173.6 (C3), 
170.2 (C1), 155.0 (C5), 135.8 (C15), 130.5 (C7 & C24), 128.5 (C13 or C12 or C9 or 
C22), 128.5 (C13 or C12 or C9 or C22), 128.2 (C9 or C10 or C22 or C15), 128.0 (C8 and 
C21), 115.6 (C14), 67.1 (C6 or C19), 67.0 (C6 or C19), 58.9 (C3), 56.1 (C2), 37.2 (C16), 






acid. (3.20). The benzyl carbamate 3.19 was dissolved in MeOH (1.5 mL) containing 
10% Pd/C (10 mg, 10 wt %). The resulting mixture was purged four times with H2,  and 
the suspension stirred under H2 (1 atm) for 14 h. The mixture was filtered through a pad 
of celite, and the pad was washed with MeOH. The combined filtrate and washings were 
concentrated to dryness under reduced pressure to yield 59 mg (99%) of the title 
compound as a clear glass. 1H NMR (400 MHz, CD3OD): δ 7.13 (d, J = 8.4 Hz, 2 H), 
6.76 (d, J = 8.4 Hz, 2 H), 4.04 (t, J = 7.6 Hz, 1 H), 3.05 (dd, J = 13.8, 8.2 Hz, 1 H), 2.96 
(dd, J = 13.8, 8.2 Hz, 1 H), 2.23 (d, J = 13.6 Hz, 1 H), 1.85-1.76 (comp, 2 H), 1.67-1.63 
(m, 1 H), 1.52-1.12 (comp, 5 H), 1.28-1.05 (q, J = 12.8 Hz, 1 H); 13C NMR (100 MHz, 
CD3OD): δ 181.3, 169.6, 158.0, 131,6, 126.9,116.7, 62.9, 56.2, 38.1, 35.4, 31.7, 26.6, 
22.8, 22.7. Mass spectrum (ESI) m/z 307.1652 [C16H23N2O4 (M+H)+ requires 307.1657]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.13 (d, J = 8.4 Hz, 2H, C7-
H), 6.76 (d, J = 8.4 Hz, 2H, C8-H), 4.04 (t, J = 7.6 Hz, 1 H, C4-H), 3.05 (dd, J = 13.8, 8.2 
Hz, 1H, C5-H), 2.96 (dd, J = 13.8, 8.2 Hz, 1H, C5-H), 2.23 (app d, J = 13.6 Hz, 1H, C10-
H or C10’-H), 1.85-1.76 (comp, 2 H, C10-H or C10’-H), 1.66 (m, 1H, C10-H or C10’-
H), 1.52-1.12 (comp, 5 H, C11-H and C12-H and C11’-H), 1.28-1.05 (q, J = 12.8 Hz, 1 
H, C11-H or C12-H or C11’-H); 13C NMR (100 MHz, CD3OD) δ 181.3 (C1), 169.6 (C3), 
158.0 (C9), 131.6 (C7), 126.9 (C6), 116.7 (C8), 62.9 (C2), 56.2 (C3), 38.1 (C5), 35.4 
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(C10 or C10’), 31.7 (C10 or C10’), 26.6 (C11,  C12, or C11’ ), 22.8 (C11, C12 or C11’ ), 






cyclohexanecarboxylic acid. (3.21) Acetic anhydride was added to a solution of 3.20 
(634 mg, 2.07 mmol) in dioxane/H2O (1:1, 60 mL). This mixture was stirred at room 
temperature for 30 min when it was then concentrated to dryness under reduced pressure. 
Azeotropic removal of Ac2O was accomplished via the addition of toluene (1.5 mL) to 
the reaction vessel followed by concentration under reduced pressure. This procedure was 
repeated two more times followed by drying in vacuo, which afforded 743 mg (100 %) of 
product as a glass. 1H NMR (400 MHz, CD3OD) δ 7.08 (d, J = 8.4 Hz, 2 H), 6.79 (d, J = 
8.4 Hz, 2 H), 4.64 (dd, J = 8.6, 6.2 Hz, 1 H), 3.00 (dd, J = 13.8, 6.2 Hz, 1 H), 2.76 (dd, J 
= 13.8, 6.2 Hz, 1 H), 2.08-1.97 (comp, 2 H), 1.90 (s, 3 H), 1.76 (td, J = 12.8, 3.6 Hz, 2 
H), 1.61-1.21 (comp, 6 H); 13C NMR (100 MHz, CD3OD) δ 177.8, 173.2, 173.0, 157.2, 
131.4, 129.2, 116.2, 60.3, 56.0, 38.2, 33.4, 33.0, 26.4, 22.5, 22.4. Mass spectrum (ESI) 
m/z 349.1758 [C18H25N2O5 (M+H) requires 349.1763]. 
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NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.08 (d, J = 8.4 Hz, 2 H, C9-
H), 6.79 (d, J = 8.4 Hz, 2 H, C10-H), 4.64 (dd, J = 8.6, 6.2 Hz, 1 H, C4-H), 3.00 (dd, J = 
13.8, 6.2 Hz, 1 H, C7-H), 2.76 (dd, J = 13.8, 6.2 Hz, 1 H, C7-H), 2.08-1.97 (comp, 2 H, 
C12-H or C12’-H), 1.90 (s, 3 H, C6-H), 1.76 (td, J = 12.8, 3.6 Hz, 2 H, C12-H or C12’-
H), 1.61-1.21 (comp, 6 H, C13-H, C14-H, and C13’-H); 13C NMR (100 MHz, CD3OD) δ 
177.8 (C1), 173.2 (C3), 173.0 (C5), 157.2 (C11), 131.4 (C9), 129.2 (C8), 116.2 (C10), 
60.3 (C2), 56.0 (C4), 38.2 (C7), 33.4 (C12, C12’ or C14 or C6), 33.0 (C12, C12’ or C14 




carboxylic  acid (3.15). 1-H-Tetrazole (785 mg, 11.2 mmol) and 
diisopropylphosphoramidite were added to a solution of 3.21 in DMF (21 mL) at 0 °C, 
and the solution was stirred at 0 °C for 1 h and then at room temperature for 15 h. The 
solution was cooled to 0 °C, and 6 M tert–butyl hydroperoxide in decane (5.3 mL) was 
added. The resulting solution was stirred at 0 °C for 30 min and then at room temperature 
for 5 h, whereupon it was cooled to 0 °C and 5% aqueous NaHSO3 (5 mL) was added. 
The solution was stirred at 0 °C for 30 min and then at room temperature for 2 h. The 
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mixture was transferred to a separatory funnel containing H2O (20 mL), and the layers 
were separated. The aqueous layer was extracted with CH2Cl2  (15 mL x 3) whereupon 
the combined organic layers were dried (Na2SO4) and concentrated under reduced 
pressure. The residue was triturated with Et2O (4 x 5 mL) to yield 250 mg (20%) of the 
title compound. 1H NMR (400 MHz, CDCl3) δ 7.69 (br s, 1 H), 7.34-7.27 (comp, 10 H), 
7.18 (d, J = 8.4 Hz, 2 H), 7.06 (d, J = 8.4 Hz, 2 H), 5.08 (app d, J = 6.4 Hz, 4 H), 4.83 
(dd, J = 14.4, 6.8 Hz, 1 H), 3.11-3.97 (comp, 2 H), 1.98-1.90 (comp, 2H), 1.93 (s, 3 H), 
1.77-1.65 (comp, 2 H), 1.56-1.02 (comp, 6 H); 13C NMR (100 MHz, CDCl3): δ 176.7, 
171.5, 171.4, 149.3, 149.2, 135.3, 135.2, 133.8, 130.8, 128.7, 128.6, 128.0, 120.0, 119.98, 
70.1, 70.0, 59.1, 54.4, 36.8, 32.4, 31.4, 25.0, 22.7, 21.2, 21.1. Mass spectrum (ESI) m/z 
607.2211 [C32H36N2O8P (M+H) requires 607.2215]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.69 (br s, 1H, N-H), 7.34-
7.27 (comp, 10 H, C17-H, C18-H, C19-H), 7.18 (d, J = 8.4 Hz, 2 H, C9-H), 7.06 (d, J = 
8.4 Hz, 2 H, C10-H), 5.08 (app d, J = 6.4 Hz, 4 H, C15-H), 4.83 (dd, J = 14.4, 6.8 Hz, 1 
H, C4-H), 3.10-2.97 (comp, 2 H, C7-H), 1.98-1.90 (comp, 2 H, C12’-H or C12-H), 1.93 
(s, 3 H, C6-H), 1.77-1.65 (comp, 2 H, C12-H or C12’-H), 1.56-1.02 (comp, 6 H, C13-H 
& C14-H & C13’-H); 13C NMR (100 MHz, CDCl3): δ 176.7 (C1), 171.5 (C5 or C3), 
171.4 (C5 or C3), 149.3 (C11 or C8), 149.2 (C11 or C8), 135.3 (C15), 135.2 (C15), 133.8 
(C9, C16, or C19), 130.8 (C9 or C16 or C19), 128.7 (C9 or C16 or C19), 128.6 (C18), 
128.0 (C17), 120.0 (C10), 119.98 (C10), 70.1 (C3), 59.1 (C4), 54.4 (C2), 36.8 (C7), 32.4 
(C12 or C12’), 31.4 (C12 or C12’), 25.0 (C6 or C13 or C14 or C13’), 22.7 (C6 or C13 or 
C14 or C13’), 21.2 (C6 or C13 or C14 or C13’), 21.1 (C6 or C13 or C14 or C13’). 
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Representative procedure for the synthesis of aspargine residues. 
 
 
2(S)-Amino-N’-benzylsuccinamide (3.43). Prepared from 3.23 and Cbz-Asn 
according to the general method A. The crude product was dissolved in MeOH 
containing 10% Pd/C (18 mg), and the mixture was purged four times with H2. The 
suspension was stirred under H2 (1 atm) for 2 h. The mixture was filtered through a pad 
of celite, and the pad was washed with MeOH (5.2 mL). The combined filtrate and 
washings were concentrated under reduced pressure to yield 78 mg (64%) of the title 
compound as a white solid over two steps: mp: 143-144 °C. 1H NMR (400 MHz., 
CD3OD) δ 7.31-7.29 (comp, 3 H), 7.25-7.21 (comp, 2 H), 3.70 (dd, J = 8.0, 5.1 Hz, 1 H), 
3.31-3.30 (comp, 2 H), 2.61 (dd, J = 15.5, 8.0 Hz, 1 H), 2.47 (dd, J = 15.5, 8.0 Hz, 1 H), 
1.82 (p, J = 7.5 Hz, 2 H); 13C (150 MHz) 175.1, 174.7, 138.6, 128.4, 127.4, 127.0, 52.2, 
42.9, 39.9. mass spectrum (ESI) m/z 222.1237 [C11H15N3O2 (M+1) requires 222.1240]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.31-7.29 (comp, 3 H, C8-H 
and C9-H), 7.30-7.23 (comp, 2 H, C7-H), 3.70 (dd, J = 8.0, 5.1 Hz, C2–H), 3.31-3.30 
(comp, 2 H, C5-H), 2.61 (dd, J = 15.4, 8.0 Hz, 1 H, C3-H), 2.47 (dd, J = 15.2, 8.0 Hz, 1 
H, C3–H). 13C (150 MHz) 175.1 (C1 or C2), 174.7 (C1 or C2), 138.6 (C6), 128.4 (C6), 





2(S)-Amino-N’-phenethylsuccinamide (3.32). Prepared from 3.24 according to 
the representative procedure for the synthesis of asparagine residues to yield 168 mg 
(94%) of the title compound as a white solid over two steps. mp = 143-144 °C. 1H NMR 
(400 MHz, CD3OD) δ 7.30-7.26 (comp, 3 H), 7.24-7.18 (comp, 2 H), 3.68 (dd, J = 8.0, 
5.1 Hz, 1 H), 3.46-3.40 (comp, 2H), 2.61 (dd, J = 15.4, 8.0 Hz, 1 H), 2.47 (dd, J = 15.2, 
8.0 Hz, 1 H); 13C (150 MHz) 175.1, 174.5, 139.3, 128.7, 128.4, 126.2, 52.0, 40.8, 39.5, 
35.3. mass spectrum (ESI) m/z 236.1394 [C12H17N3O2 (M+1) requires 236.1394]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.30-7.26 (comp, 3 H, C10–
H and C11–H), 7.24-7.18 (comp, 2 H, C9–H), 3.68 (dd, J = 8.0, 5.1 Hz C2–H), 3.46-3.40 
(comp, 2 H, C5–H), 2.81 (t, J = 7.1 Hz, 2 H), 2.61 (dd, J = 15.4, 8.0 Hz, 1 H, C3–H), 
2.47 (dd, J = 15.2, 8.0 Hz, 1 H, C3–H), 1.82 (p, J = 7.52 Hz, 2H, ); 13C (150 MHz) 175.1 
(C1 or C4), 174.5 (C1 or C4), 139.3 (C8), 128.7 (C10), 128.4 (C9), 126.2 (C11), 52.0 
(C2), 40.8 (C5), 39.5 (C3), 35.3 (C6). 
 
 
2(S)-Amino-N’-(3-phenylpropyl)succinamide (3.33). Prepared from 3.26 
according to the representative procedure for the synthesis of asparagine residues to yield 
18 mg (24%) of the title compound as a white solid over two steps. mp = 170-172 °C. 1H 
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NMR (400 MHz, CD3OD) δ 7.27-7.14 (comp, 5 H), 3.64 (dd, J = 8.0, 5.5 Hz, 1 H), 3.23 
(dd, J = 10.0, 5.5 Hz, 2 H), 2.66-2.58 (comp, 3 H), 2.46 (dd, J = 15.0, 8.0 Hz, 1 H), 1.82 
(p, J = 7.52 Hz, 2 H); 13C (150 MHz) 176.2, 175.8, 143.0, 129.5, 129.4, 126.9, 53.3, 41.2, 
40.0, 34.1, 32.2. mass spectrum (ESI) m/z 250.1304 [C13H17N4O2 (M+1) requires 
250.1304]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.27-7.14 (comp, 5 H, C9–H 
and C10–H and C11–H), 3.64 (dd, J = 8.0, 5.5 Hz, 1 H, C2-H), 3.23 (dd, J = 10.0, 5.5 
Hz, 2 H, C5-H), 2.66-2.58 (comp, 3 H, C7-H and C3-H), 2.46 (dd, J = 15.0, 8.0 Hz, 1 H, 
C3-H) 1.82 (p, J = 7.52 Hz, 2 H, C6–H); 13C (150 MHz) 176.2 (C1 or C4), 175.8 (C1 or 
C4), 143.0 (C8), 129.5 (C10), 129.4 (C9), 126.9 (C11), 53.3 (C2), 41.2 (C5), 40.0 (C3), 




2(S)-Amino-N’-(4-phenylbutyl)succinamide (3.34). Prepared from 3.26 
according to the representative procedure for the synthesis of asparagine residues to yield 
20 mg (50%) of the title compound as a white solid over two steps: mp = 119-121 °C. 1H 
NMR (400 MHz, CD3OD) δ 7.26-7.13 (comp, 5 H), 3.62 (dd, J = 8.0, 5.5 Hz, 1 H), 3.23-
3.19 (comp, 2 H), 2.66-2.58 (comp, 3 H), 2.46 (dd, J = 15.0, 8.0 Hz, 1 H), 1.82 (p, J = 7.5 
Hz, 2 H), 1.56 (p, J = 7.5 Hz, 2 H); 13C (150 MHz) δ 176.2, 175.8, 143.0, 129.5, 129.4, 
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126.9, 53.3, 41.2, 40.0, 34.1, 32.2, 30.9. mass spectrum (ESI) m/z 286.15265 [C14H21N3O2 
(M+Na) requires 286.1526]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.26-7.13 (comp, 5 H, C10-
H, C11-H, and C12-H), 3.62 (dd, J = 8.0 Hz, 5.5 Hz, 1 H, C2-H), 3.23-3.19 (comp, 2H, 
C5-H), 2.66-2.58 (comp, 3H, C8–H and C3-H), 2.46 (dd, J = 15.0, 8.0 Hz, 1H, C3-H), 
1.82 (p, J = 7.5 Hz, 2H, C6-H or C7-H), 1.56 (p, J = 7.5 Hz, 2H, C6-H or C7-H); 13C 
(150 MHz) δ 176.2 (C1 or C4), 175.8 (C1 or C4), 143.0 (C10, C11 or C12), 129.5 (C10, 
C11 or C12), 129.4 (C10, C11 or C12), 126.9 (C10, C11 or C12), 53.3 (C2), 41.2 (C5), 




2(S)-Amino-N’-(5-phenylpentyl)succinamide (3.35) Prepared from 3.27 
according to the representative procedure for the synthesis of asparagine residues to yield 
29 mg (70%) of the title compound  as a glass over two steps. 1H NMR (400 MHz, 
CD3OD) δ 7.11-7.10 (comp, 5 H), 3.63 (dd, J = 8.0, 5.2 Hz, 1 H), 3.22 (dd, J = 14.2, 6.8 
Hz, 1 H), 3.15 (dd, J = 14.2, 7.2 Hz, 1 H), 2.63-2.57 (comp, 3 H), 2.43 (dd, J = 15.2, 8.0 
Hz, 1 H), 1.63 (p, J = 7.6, 2 H), 1.54 (p, J = 7.2 Hz, 2 H), 1.40-1.32 (comp, 2 H); 13C 
NMR (100 MHz, CD3OD): δ 176.3, 175.9, 143.8, 129.4 (2C), 129.3 (2C), 126.7, 53.4, 
41.3, 40.4, 36.8, 32.4, 30.3, 27.5. Mass spectrum (ESI) m/z 278.1863 [C15H24N3O2 
(M+H)+ requires 278.1860].  
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NMR Assignments. 1H NMR (400 MHz, CD3OD): δ 7.11-7.10 (comp, 5 H, C11–
H, and C12–H, and C13–H), 3.63 (dd, J = 8.0, 5.2 Hz, 1 H, C2-H), 3.22 (dd, J = 14.2, 5.2 
Hz, 1 H, C5-H), 3.15 (dd, J = 14.2, 8.0 Hz, 1 H, C3–H), 2.63-2.57 (comp, 3 H, C3–H and 
C9–H), 2.43 (dd, J = 14.2, 8.0 Hz, 1 H), 1.63 (p, J = 7.6, 2 H, C6–H or C8–H), 1.54 (p, J 
= 7.6 Hz, 2 H, C6–H or C8–H), 1.40-1.32 (comp, 2 H, C7–H); 13C NMR (100 MHz, 
CD3OD): δ 176.3 (C1 or C4), 175.9 (C1 or C4), 143.8 (C11), 129.4 (2C), 129.3 (2C), 
126.7 (, 53.4 (C1), 41.3 (C5), 40.4 (C3), 36.8 (C9), 32.4 (C6, C7, or C8), 30.3 (C6, C7, or 




2(S)-Amino-N’-(3-(4-methoxyphenyl)propyl)succinamide (3.69). Prepared 
from 3.59 according to the representative procedure for the synthesis of asparagine 
residues to yield 83 mg (99%) of the title compound as a white solid: mp = 204–205 °C. 
1H NMR (400 MHz, CD3OD) δ 7.10 (d, J = 6.5 Hz, 2 H), 6.8 (d, J = 6.5 Hz, 2 H), 3.66-
3.62 (comp, 1 H), 3.23-3.19 (comp, 2 H), 2.66-2.44 (comp, 4 H), 2.15, (s, 3 H), 1.78 (p, J 
= 7.1 Hz, 2 H); 13C (150 MHz) δ 176.2, 175.8, 143.0, 129.5, 129.4, 126.9, 53.3, 41.2, 
40.0, 34.1, 32.2, 30.9. mass spectrum (ESI) m/z 280.1658 [C14H22N3O3 (M+1) requires 
280.1656]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.10 (d, J = 6.5 Hz, 2 H, C9-
H), 6.8 (d, J = 6.5 Hz, 2 H, C10-H), 3.66-3.62 (comp, 1 H, C2-H), 3.23-3.19 (comp, 2 H, 
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C5-H), 2.66-2.44 (comp, 4 H, C7-H and C5-H), 2.15 (s, 3H, C12-H), 1.78 (p, J = 7.11 
Hz, 2 H, C6-H); 13C (150 MHz) 176.2 (C1–H or C4–H), 175.8 (C1–H or C4–H), 143.0 
(C11), 129.5 (C9), 129.4 (C8), 126.9 (C10), 53.3 (C12), 41.2 (C5–H), 40.0 (C7–H), 34.1 




Prepared from 3.58 according to the representative procedure for the synthesis of 
asparagine residues to yield 69 mg (65%) of the title compound as a white solid over two 
steps. mp = 119-120 °C. 1H NMR (400 MHz, CD3OD) δ 7.55 (d, J = 8.0 Hz, 2 H), 7.40 
(d, J = 8.0 Hz, 2 H), 3.47 (dd, J = 7.1, 5.5 Hz, 1 H), 3.24-3.19 (comp, 2 H), 2.72 (t, J = 
7.8 Hz, 2 H), 2.62 (dd, J = 15.4, 7.1 Hz, 1 H), 2.62 (dd, J = 15.4, 7.1 Hz, 1 H) 1.82 (p, J = 
7.52 Hz, 2 H); 13C (150 MHz) δ 210.0, 176.2, 175.8, 147.8, 130.1, 129.2, 127.0, 126.2, 
124.8, 122.7, 41.0, 39.8, 33.8, 31.9, 30.7. mass spectrum (ESI) m/z 318.1421 
[C14H19N3O2F3 (M+1) requires 318.1421]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.55 (d, J = 8.0 Hz, 2 H, C9-
H), 7.40 (d, J = 8.0 Hz, 2 H, C10-H), 3.47 (dd, J = 7.1 Hz, 5.5 Hz, 1 H, C2–H), 3.24-3.19 
(comp, 2 H, C5–H), 2.72 (t, J = 7.8 Hz, 2 H, C7–H), 2.64 (dd, J = 15.4, 7.1 Hz, 1 H, C3–
H), 2.62 (dd, J = 15.4, 7.1 Hz, 1 H, C3-H) 1.82 (p, J = 7.52 Hz, 2 H); 13C (150 MHz) δ 
210.0 (C12), 176.2 (C1 and C4), 175.8 (C1 and C4), 147.8 (C11), 130.1 (C-Ar), 129.2 
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(C-Ar), 127.0 (C-Ar), 126.2 (C-Ar), 124.8 (C-Ar), 122.7 (C-Ar), 41.0 (C3), 39.8 (C5), 





2(S)-Amino-N’-(5-methylhexyl)succinamide (3.64). Prepared from 3.54 
according to the representative procedure for the synthesis of asparagine residues to yield 
83 mg (>99%) of the title compound as a white solid over two steps: decomp at 210 °C. 
1H NMR (400 MHz, CD3OD) δ 3.61 (dd, J = 8.2, 5.1 Hz, 1 H), 3.24-3.12 (comp, 2 H), 
2.62 (dd, J = 15.2, 8.2 Hz, 1 H), 2.42 (dd, J = 15.2, 8.2 Hz, 2 H), 1.59-1.47 (comp, 3 H), 
1.24-1.20 (comp, 1-H), 0.89 (d, J = 6.5 Hz); δ 13C (150 MHz) 221.5, 39.3, 39.1, 29.5, 
27.9, 24.6, 21.8.  mass spectrum (ESI) m/z 252.1682 [C11H23N3O2 (M+Na+1) requires 
252.1683]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 3.61 (dd, J = 8.2, 5.1 Hz, 1 
H, C2–H), 3.24-3.12 (comp, 2 H, C5-H), 2.62 (dd, J = 15.2, 8.2 Hz, 1 H, C3–H), 2.42 
(dd, J = 15.2, 8.2 Hz, 1 H, C3-H), 1.59-1.47 (comp, 3 H, C6-H or C7-H), 1.38-1.24 
(comp, 2 H, C6-H or C7-H), 1.24-1.20 (comp, 3 H, C9–H and C8–H), 0.89 (d, J = 6.5 
Hz, 6 H, C10–H); δ 13C (150 MHz) 221.5 (C1 and C4), 39.3, (C5), 39.1 (C6), 39.1 (C3), 
29.5 (C7, C8, C9, or C10), 27.9 (C7, C8, C9, or C10), 24.6 (C7, C8, C9, or C10), 21.8 
(C7, C8, C9, or C10). 
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2(S)-Amino-N’-(4-methylpentyl)succinamide (3.65). Prepared from 3.55 
according to the representative procedure for the synthesis of asparagine residues to yield 
89 mg (67%) of the title compound as a glass over two steps. 1H NMR (400 MHz, 
CD3OD) δ 3.41 (dd, J = 7.1, 5.5 Hz, 1 H), 3.24-3.12 (comp, 2H), 2.62 (dd, J = 15.2, 7.1 
Hz, 1 H), 2.53-2.19 (comp, 2 H), 1.59-1.47 (comp, 3 H), 1.24-1.20 (comp, 1 H), 0.89 (d, 
J = 6.5 Hz). mass spectrum (ESI) m/z 216.1706 [C10H22N3O2 (M+1) requires 216.1705]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ  3.41 (dd, J = 7.1, 5.5 Hz, 1 
H, C2–H), 3.24-3.12 (comp, 2 H, C5–H), 2.62 (dd, J = 15.2, 7.1 Hz, 1 H, C3–H), 2.53-
2.19 (comp, 2 H, C6-H), 1.59-1.47 (comp, 2 H, C7-H), 1.24-1.20 (comp, 1 H, C8-H), 




2(S)-Amino-N’-(3-cyclohexylpropyl)succinamide (3.63). Prepared from 3.53 
according to the representative procedure for the synthesis of asparagine residues to yield 
800 mg (72%) of the title compound as a white solid: mp = 167-168 °C. 1H NMR (400 
MHz, CD3OD) δ 4.13 (dd, J = 8.5, 4.8 Hz, 1 H), 3.25-3.12 (comp, 2 H), 2.84 (dd, J = 
17.2, 4.8 Hz, 1 H), 2.74 (dd, J = 17.2, 4.8 Hz, 1 H), 1.79-1.62 (comp, 5 H), 1.55-1.51 
(comp, 2 H), 1.27-1.18 (comp, 6 H), 0.94-0.84 (comp, 2 H); δ 13C (150 MHz) 221.5, 
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211.3, 39.8, 37.5, 35.1, 34.5, 33.3, 26.55, 26.45, 26.23. mass spectrum (ESI) m/z 
256.2025 [C13H26N3O2 (M+Na+1) requires 256.2020]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ  4.13 (dd, J = 8.5, 4.8 Hz, 1 
H, C2-H), 3.25-3.12 (comp, 2 H, C5-H), 2.84 (dd, J = 17.2, 4.8 Hz, 1 H, C3-H), 2.74 dd, 
J = 17.2, 4.8 Hz, 1 H, C3–H), 1.79-1.62 (comp, 5 H, C6–H, C7–H, C8–H, C9–H, or 
C10–H), 1.55-1.51 (comp, 2 H, C6–H, C7–H, C8–H, C9–H, or C10–H), 1.27-1.18 
(comp, 6 H, C6–H, C7–H, C8–H, C9–H, or C10–H), 0.94-0.84 (comp, 2 H, C6–H, C7–
H, C8–H, C9–H, or C10–H); δ  13C (150 MHz) 221.5, (C1 or C4) 211.3 (C1 or C4), 39.8 
(C5), 37.5 C3), 35.1 (C6), 34.5 (C7, C8, C9,  or C10), 33.3 (C7, C8, C9,  or C10), 26.55 
(C7, C8, C9,  or C10) , 26.45, (C7, C8, C9,  or C10) 26.23 (C7, C8, C9,  or C10). 
 




yl)cyclohexyl)amino)-3-oxopropyl)phenyl dehydrogenate phosphate (3.06). Prepared 
from 3.31 and 3.15 according to the general method A. The crude product was dissolved 
in MeOH containing 10% Pd/C (4 mg), and the mixture was purged four times with H2. 
The suspension was stirred under H2 (1 atm) for 2 h. The mixture was filtered through a 
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pad of celite, and the pad was washed with MeOH (5.0 mL). The combined filtrate and 
washings were concentrated under reduced pressure to yield 14 mg (72%) of the title 
compound over two steps. The crude material was purified via preparative RP HPLC 
using a gradient of 10% B to 95% B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.31-
7.24 (comp, 5 H), 7.19-7.14 (comp, 4 H), 4.60 (dd, J = 13.3, 4.8 Hz, 2 H), 4.47 (dd, J = 
15.2, 5.1 Hz, 1 H), 4.35 (dd, J = 13.3 Hz, 4.8 Hz, 1 H), 2.97 (dd, J = 14.4, 5.1 Hz, 1 H), 
2.86 (dd, J = 14.4, 5.1 Hz , 1 H), 2.78-2.71 (comp, 2 H), 2.00-1.92 (comp, 2 H), 1.82 (s, 3 
H), 1.76-1.69 (comp, 2 H), 1.56-1.46 (br, 3 H), 1.27–1.18 (br, 3 H); 13C (150 MHz, 
CD3OD) δ 176.7, 175.6, 174.4, 174.3, 173.6, 139.8, 134.1, 131.3, 129.4, 128.4, 128.1, 
121.3, 61.3, 61. 2, 56.3, 52.3, 44.1, 37.1, 36.7, 33.0, 32.60, 26.2, 22.2, mass spectrum 
(ESI) m/z 654.23004 [C29H44N5O9P Na (M+1) requires 654.2300]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.31-7.24 (comp, 5 H, C7-
H, or C22-H, C23-H or C24-H), 7.19-7.14 (comp, 4 H, C8-H or C22-H or C23-H or C24-
H), 4.60 (dd, J = 13.3 Hz, 4.8 Hz, 2 H, C20-H), 4.47 (dd, J = 15.2, 5.1 Hz, 4.1 Hz, 1 H, 
C3-H), 4.35 (dd, J = 13.3, 4.8 Hz, 1 H, C15-H), 2.97 (dd, J = 14.4, 5.1 Hz, 1 H, C5-H), 
2.86 (dd, J = 14.4, 5.1 Hz, 1 H, C5-H), 2.78-2.71 (comp, 2 H, C16-H), 2.00-1.92 (comp, 
2 H, C11-H), 1.82 (s, 3 H, C1-H), 1.76-1.69 (comp, 2 H, C11-H), 1.56-1.46 (br, 3 H, 
C13-H and C-12H), 1.27–1.18 (br, 3 H); 13C (150 MHz, CD3OD) δ 176.7 (C9 or C16), 
175.6 (C9 or C16), 174.4 (C2, or C17 or C18), 174.3 (C2, or C17 or C18), 173.6 (C2, or 
C17 or C18), 139.8 (C9), 134.1 (C7), 131.3 (C6), 129.4 (C8), 128.4 (C–Ar), 128.1 (C–
Ar), 121.3 (C–Ar), 61.3 (C3 or C10 or C15), 61.2 (C3 or C10 or C15), 56.3 (C3 or C10 
or C15), 52.3, (C3 or C10 or C15) 44.1 (C20), 37.1 (C5 or C17), 36.7 (C5 or C17), 33.0 
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(C11), 32.60 (C11’), 26.2 (C12 or C12’ or C13), 22.3 (C12 or C12’ or C13), 22.2 (C12 or 
C12’ or C13). 
 
4(S)-2-Acetamido-3-((1-(((S)-4-amino-1,4-dioxo-1-(phenethylamino)butan-2-
yl)carbamoyl)cyclohexyl)amino)-3-oxopropyl)phenyl dihydrogen phosphate (3.07). 
Prepared from 3.24 according to the representative procedure for the synthesis of 
tripeptides to yield 27 mg (34%) of the title compound as over two steps. The crude 
material was purified via preparative RP HPLC using a gradient of 10% B to 95% B over 
30 min. 1H NMR (400 MHz, CD3OD) δ 7.27 – 7.24 (comp, 6 H), 7.17-7.14 (comp, 3 H), 
4.65 (dd, J = 9.5, 6.3 Hz, 1 H), 4.53 (dd, J = 6.9, 5.1 Hz, 1 H), 3.42-3.38 (comp, 2 H), 
3.13-3.09 (comp, 1 H), 2.94-2.86 (comp, 1 H), 2.84–2.68 (comp, 4H), 1.98-1.95 (br, 2 
H), 1.88 (s, 3 H), 1.8-1.71 (br, 3 H), 1.54 (comp, 3 H), 1.4-1.2 (m, 4 H); 13C (150 MHz, 
CD3OD) δ 176.6, 175.7, 174.2, 173.6, 172.9, 140.5, 134.7, 131.4, 129.8, 129.4, 127.3, 
121.4, 61.3, 56.3, 52.1, 42.4, 37.2, 36.7, 36.5, 32.8, 26.2, 22.3. mass spectrum (ESI) m/z 
668.2456 [C30H39N5O9P-1 (M+1) requires 668.2464]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.27 – 7.24 (comp, 6 H, C7-
H, or C21-H, C22-H or C23-H), 7.17-7.14 (comp, 3 H, C8–H and C25–H), 4.65 (dd, J = 
9.5, 6.3 Hz, 1 H, C3–H), 4.53 (dd, J = 6.9, 5.1 Hz, 1 H, C14–H), 3.42-3.38 (comp, 2 H, 
C17-H), 3.13-3.09 (comp, 1 H, C5-H), 2.94-2.86 (comp, 1 H, C5-H), 2.84–2.68 (comp, 4 
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H, C21–H and C17–H) 1.98-1.95 (comp, 2 H, C11–H), 1.88 (s, 3 H, C1–H), 1.8-1.71 (br, 
2 H, C11’–H), 1.54–1.44 (br, 3 H, C12–H and C13–H), 1.4-1.2 (br, 4 H C12’–H and 
C13–H). 13C (150 MHz, CD3OD) δ 176.6 (C9 or C16), 175.7 (C9 or C16), 174.2 (C2, 
C17, or C18), 173.6 (C2, C17, or C18), 172.9 (C2, C17, or C18), 140.5 (C–Ar), 134.7 
(C–Ar), 131.4 (C–Ar), 129.8 (C–Ar), 129.4 (C–Ar), 127.3 (C–Ar), 121.4 (C–Ar), 61.3 
(C3, C10, or C15), 56.3 (C3, C10, or C15), 52.1 (C3, C10, or C15), 42.4 (C20), 37.2 (C5 






dihydrogen phosphate (3.08). Prepared from 3.25 according to the representative 
procedure for the synthesis of tripeptides to yield 9 mg (28%) of the title compound over 
two steps. The crude material was purified via preparative RP HPLC using a gradient of 
10% B to 95% B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.24 – 7.19 (comp, 6 H), 
7.14-7.12 (comp, 3 H), 4.65 (dd, J = 9.5, 6.3 Hz, 1 H), 4.53 (dd, J = 6.9, 5.1 Hz, 1 H), 
3.26-3.22 (comp, 2 H), 3.13–3.11 (comp, 1 H), 2.92–2.71 (comp, 3 H) 2.66-2.62 (t, J = 
7.5 Hz, 2 H), 2.05-1.93 (br s, 2 H), 1.88 (s, 3 H), 1.8-1.71 (comp, 3 H), 1.54 (br s, 1 H), 
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1.23 (br s, 3 H); 13C (150 MHz, CD3OD) δ 175.5, 174.5, 173.1, 172.4, 171.8, 151.6, 
139.3, 133.1, 130.1, 128.6, 128.3, 126.1, 120.2, 60.0, 55.2, 51.0, 41.2, 36.0, 35.6, 35.3, 
31.6 (2), 25.0, 21.1. mass spectrum (ESI) m/z 660.2793 [C31H43N5O9P-1 (M+1) requires 
660.2793]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.24 – 7.19 (comp, 6 H, C7-
H, or C24-H, C25-H or C26-H), 7.14-7.12 (comp, 3 H, C8–H and C26–H), 4.65 (dd, J = 
9.5, 6.3 Hz, 1 H, C3-H), 4.53 (dd, J = 6.9, 5.1 Hz, 1 H, C15-H), 3.26-3.22 (comp, 2 H, 
C20-H), 3.13–3.11 (comp, 1 H, C4-H), 2.92–2.71 (comp, 3 H, C22-H and C4-H) 2.66-
2.62 (t, J = 7.5 Hz, 2 H, C21-H), 2.05-1.93 (br s, 2 H, C11-H), 1.88 (s, 3 H, C1-H), 1.8-
1.71 (m, 3.6 H, C11’-H), 1.54 (br s, 3 H, C12-H and C13-H), 1.23 (br s, 3 H, C12’-H and 
C13-H ). 13C (150 MHz, CD3OD) δ 175.5 (C4 or C14), 174.5 (C4 or C14), 173.1 (C2, 
C18, or C19), 172.4 (C2, C18, or C19), 171.8 (C2, C18, or C19), 151.6 (C-Ar), 139.3 (C-
Ar), 133.1(C-Ar), 130.1 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 126.1 (C-Ar), 120.2(C-Ar), 
60.0 (C3, C10, C15), 55.2 (C3, C10, C15), 51.0 (C3, C10, C15), 41.2 (C20), 36.0(C22), 









dihydrogen phosphate (3.09). Prepared from 3.26 according to the representative 
procedure for the synthesis of tripeptides to yield 20 mg (15%) of the title compound 
over two steps. The crude material was purified via preparative RP HPLC using a 
gradient of 10% B to 95% B over 30 min.1H NMR (400 MHz, CD3OD) δ 7.23 – 7.19 
(comp, 6 H), 7.14-7.12 (comp, 3 H), 4.66 (dd, J = 9.5, 6.1 Hz, 1 H), 4.53 (dd, J = 6.9, 5.1 
Hz, 1 H), 3.26-3.08 (comp, 3 H), 2.92-2.76 (comp, 3 H), 2.66-2.62 (t, J = 7.5 H, 2 H), 
2.05-1.93 (br s, 2 H), 1.88 (s, 3 H), 1.8-1.71 (comp, 3 H), 1.54 (br s, 3 H), 1.23 (br s, 3 
H); 13C (150 MHz, CD3OD) δ 176.6, 175.6, 174.2, 173.6, 172.9, 143.7, 131.4, 129.5, 
129.3, 126.7, 121.4, 61.2, 52.3, 40.4, 37.1, 36.7, 36.5, 33.0, 32.6, 29.9, 29.8, 26.2, 22.3, 
22.2 mass spectrum (ESI) m/z 672.2804 [C32H44N5O9P-1 (M+1) requires 672.2802]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.23 – 7.19 (comp, 6 H, C7-
H, or C24-H, C25-H or C26-H), 7.14-7.12 (comp, 3 H, C8–H and C26–H),  4.66 (dd, J = 
9.5, 6.1 Hz, 1 H, C3-H), 4.53 (dd, J = 6.9, 5.1 Hz, 1 H, C15–H), 3.26-3.08 (comp, 3 H, 
C19–H), 2.92-2.76 (comp, 3 H, C22–H and C4–H), 2.66-2.62 (comp, 2 H, C20–H or 
C21–H), 2.05-1.93 (m, 2 H, C11–H), 1.88 (s, 3 H, C1–H), 1.8-1.71 (m, 3.6 H, C11’–H), 
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1.54 (br s, 3 H, C12–H and C13–H), 1.23 (br s, 3 H, C12’–H, C13–H). 13C (150 MHz, 
CD3OD) δ 176.6 (C9 or C14), 175.6 (C9 or C14), 174.2 (C2, C17, or C18), 173.6 (C2, 
C17, or C18), 172.9 (C2, C17, or C18), 143.7 (C–Ar), 131.4 (C–Ar), 129.5 (C–Ar), 129.3 
(C–Ar), 126.7 (C–Ar), 121.4 (C–Ar), 61.2 (C3-H, C10–H, or C15–H), 56.9 (C3-H, C10–
H, or C15–H), 52.3 (C3-H, C10–H, or C15–H), 40.4 (C19–H), 37.1 (C22), 36.7 (C4 or 
C16), 36.5 (C4 or C16), 33.0 (C11 or C11’), 32.6 (C11 or C11’), 29.9 (C20 or C21), 29.8 





phosphate (3.48) Prepared from 3.59 according to the representative procedure for the 
synthesis of tripeptides to yield 15 mg (20%) of the title compound over two steps. The 
crude material was purified via preparative RP HPLC using a gradient of 10% B to 95% 
B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.22 (d, J = 8.2 Hz, 2 H), 7.14-7.10 
(comp, 4 H), 6.77 (d, J = 8.2 Hz, 2 H), 4.65 (dd, 1.0 H, J = 9.2, 6.2 Hz, 1 H), 4.54-4.50 
(comp, 1 H), 3.73 (s, 3 H), 3.33-3.27 (comp, 2 H), 3.13-3.10 (dd, J = 14.0, 6.2 Hz, 1 H), 
2.91-2.75 (comp, 3 H), 2.57 (t, J = 7.52 Hz, 2 H), 2.00-1.88 (br s, 2 H), 1.88 (s, 3 H), 
1.82-1.71 (comp, 5 H), 1.56-1.54 (comp, 4 H); 13C NMR (125 MHz, CD3OD) δ 176.6, 
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175.7, 174.3, 173.6, 172.9, 159.3, 151.7, 135.2, 134.7, 131.4, 130.4, 121.3, 114.8, 61.2, 
56.3, 55.6, 52.3, 40.3, 37.1, 36.6, 33.1, 32.4, 26.2, 22.3, 22.2. mass spectrum (ESI) m/z 
638.2963 [C32H45N5O10P-1 (M+1) requires 638.2960]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.22 (d, J = 8.2 Hz, 2 H, 
C24–H), 7.14-7.10 (comp, 2 H, C7-H and C8-H), 6.77 (d, J = 8.2 Hz, 2 H, C25-H), 4.65 
(dd, 1 H, J = 9.2, 6.2 Hz, C3-H), 4.54-4.50 (comp, 1 H, C15-H), 3.73 (s, 3 H, C27-H), 
3.23 (dd, J = 13.1, 6.8 Hz, 2 H, C20-H), 3.12 (dd, J = 14.0, 6.2 Hz, 1 H, C5–H), 2.91-
2.75 (comp, 3 H C5–H and C22–H), 2.57 (t, J = 7.52 Hz, 2 H, C21–H), 2.00-1.88 (comp, 
3 H, C11–H), 1.88 (s, 3 H, C1–H), 1.82-1.71 (comp, 5 H, C11’–H), 1.56-1.54 (comp, 3 
H, C13–H and C12–H or C12’–H), 1.23 (br s, 3 H, C13–H and C12–H or C12’–H). 13C 
NMR (125 MHz, CD3OD) δ 176.6 (C9 or C14), 175.7 (C9 or C14), 174.3 (C2, C17, or 
C18), 173.6 (C2, C17, or C18), 172.9 (C2, C17, or C18), 159.3 (C-Ar), 151.7 (C-Ar), 
135.2 (C-Ar), 134.7 (C-Ar), 131.4 (C-Ar), 130.4 (C-Ar), 121.3 (C-Ar), 114.8 (C-Ar), 
61.2 (C3-H, C10–H, or C15–H), 56.3 (C3-H, C10–H, or C15–H), 55.6 (C27), 52.3 (C3-
H, C10–H, or C15–H), 40.3 (C20), 37.1 (C22), 36.6 (C5 or C17), 33.1 (C3-H, C10–H, or 






phosphate (3.47). Prepared from 3.58 according to the representative procedure for the 
synthesis of tripeptides to yield 31 mg (94%) of the title compound over two steps. The 
crude material was purified via preparative RP HPLC using a gradient of 10% B to 95% 
B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.47 (d, J = 8.2 Hz, 2 H), 7.36 (d, J = 8.0 
Hz, 2 H), 7.22 (d, J = 8.2 Hz, 2 H), 7.14 (d, J = 8.0 Hz, 2 H), 4.65 (dd, J = 8.5, 7.5 Hz, 1 
H), 4.53-4.51 (m, 1 H), 3.22 (t, J = 6.59 Hz, 2 H), 3.11 (dd, J = 14.0, 6.1 Hz, 1 H), 2.91-
2.75 (comp, 3 H), 2.00-1.88 (comp, 3 H), 1.88 (s, 3 H), 1.82-1.71 (comp, 5 H), 1.56-1.54 
(comp, 4 H); 13C NMR (125 MHz, CD3OD) δ 176.6, 175.7, 174.3, 173.6, 172.9, 159.3, 
151.7, 135.2, 134.7, 131.4, 130.4, 121.3, 114.8, 61.2, 56.3, 55.6, 52.3, 40.3, 37.1, 36.6, 
33.1, 32.4, 26.2, 22.3, 22.2.  mass spectrum (ESI) m/z 726.2527 [C32H40N5O9P-1 (M-1) 
requires 726.2521]. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.47 (d, J = 8.2 Hz, 2 H, 
C24–H), 7.36 (d, J = 8.0 Hz, 2 H, C6–H), 7.22 (d, J = 8.2 Hz, 2 H, C23–H), 7.14 (d, J = 
8.0 Hz, 2 H, C7–H), 4.65 (dd, J = 8.5, 7.5 Hz, 1 H, C3-H), 4.53-4.51 (m, 1 H, C15-H), 
3.22 (t, J = 6.59 Hz, 2 H, C19-H), 3.13-3.10 (dd, J = 14.0, 6.1 Hz, 1 H, C4–H), 2.91-2.75 
(comp, 3 H C21-H and C4-H), 2.00-1.88 (comp, 2 H, C11–H), 1.88 (s, 3 H, C1–H), 1.82-
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1.71 (comp, 2 H C11’–H), 1.56-1.54 (comp, 4 H, C13 and C12 or C12’), 1.23 (comp, 3 
H, C13–H and C12–H or C12’–H); 13C NMR (125 MHz, CD3OD) δ 176.6 (C9 or C14), 
175.7 (C9 or C14), 174.3 (C2, C17, or C18), 173.6 (C2, C17, or C18), 172.9 (C2, C17, or 
C18), 159.3 (C8), 151.7 (C–Ar), 135.2 (C–Ar), 134.7 (C–Ar), 131.4 (C–Ar),  130.4 (C–
Ar), 121.3 (C–Ar), 114.8 (C–Ar), 61.2 (C3-H, C10–H, or C15–H), 56.3 (C3-H, C10–H, 
or C15–H), 55.6 (C3-H, C10–H, or C15–H), 52.3 (C19), 40.3 (C21), 37.1 (C22), 36.6 
(C4 or C16), 33.1 (C4 or C16), 32.4 (2) (C11 and C11’), 26.2 (C20), 22.3 (C13), 22.2 







phosphate (3.43). Prepared from 3.55 and 3.15 according to the representative procedure 
for the synthesis of tripeptides to yield 12 mg (87%) of the title compound over two 
steps. The crude material was purified via preparative RP HPLC using a gradient of 10% 
B to 95% B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.26 (d, J = 8.2 Hz, 2 H), 7.14 
(d, J = 8.2 Hz, 2 H), 4.62-4.68 (m, 1 H), 4.47-54 (m, 1 H), 3.08-3.20 (comp, 3 H), 2.91 
(dd, J = 9.2 Hz, 7.2 Hz, 1 H), 2.80 (dd, J = 12.3 Hz, 7.0 Hz, 1 H), 2.73 (dd, J = 12.3 Hz, 
7.0 Hz, 1 H), 2.00-1.92 (comp, 2 H), 1.91 (s, 3 H), 1.74-1.61 (comp, 2 H), 1.52-1.49 
(comp, 5 H), 1.38 (m, 1 H) 1.22-1.17 (comp, 4 H), 0.87 (d, J = 6.5 Hz, 6 H); 13C NMR 
(125 MHz, CD3OD) 176.6, 175.7, 174.3, 173.6, 152.0, 134.6, 131.4, 121.4, 61.2, 56.4, 
52.3, 41.0, 37.14, 37.05, 33.0, 32.5, 29.0, 28.2, 26.2, 23.0, 22.3, 22.2. mass spectrum 
(ESI) m/z 624.2806 [C28H43N5O10NaP+1 (M+1) requires 624.2804]. 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.26 (d, J = 8.2 Hz, 2 H, 
C7–H), 7.14 (d, J = 8.2 Hz, 2 H, C8–H), 4.65 (comp, 1 H, C3–H), 4.51 (comp, 1 H, C15–
H), 3.16 (m, 3 H, C20–H and C5–H), 2.91 (dd, J = 9.2 Hz, 7.2 Hz, 1 H, C5–H ), 2.80 (dd, 
J = 12.3 Hz, 7.0 Hz, 1 H, C17-H), 2.73 (dd, J = 12.3 Hz, 7.0 Hz, 1 H, C17–H), 2.00-1.92 
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(comp, 2 H, C11–H), 1.91 (s, C1-H), 1.74-1.61 (comp, 2 H, C11’–H), 1.52-1.49 (br s, 3 
H, C13–H and C12–H or C12’–H ), 1.21–1.19 (br s, 3 H, C13–H and C12–H or C12’–H 
); 13C NMR (125 MHz, CD3OD) δ 176.58 (C4 or C14), 175.5 (C4 or C14), 174.3 (C2, 
C18, or C19), 173.6 (C2, C18, or C19), 172.8 (C2, C18, or C19), 152.0 (C9), 134.6 C7), 
131.4 (C6), 121.4 (8), 61.2 (C3, C10 or C15), 56.4 (C3, C10 or C15), 52.3 (C3, C10 or 
C15),41.0 (C20), 37.14 (C5 or C17), 37.10 (C5 or C17), 36.8 (C11 or C11’)), 33.0 (C11 
or C11’), 32.5 (C21, C22, C23, C24, or C25), 29.0 (C21, C22, C23, C24, or C25), 28.2 
(C21, C22, C23, C24, or C25), 26.1 (C21, C22, C23, C24, or C25), 23.0 (C21, C22, C23, 





phosphate (3.44). Prepared from 3.54 according to the representative procedure for the 
synthesis of tripeptides to yield 13 mg (22%) of the title compound over two steps. The 
crude material was purified via preparative RP HPLC using a gradient of 10% B to 95% 
B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.19 (d, J = 8.2 Hz, 2 H), 7.05 (d, J = 8.2 
Hz, 2 H), 4.57-4.55 (dd, 1 H, J = 8.9, 6.2 Hz, 1 H), 4.54-4.48 (dd, J = 7.2, 5.5 Hz, 1 H), 
3.10-3.01 (comp, 3 H), 2.85-2.79 (comp, 1 H), 2.74-2.61 (comp, 2 H), 2.00-1.88 (comp, 5 
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H), 1.74-1.61 (comp, 2 H), 1.52-1.49 (comp, 6 H), 1.29-1.12 (comp, 7 H) 0.78-0.76 
(comp, 6 H); 13C NMR (125 MHz, CD3OD) 176.6, 175.7, 174.3, 173.6, 152.0, 134.643, 
131.4, 121.4, 61.2, 56.4, 52.3,41.1, 37.1, 37.0, 33.0, 32.5, 29.0, 28.2, 26.2, 23.0, 22.2, 
22.2 mass spectrum (ESI) m/z 638.2963 [C29H45N5O9P-1 (M+1) requires 638.2960.] 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.19 (d, J = 8.2 Hz, 2 H, C6-
H), 7.05 (d, J = 8.2 Hz, 2 H, C7-H), 4.57-4.55 (dd, 1 H, 8.9 Hz, 6.2 Hz, C3-H), 4.54-4.48 
(m, 1 H, C15-H), 3.10-3.01 (comp, 3 H, C19-H and C4-H), 2.85-2.79 (m, 1 H, C4-H), 
2.74-2.61 (comp, 2 H, C16-H), 2.00-1.88 (comp, 5 H, C11-H and C1-H), 1.74-1.61 
(comp, 2 H, C11-H), 1.52-1.49 (comp, 6.0 H, C12-H, C13-H, C20-H, C21-H, C22-H or 
C23-H ), 1.29-1.12 (comp, 7 H, C12-H, C13-H, C20-H, C21-H, C22-H or C23-H) 0.78-






phosphate (3.63). Prepared from 3.53 according to the representative procedure for the 
synthesis of tripeptides to yield 19 mg (75%) of the title compound over two steps. The 
crude material was purified via preparative RP HPLC using a gradient of 10% B to 95% 
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B over 30 min. 1H NMR (400 MHz, CD3OD) δ 7.28-7.26 (comp, 2 H), 7.15-7.13 (comp, 
2 H), 4.68-4.64 (comp, 1 H), 4.54-4.48 (comp, 1 H), 3.19-3.07 (comp, 3 H), 2.92-2.89 
(dd, J = 13.7 Hz, 9.6 Hz, 1 H), 2.83-2.79 (comp, 2 H), 2.00-1.92 (br d, 2 H), 1.88 (s, 3 H), 
1.74-1.61 (comp, 7.0 H), 1.59-1.49 (comp, 5 H), 0.87-0.85 (comp, 2 H), 1.24-1.08 (comp, 
9 H) 0.95-0.81 (comp, 2 H); 13C NMR (125 MHz, CD3OD) 177.6, 176.58, 175.6, 174.3, 
173.7, 173.0, 172.8, 152.18, 134.28, 131.4, 131.3, 121.4, 61.3, 61.2, 60.2, 56.4, 55.7, 
52.2, 41.0, 38.8, 38.0, 37.0, 36.7, 35.7, 34.5, 33.3, 31.8, 32.4, 27.77, 27.68, 26.4, 26.2, 
22.45, 22.42, 22.37, 22.31, 22.2. mass spectrum (ESI) m/z 664.3120 [C31H47N5O9P-1 
(M+1) requires 664.3117] 
NMR Assignments. 1H NMR (400 MHz, CD3OD) δ 7.28-7.24 (comp, 2 H, C6-
H), 7.15-7.13 (comp, 2 H, C7-H), 4.68-4.64 (m, 1 H, C3-H), 4.54-4.48 (m, 1 H, C15-H), 
3.19-3.07 (comp, 2 H, C19-H and C4-H), 2.92-2.89 (dd, J = 13.7, 9.6 Hz, 1 H, C4-H), 
2.83-2.79 (comp, 2 H, C16-H), 2.00-1.92 (comp, 2 H, C11-H), 1.88 (s, 3 H, C1-H), 1.74-
1.61 (comp, 4 H, C11-H and C23-H), 1.52-1.49 (comp, 5 H, C20-H, C21-H and C22-H), 
0.87-0.85 (comp, 2 H, C24-H or C25-H); 13C NMR (125 MHz, CD3OD) 177.6 (C9 or 
C14), 175.6 (C9 or C14), 174.3 (C2, C17, or C18), 173.7 (C2, C17, or C18), 173.0 (C2, 
C17, or C18), 172.8 (C2, C17, or C18), 152.18 (C8), 134.28 (C6), 131.4 (C5), 121.4 
(C7), 61.3 (C3, C10, or C15), 61.2 (C3, C10, or C15), 60.2 (C3, C10, or C15), 56.4, 55.7, 
52.2, 41.0 (C19), 38.8 (C4 or C16), 38.0 (C4 or C16), 37.0 (C11), 36.7 (C11’), 35.7 
(C22, C23, C24, C21, or C20) 34.5 (C22, C23, C24, C21, or C20), 33.3 (C22, C23, C24, 
C21, or C20), 31.8 (C22, C23, C24, C21, or C20), 32.4 (C22, C23, C24, C21, or C20), 
27.77 (C22, C23, C24, C21, or C20), 26.4, (C22, C23, C24, C21, or C20) 22.45, (C22, 




N-TFA-Ile-Asn-N-(propylCyHex) (3.71) Prepared from 3.70 and Boc-Ile 
according to the general method B to give the crude product as a white solid: mp = 182-
183 °C. The white solid was then dissolved in CH2Cl2 (2.0 mL) whereupon TFA (530 
mg, 4.6 mmol) was added to the mixture and the resulting solution was allowed to stir for 
8 h at room temperature.  It was then concentrated to dryness under reduced pressure to 
give a brown solid.  The crude solid was triturated with Et2O to provide 252 mg (46%, 2 
steps) of the title compound as a white powder. 1H NMR (400 MHz, CD3OD) δ 4.73 
(comp, 1 H), 3.70 (comp, 1 H), 3.18-3.08 (comp, 2 H), 2.74-2.61 (comp, 2 H), 1.94-1.90 
(m, 1 H), 1.72-1.63 (comp, 5 H), 1.60-1.55 (comp, 1H), 1.49 (p, J = 8.0 Hz, 2 H), 1.29-
1.14 (comp, 7 H), 1.01 (d, J = 7.3 Hz, 3 H), 0.96 (t, J = 7.3 Hz, 3 H), 0.92-0.84 (comp, 2 
H); 13C NMR (125 MHz, CD3OD) δ 174.5, 172.3, 169.3, 58.9, 51.7, 40.9, 38.7, 38.0, 
37.8, 35.7, 34.5, 27.7, 27.5, 25.4, 11.6 mass spectrum (ESI) m/z 369.2861 
[C19H37N4O3(M+1) requires 369.2860]. 
NMR Assignments: 1H NMR (400 MHz, CD3OD) δ 4.73 (comp, 1 H, C7-H), 
3.70 (comp, 1 H, C1-H), 3.18-3.08 (comp, 2 H, C11-H), 2.74-2.61 (comp, 2 H, C8-H), 
1.94-1.90 (m, 1 H, C2-H), 1.72-1.63 (comp, 5 H, C12-H, C13-H, C14-H, C15-H, C16-H 
or C17-H), 1.60-1.55 (m, 1H, C12, C13, C14, C15, C16 or C17-H), 1.49 (p, J = 8.0 Hz, 2 
H, C4-H3), 1.29-1.14 (comp, 7 H, C12-H, C13-H, C14-H, C15-H, C16-H or C17-H), 
1.01 (d, J = 7.3 Hz, 3 H, C3-H), 0.96 (t, J = 7.3 Hz, 3 H, C5-H), 0.92-0.84 (comp, 2 H, 
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C12, C13, C14, C15, C16 or C17-H); 13C NMR (125 MHz, CD3OD) δ 174.5 (C9), 172.3 
(C10), 169.3 (C6), 58.9 (C1), 51.7 (C7), 40.9 (C11), 38.7 (C8), 38.0 (C2), 37.8 (C13, 
C15, or C15’), 35.7 (C13, C15, or C15’), 34.5 (C13, C15, or C15’), 27.7 (C18, C22, or 
C23), 27.5 (C4), 25.4 (C3), 11.6 (C5). 
 
N-TFA-Tyr-Ile-Asn-N-(propyl-CyHex) (3.72). Prepared from 3.71 and Boc-Tyr 
according to the general method B to give the crude product as a white solid: mp = 206–
208 °C. The white solid was then dissolved in CH2Cl2 (2.0 mL) whereupon TFA (530 
mg, 4.6 mmol) was added to the mixture and the resulting solution was allowed to stir for 
8 h at room temperature.  It was then concentrated to dryness under reduced pressure to 
give a brown solid. The crude solid was triturated with Et2O to provide 178 mg (66%, 2 
steps) of the title product as a clear glass. 1H NMR (600 MHz, CD3OD) δ 7.11-7.09 
(comp, 2 H), 6.79-6.76 (comp, 2H), 4.67 (t, J = 6.6 Hz, 1 H), 4.22 (d, J = 7.5 Hz, 1 H), 
4.1 (m, 1 H), 3.20-3.13 (comp, 3 H) 2.93-2.87 (m, 1 H) 2.73-2.64 (comp, 2 H), 1.86-1.82 
(comp, 1 H), 1.72-1.62 (comp, 5 H), 1.58-1.55 (m, 1H), 1.49 (p, J = 7.6 Hz, 2 H), 1.29-
1.14 (comp, 7 H), 0.94 (d, J = 7.5 Hz, 3 H), 0.91 (t, J = 7.5 Hz, 3 H), 0.92-0.84 (comp, 2 
H);  13C NMR (125 MHz, CD3OD) δ 174.7, 172.6, 172.5, 170.0, 158.3, 131.6, 125.9, 
116.9, 116.3, 59.6, 55.7, 51.7, 40.9, 38.7, 38.2, 37.87, 37.80, 35.7, 34.5, 27.8, 27.5, 26.0, 
15.9, 11.5. mass spectrum (ESI) m/z 532.3497 [C28H46N5O3(M+1) requires 532.3499]. 
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NMR Assignments:  1H NMR (600 MHz, CD3OD) δ 7.11-7.09 (comp, 2 H, C4-
H), 6.79-6.76 (comp, 2H, C5-H), 4.67 (t, J = 6.6 Hz, 1.0 H, C1-H), 4.22 (d, J = 7.5 Hz, 1 
H, C13-H), 4.1 (m, 1 H, C8-H), 3.20-3.13 (comp, 3 H, C17-H and C2-H) 2.93-2.87 (m, 1 
H, C2-H) 2.73-2.64 (comp, 2 H, C14-H), 1.86-1.82 (m, 1 H, C9-H), 1.72-1.62 (comp, 5 
H, C18-H or C19-H or C20-H or C21-H or C22-H or C23-H), 1.58-1.55 (comp, 1H, C18 
or C19-H or C20-H or C21-H or C22-H or C23-H), 1.49 (p, J = 7.6 Hz, 2 H, C11-H), 
1.29-1.14 (comp, 7 H, C18 or C19 or C20 or C21 or C22 or C23-H), 0.94 (d, J = 7.5 Hz, 
3 H, C10-H), 0.91 (t, J = 7.5 Hz, 3 HC12-H), 0.92-0.84 (comp, 2 H, C18 or C19 or C20 
or C21 or C22 or C23-H);  13C NMR (125 MHz, CD3OD) δ 174.7 (C15), 172.6 (C16), 
172.5 (C1), 170.0 (C6), 158.3 (C6), 131.6 (C4), 125.9 (C3), 116.9 (C5), 116.3 (C5), 59.6 
(C1), 55.7 (C13), 51.7 (C8), 40.9 (C14), 38.7 (C2), 38.2 (C17), 37.9  (C19 or C21 or 
C21’), 37.8, (C19 or C21 or C21’) 35.7 (C19 or C21 or C21’), 34.5 (C18, C20 or C22), 
27.8 (C18, C20 or C22), 27.5 (C18, C20 or C22), 26.0 (C11), 15.9 (C10), 11.5 (C12).    
 
 
N-Acyl-Tyr-Ile-Asn-N-(propyl-CyHex) (3.73) Prepared from 3.72 and AcOH 
according to the general method B to yield 53 mg of the crude  product (63%) as a white 
solid: decomp at 252 °C. 1H NMR (600 MHz, CD3OD) δ 7.06-7.05 (comp, 2 H), 6.70-
6.68 (comp, 2 H), 4.63 (t, J = 6.7 Hz, 1 H), 4.58-4.57 (m, 1 H), 4.11 (d, J = 7.0 Hz, 1 H), 
3.19-3.10 (comp, 2 H) 3.06-3.02 (m, 1 H), 2.80-2.76 (m, 1H), 2.73-2.64 (comp, 2 H), 
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1.90 (s, 3 H), 1.86-1.82 (m, 1 H), 1.72-1.62 (comp, 6 H), 1.54-1.49 (comp, 4 H), 1.29-
1.14 (comp, 9 H), 0.93-0.85 (comp, 10 H);  13C NMR (150 MHz, CD3OD) δ 171.8, 
171.5, 170.4, 170.2, 169.2 155.6, 130.0, 128.1, 114.7, 57.1, 54.1, 49.7, 36.8, 36.7, 36.6, 
36.2, 33.9, 32.7, 26.3, 26.1, 25.8, 24.2, 22.4, 15.2, 11.1. mass spectrum (ESI) m/z 
573.3448 [C30H46N5O6 (M-1) requires 573.3454]. 
NMR assignment: 1H NMR (600 MHz, CD3OD) δ 7.06-7.05 (comp, 2 H, C4-H), 
6.70-6.68 (comp, 2H, C5-H), 4.63 (t, J = 6.7 Hz, 1.0 H, C1-H), 4.57 (comp, 1 H, C13-H), 
4.11 (d, J = 7.0 Hz, 1 H, C8-H), 3.19-3.10 (comp, 2H, C17-H) 3.06-3.02 (m, 1 H, C2-H), 
2.80-2.76 (comp, 1H, C2-H), 2.73-2.64 (comp, 2 H, C14-H), 1.90 (s, 3 H, C25-H), 1.86-
1.82 (comp, 1 H, C9-H), 1.72-1.62 (comp, 6 H, C18-H, C19-H or C20-H or C21-H or 
C22-H or C23-H), 1.54-1.49 (comp, 4 H), 1.29-1.14 (comp, 9 H, C11-H or C18-H or 
C19-H or C20-H or C21-H or C22-H or C23-H), 0.93-0.85 (comp, 10 H, C10-H or C12-
H or C18-H or C19-H or C20-H or C21-H or C22 -H or C23-H); 13C NMR (125 MHz, 
CD3OD) δ 171.8 (C15), 171.5 (C16), 170.4 (C6), 170.2 (C1), 169.2 (C24), 155.6 (C6), 
130.0 (C4), 128.1 (C3), 114.7 (C5), 57.1 (C1), 54.1 (C13), 49.7 (C13), 36.8 (C19 or C21 
or C21’), 36.7 (C19 or C21 or C21’), 36.6 (C19 or C21 or C21’), 36.2, 33.9 (C18, C20 or 
C22), 32.7 (C18, C20 or C22), 26.3 (C18, C20 or C22), 26.1, 25.8, 24.2 (C25), 22.4 




N-Acyl-pTyr-Ile-Asn-N-(propyl-Cy) (3.75). 1-H- Tetrazole (24 mg, 0.35 mmol) 
(785 mg, 11.2 mmol) and diisopropylphosphoramidite (94 µL, 0.28 mmol) were added to 
a solution of 3.77 (40 mg, 0.070 mmol)  in DMF (2 mL) at 0 °C, and the solution was 
stirred at 0 °C for 1 h and then at room temperature for 15 h. The solution was cooled to 0 
°C, and 6 M tert–butyl hydroperoxide in decane (34 mg, 0.17 mL) was added. The 
resulting solution was stirred at 0 °C for 30 min and then at room temperature for 5 h, 
whereupon it was cooled to 0 °C and 5% aqueous NaHSO3 (5 mL) was added. The 
solution was stirred at 0 °C for 30 min and then at room temperature for 2 h. The mixture 
was transferred to a separatory funnel containing H2O (20 mL), and the layers were 
separated. The aqueous layer was extracted with CH2Cl2  (3 x 15 mL) whereupon the 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. 
The residue was triturated with Et2O (4 x 5 mL) to yield 250 mg (20%) of the product as 
a white solid.  
The product was dissolved in MeOH (0.5 mL) containing 10% Pd/C (1 mg, 10 wt 
%). The resulting mixture was purged four times with H2, and the suspension stirred 
under H2 (1 atm) for 14 h. The mixture was filtered through a pad of celite and the pad 
was washed with MeOH. The combined filtrate and washings were concentrated to 
dryness under reduced pressure to yield 4 mg (99%) of the title compound as a clear 
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glass. 1H NMR (600 MHz, CD3OD) δ 7.22 (d, J = 8.5 Hz, 2 H), 7.13 (d, J = 8.5 Hz, 2H), 
4.65-4.60 (comp, 2 H), 4.13 (d, J = 7.0 Hz, 1 H), 3.17-3.10 (comp, 3 H), 2.87-2.83 (m, 1 
H) 2.70-2.68 (comp, 2 H), 1.86-1.82 (m, 1 H), 1.72-1.62 (comp, 5 H), 1.55-1.48 (comp, 3 
H), 1.29-1.14 (comp, 8 H), 0.93-0.85 (comp, 9 H). mass spectrum (ESI) m/z 652.3117 
[C30H47N5O9P (M-1) requires 652.3190]. 
NMR assignment: 1H NMR (600 MHz, CD3OD) δ 7.22 (d, J = 8.5 Hz, 2 H, C4-
H), 7.13 (d, J = 8.3 Hz, 2 H, C5-H), 4.65-4.60 (comp, 2 H, C1-H and C13-H), 4.13 (d, J 
= 7.0 Hz, 1 H, C-8-H), 3.17-3.10 (comp, 3 H, C2-H and C17-H), 2.87-2.83 (m, 1H, C2-
H) 2.70-2.68 (comp, 2 H, C14-H), 1.86-1.82 (comp, 1 H, C9-H), 1.72-1.62 (comp, 5 H, 
C18-H, C19-H, C20-H, C21-H, C22-H, C23-H), 1.55-1.48 (comp, 3 H, C11-H and C20-
H), 1.29-1.14 (comp, 8 H, C18-H, C19-H, C20-H, C21-H, C22-H, C23-H), 0.93-0.85 






General procedure for Sonogashira Cross Coupling. 
Triethylamine (2.9 g, 16.7 mmol) was added to a solution of the aryl iodide (3.3  
mmol), alkynol (4.00 mmol), PdCl2 (18 mg, 0.10 mmol), PPh3 (80 mg, 0.3 mmol), and 
CuI (37.9 mg, 0.2 mmol) in MeCN (5.0 mL), and the mixture was stirred at 0 ºC for 10 
min.  The ice bath was removed, and stirring was continued for 14 h at room temperature.  
The resulting mixture was diluted with Et2O (10 mL) then washed with brine (3 x 10 mL) 
and aqueous NH4Cl (2 x 10 mL).  The organic layer was dried (MgSO4) and concentrated 




4-(p-Tolyl)but-3-yn-1-ol (4.12). Prepared from 4.04 and 4.24 according to the 
general procedure for Sonogashira cross coupling.  The crude product was purified by 
silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 40 mg (74%) of the 
title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 8.1 Hz, 2 H), 
7.09 (d, J = 8.1 Hz, 2 H), 3.80 (t, J = 6.2 Hz, 2 H), 2.68 (t, J = 6.2 Hz, 2 H), 2.34 (s, 3 H); 
13C (150 MHz, CDCl3) δ 138.2, 131.8, 129.5, 120.4, 85.7, 82.8, 61.4, 24.1, 21.7. IR (neat) 
3349, 2919, 2236, 1509 cm-1. mass spectrum (ESI) m/z 160.0888 [C11H12O requires 
160.0888]. 
NMR Assignment: 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 7.9 Hz, 2 H, C6-









H, C2-H), 2.34 (s, 3 H, C9-H). 13C (150 MHz, CDCl3) δ 138.2 (C8), 131.8 (C7), 129.5 
(C6), 120.4 (C5), 85.7 (C3), 82.8 (C4), 61.4 (C1), 24.1 (C2), 21.7 (C9).  
 
 
4-(4-(Trifluoromethyl)phenyl)but-3-yn-1-ol (4.11). Prepared from 4.03 and 4.24 
according to the general procedure for Sonogashira cross coupling.  The crude product 
was purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 87 
mg (99%) of the title compound as a clear oil.1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 
8.9 Hz, 2 H), 7.49 (d, J = 8.9 Hz, 2 H), 3.84-3.80 (comp, 2 H), 2.71 (t, J = 6.5 Hz, 2 H); 
13C (150 MHz, CDCl3) δ 132.1, 129.9 (q, J = 32.3 Hz), 127.5, 125.4, 124.5 (q, J = , 89.5, 
81.4, 61.2, 24.0. IR (neat) 3349, 2890, 2237, 1615, 1406 cm-1. mass spectrum (CI) m/z 
214.0604 [C11H9OF3 requires 214.0605]. 
NMR Assignment: 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.9 Hz, 2 H, C7-
H), 7.49 (d, J = 8.9 Hz, 2 H, C6-H), 3.84-3.80 (comp, 2 H, C1-H), 2.71 (t, J = 6.5 Hz, 2 
H, C2-H). 13C (150 MHz, CDCl3) δ 132.1 (C9), 129.9 (q, J = 32.3 Hz, C8), 127.5 (C6), 




4-(3,4-Dichlorophenyl)but-3-yn-1-ol (4.10). Prepared from 4.03 and 4.24 

















was purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 56 
mg (41%) of the title compound as a clear oil.1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 
1.7 Hz, 1 H), 7.31 (d, J = 8.2 Hz, 1 H), 7.18 (dd, J = 8.2, 1.7 Hz, 1 H), 3.79 (t, J = 6.2 Hz, 
2 H), 2.65 (t, J = 6.2 Hz, 2 H). 13C (150 MHz, CDCl3) δ 133.5, 132.6, 132.4, 131.0, 
130.5, 123.6, 89.1, 80.3, 61.1, 23.9. IR (Neat) 3349, 2890, 2237, 1406, 1131 cm-1. mass 
spectrum (CI) m/z 213.9949 [C10H8OCl2 requires 213.9952]. 
NMR Assignment: 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 1.7 Hz, 1 H, C10-
H), 7.31 (d, J = 8.2 Hz, 1 H, C7-H), 7.18 (dd, J = 8.2, 1.7 Hz, 1 H, C6-H), 3.79 (t, J = 6.2 
Hz, 2 H, C1-H), 2.65 (t, J = 6.2 Hz, 2 H, C2-H). 13C (150 MHz, CDCl3) δ 133.5 (C9), 
132.6 (C6), 132.4 (C8), 131.0 (C7), 130.5 (C10), 123.6 (C5), 89.1 (C3), 80.3 (C4), 61.1 
(C2), 23.9 (C1). 
 
 
4-(4-Chlorophenyl)but-3-yn-1-ol (4.09). Prepared from 4.01 and 4.24 according 
to the general procedure for Sonogashira cross coupling. The crude product was purified 
by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 87 mg (78%) of 
the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.2 Hz, 2 H), 
7.27 (d, J = 8.2 Hz, 2 H), 3.81 (t, J = 6.5 Hz, 2 H), 2.65 (t, J = 6.5 Hz, 2 H). The title 

















3-(4-(Trifluoromethyl)phenyl)prop-2-yn-1-ol. (4.14) Prepared from 4.06 and 
4.23 according to the general procedure for Sonogashira cross coupling.  The crude 
product was purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to 
yield 87 mg (92%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 
7.37 (d, J = 8.2 Hz, 2 H), 7.27 (d, J = 8.2 Hz, 2 H), 4.52 (s, 2 H); 13C (150 MHz, CDCl3) 
δ 132.1, 130.6 (q, J = 32.1 Hz), 126.6, 125.5, 122.7, 89.9, 84.5, 51.5. IR (Neat) 3349, 
2927, 2236, 1615, 1407 cm-1. mass spectrum (CI) m/z 200.0445 [C10H7OF3 requires 
200.0449]. 
NMR Assignment: 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.2 Hz, 2 H, C5-
H), 7.27 (d, J = 8.2 Hz, 2 H, C6-H), 4.52 (s, 2 H, C1-H).13C (150 MHz, CDCl3) δ 132.1 
(C5), 130.6 (q, J = 32.1 Hz, C7), 126.6 (C6), 125.5 (C8), 122.7 (C4), 89.1 (C2), 84.3 
(C3), 51.7 (C1). 
 
General procedure for the hydrogenation of the alkynols. 
A solution of the alkynol (0.344 mmol) in MeOH (3.4 mL) containing 10% Pd/C 
(9.0 mg) or 5% PtO2 (5.0 mg) was stirred under H2 (1 atm) for 1 h.  The catalyst was 
removed by filtration through a pad of celite, and the filtrate was concentrated under 





4-(4-(Trifluoromethyl)phenyl)butan-1-ol (4.18). Prepared from 4.11 according 
to the general procedure for the hydrogenation of alkynols using Pd/C.  The crude 
product was purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to 
yield 120 mg (59%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 
7.52 (d, J = 8.2 Hz, 2 H), 7.27 (d, J = 8.2 Hz, 2 H), 3.67 (t, J = 6.2 Hz, 2 H), 2.71 (t, J = 
7.5 Hz, 2 H), 1.76-1.69 (comp, 2 H), 1.64-1.57 (comp, 2 H). 13C (150 MHz, CDCl3) δ 
146.7, 128.9, 128.3 (q, J = 32.3 Hz), 125.4, 124.6, 62.8, 35.7, 32.4, 27.5. IR (Neat) 3339, 
2940, 2866, 1327, 1122 cm-1. mass spectrum (ESI) m/z 218.0915 [C11H13OF3 requires 
218.0918]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.2 Hz, 2 H, C7-
H), 7.27 (d, J = 8.2 Hz, 2 H, C6-H), 3.67 (t, J = 6.2 Hz, 2 H, C1-H), 2.71 (t, J = 7.5 Hz, 2 
H, C4-H), 1.76-1.69 (comp, 2 H, C2-H or C3-H), 1.64-1.57 (comp, 2 H, C2-H or C3-H). 
13C (150 MHz, CDCl3) δ 146.7 (C6), 128.3 (q, J = 32.3 Hz, C8), 128.3 (C9), 125.4  (C7), 




4-(4-Chlorophenyl)butan-1-ol (4.16). Prepared from 4.09 according to the 
general procedure for the hydrogenation of alkynols using PtO2.  The crude product was 
purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 70 mg 
(86%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.2 
Hz, 2 H), 7.10 (d, J = 8.2 Hz, 2 H), 3.66 (t, J = 6.5 Hz, 2 H), 2.60 (t, J = 7.2 H, 2 H), 
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1.70-1.56 (comp, 4 H); 13C (150 MHz, CDCl3) δ 140.9, 131.7, 130.0, 128.6, 63.0, 35.2, 
32.4, 27.7. IR (Neat) 3343, 2940, 2862, 2360, 1492 cm-1. mass spectrum (CI) m/z 
184.0654 [C10H13OCl requires 184.0655]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.2 Hz, 2 H, C6-
H), 7.10 (d, J = 8.2 Hz, 2 H, C7-H), 3.66 (t, J = 6.5 Hz, 2 H, C1-H), 2.60 (t, J = 7.2 H, 2 
H, C4-H), 1.70–1.56 (comp, 4 H, C2-H and C3-H). 13C (150 MHz, CDCl3) δ 140.9 (C8), 




4-(p-Tolyl)butan-1-ol (4.19). Prepared from 4.12 according to the general 
procedure for the hydrogenation of the alkynols using Pd/C.  The crude product was 
purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 134 mg 
(99%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.12-7.08 
(comp, 4 H), 3.66 (t, J = 6.5 Hz, 2 H), 2.61 (t, J = 7.2 Hz, 2 H), 2.32 (s, 3 H), 1.72-1.56 
(comp, 4 H); 13C (150 MHz, CDCl3) δ 139.6, 135.4, 129.3, 128.6, 62.9, 35.5, 32.5, 28.0, 
21.3. IR (Neat) 3336, 2935, 2860, 1515 cm-1. mass spectrum (CI) m/z 164.1201 [C11H16O 
requires 164.1201]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.12-7.08 (comp, 4 H, C6-H 
and C7-H), 3.66 (t, J = 6.5 Hz, 2 H, C1-H), 2.61 (t, J =  7.2 Hz, 2 H, C4-H), 2.32 (s, 3 H, 
C9-H), 1.72-1.56 (comp, 4 H, C2-H and C3-H). 13C (150 MHz, CDCl3) δ 139.6, (C8) 
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135.4 (C5), 129.3 (C6), 128.6 (C7), 62.9 (C1), 35.5 (C4), 32.5 (C2 or C3), 28.0 (C2 or 




4-(4-Methoxyphenyl)butan-1-ol (4.20). Prepared from 4.13 according to the 
general procedure for the hydrogenation of alkynols using Pd/C.  The crude product was 
purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 122 mg 
(84%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 8.5 
Hz, 2 H), 6.82 (d, J = 8.5 Hz, 2 H), 3.79  (s, 3 H), 3.66 (t, J = 6.5 Hz, 2 H), 2.59 (t, J = 
7.5 H, 2 H), 1.72–1.57 (comp, 4 H); 13C (150 MHz, CDCl3) δ 157.9, 134.7, 129.5, 113.9, 
63.0, 55.5, 34.9, 32.5, 28.0. IR (Neat) 3340, 2935, 2860, 1512, 1244 cm-1. mass spectrum 
(CI) m/z 180.1151 [C11H16O2 requires 180.1150]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 8.5 Hz, 2 H, C7-
H), 6.82 (d, J = 8.5 Hz, 2 H, C6-H), 3.79  (s, 3 H, C9-H), 3.66 (t, J = 6.5 Hz, 2 H, C1-H), 
2.59 (t, J = 7.5 H, 2 H, C4-H), 1.72–1.57 (comp, 4 H, C2-H and C3-H). 13C (150 MHz, 
CDCl3) δ 157.9 (C8), 134.7 (C5), 129.5 (C6), 113.9 (C7), 63.0 (C1), 55.5 (C9), 34.9 (C4) 





4-(3,4-Dichlorophenyl)butan-1-ol (4.17). Prepared from 4.10 according to the 
general procedure for the hydrogenation of alkynols using PtO2.  The crude product was 
purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 65 mg 
(62%) of the title compound as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.2 
Hz, 1 H), 7.27 (d, J = 2.1 Hz, 1 H), 7.01 (dd, J = 8.2, 2.1 Hz, 1 H), 3.66 (t, J = 6.2 Hz, 2 
H), 2.60 (t, J = 7.2 Hz, 2 H), 1.72–1.56 (comp, 4 H); 13C (150 MHz, CDCl3) δ 142.8, 
132.4, 130.6, 130.4, 129.9, 128.1, 62.8, 35.0, 32.3, 27.5. IR (Neat) 3342, 2937, 2862, 
1473, 1132 cm-1. mass spectrum (CI) m/z 218.0267 [C10H12OCl2 requires 218.0265]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.2 Hz, 1 H, C7-
H), 7.27 (d, J = 2.1 Hz, 1 H, C10-H), 7.01 (dd, J = 8.2, 2.1 Hz, 1 H, C6-H), 3.66 (t, J = 
6.2 Hz, 2 H, C1-H), 2.60 (t, J = 7.2 Hz, 2 H, C4-H), 1.72–1.56 (comp, 4 H, C2-H and C3-
H).  13C (150 MHz, CDCl3) δ 142.8 (C5), 132.4 (C9), 130.6 (C8), 129.9 (C10), 128.1 
(C7), 62.8 (C1), 35.0 (C4), 32.3 (C2 or C3), 27.5 (C2 or C3). 
 
 
3-(p-Tolyl)propan-1-ol (4.22). Prepared from 4.15 according to the general 
procedure for the hydrogenation of alkynols using Pd/C.  The crude product was purified 
by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to yield 70 mg (99%) of 
the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.18-7.16 (comp, 4 H), 
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3.63 (t, J = 6.5 Hz, 2 H), 2.62 (t, J = 7.2 Hz, 2 H), 2.35 (s, 3 H), 1.72-1.56 (comp, 2 H). 
13C (150 MHz, CDCl3) δ 139.0, 135.6, 129.3, 128.6, 62.5, 34.6, 31.9, 21.3. IR (Neat) 
3336, 2935, 2860, 1515 cm-1.  
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.18-7.16 (comp, 4 H, C5-H 
and C6-H), 3.63 (t, J = 6.5 Hz, 2 H, C1-H), 2.62 (t, J = 7.2 Hz, 2 H, C3-H), 2.35 (s, 3 H, 
C8-H), 1.72–1.56 (comp, 2 H, C2-H). 13C (150 MHz, CDCl3) δ 139.0 (C4), 135.6 (C7), 
129.3 (C5), 128.6 (C6), 62.5 (C1), 34.6 (C3), 31.9 (C2), 21.3 (C8). 
 
 
3-(4-(Trifluoromethyl)phenyl)propan-1-ol (4.21). Prepared from 4.14 according 
to the general procedure for the hydrogenation of alkynols using Pd/C.  The crude 
product was purified by silica gel chromatography eluting with CH2Cl2/MeOH (99:1) to 
yield 126 mg (57%) of the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 
7.52 (d, J = 7.8 Hz, 2 H), 7.27 (d, J = 7.8 Hz, 2 H), 3.69 (t, J = 6.2 Hz, 2 H), 2.76 (t, J = 
7.9 Hz, 2 H), 1.93 (comp, 2 H). 13C (150 MHz, CDCl3) δ 146.2, 129.0, 128.3 (q, J = 32.3 
Hz), 125.6, 123.2 62.2, 34.1, 32.1. IR (Neat) 3344, 2942, 2870, 1327, 1120 cm-1. mass 
spectrum (ESI) m/z 218.0915 [C10H11OF3 requires 218.0918]. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 7.8 Hz, 2 H, C5-
H), 7.27 (d, J = 7.8 Hz, 2 H, C6-H), 3.69 (t, J = 6.2 Hz, 2 H, C1-H), 2.76 (t, J = 7.9 Hz, 2 
H, C4-H), 1.93 (comp, 2 H, C2-H). 13C (150 MHz, CDCl3) δ 146.2 (C6), 129.0 (C5), 
128.3 (q, J = 32.3 Hz, C7), 125.6 (C8), 123.2 (C4), 62.2 (C1), 34.1 (C3), 32.1 (C2).
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5.3   General Procedure for Performing ITC 
Isothermal titration calorimetry (ITC) experiments were performed on a VP-ITC 
(GE Healthcare) at 298.15 K in the appropriate buffer at the given pH 7.4. A minimum of 
two experiments with each ligand were performed. Protein and ligand solutions were 
filtered using sterile 0.2 µM EO minisart filters (Sartorius Stedim Biotech). Protein 
concentration was determined by UV spectroscopy (for MUP-I: ε280 = 12,630 M-1cm-1, 
for Grb2 SH2: ε280 = 15,000 M-1cm-1). Solutions were stored at 4 °C until needed and 
degassed for 15 m. at 23 ºC using a ThermoVac vacuum chamber (GE Healthcare) 
immediately prior to ITC experiments. 
The dialysate was re-filtered using a 0.2 µM cellulose membrane filter (Whatman) 
and thoroughly degassed before being used to make ligand solutions.  Ligand solutions 
were prepared from degassed PBS dialysate that was re-filtered using a 0.2 µM cellulose 
membrane filter (Whatman).  
Titration experiments consisted of an initial 2 µL injection followed by 24 x 10 
µL injections spaced 240 s. apart using a stirring speed of 300 rpm.  The cell was cleaned 
prior to each run with 1 M NaOH followed by extensive rinsing with both water and the 
dialysate.  Between runs of different ligands the syringe was flushed extensively with the 
latter two solutions, but only PBS dialysate was used between titrations with the same 
ligand. 
Analysis of ITC Data 
ITC data were analyzed in Origin 5.0 (MicroCal). Blank experiments (ligand into 
buffer) yielded consistent heats of dilution and were fit to a line with zero slope to obtain 
the average or blank value.  Following subtraction of the blank values and removal of 
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data corresponding to the initial 2 µL injection, the adjusted data were fit to a one-site 
model of the Wiseman isotherm. 
Treatment of Experimental Error 
Error in the observed free-energies and enthalpies of binding was defined as the 
standard error in the mean of replicate experiments. These errors were propagated 
through the Gibbs equation to give errors in the observed entropies.  
 
Determination of Ligand Molecular Surface Area 
The ligands in the X-ray crystal structures were removed from the complexes and 
their Connolly or molecular surface areas were calculated based upon their bound 
conformations using Macromodel v9.1. 
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T =298 K 
Ka = 2.8 x 105 
∆G° = –7.7 kcal•mol-1 
∆H° =–11.3 kcal•mol-1 






T = 298 K 
Ka = 2.4 x 105  M-1 
∆G° = –7.2 kcal•mol-1 
∆H° =–12.4 kcal•mol-1 






T = 298 K 
Ka < 1 x 103 M-1 
∆G° = na 
∆H° =na 








T = 298 K 
Ka = 1 x 103 M-1 
∆G° = -6.9 kcal•mol-1 
∆H° =-12.2 kcal•mol-1 








T = 298 K 
Ka < 1 x 103 M-1 
∆G° = –6.9 kcal•mol-1 
∆H° =-11.4 kcal•mol-1  








T = 298 K 
Ka = 8.2 x 104 M-1 
∆G° = -6.7 kcal•mol-1 
∆H° =-8.4 kcal•mol-1 










T = 298 K 
Ka = 3.0 x 105 M-1 
∆G° = -7.5 kcal•mol-1 
∆H° =-13.8 kcal•mol-1 






T = 298 K 
Ka = 3.0 x 105 M-1 
∆G° = -7.3 kcal•mol-1 
∆H° =-11.0 kcal•mol-1 







T = 298 K 
Ka = 1.1 x 106 M-1 
∆G° = -8.3 kcal•mol-1 
∆H° =-16.5 kcal•mol-1 









T = 298 K 
Ka < 9.9 x 105 M-1 
∆G° = -7.2 kcal•mol-1 
∆H° =-12.7 kcal•mol-1 








T = 298 K 
Ka =4.3 x 105 M-1 
∆G° = -7.7 kcal•mol-1 
∆H° =-13.4 kcal•mol-1 








T = 298 K 
Ka =1.5 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-7.7 kcal•mol-1 







T = 298 K 
Ka =2.6 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-7.7 kcal•mol-1 





T = 288 K 
Ka =2.6 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-6.4 kcal•mol-1 
–T∆S° = –3.4 kcal•mol-1 
 
T = 298 K 
Ka =2.6 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-8.8 kcal•mol-1 
–T∆S° = –1.4 kcal•mol-
1 
 
T = 308 K 
Ka =2.6 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-10.5 kcal•mol-1 








T = 298 K 
Ka =4.2 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-7.7 kcal•mol-1 






T = 298 K 
Ka =2.8 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-7.9 kcal•mol-1 





T = 298 K 
Ka =9.6 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-6.7 kcal•mol-1 





 T = 298 K 
Ka =2.4 x 107 M-1 
∆G° = -10.1 kcal•mol-1 
∆H° =-8.1 kcal•mol-1 






T = 298 K 
Ka =4.9 x 107 M-1 
∆G° = -10.4 kcal•mol-1 
∆H° =-19.2 kcal•mol-1 






T = 298 K 
Ka =2.8 x 107 M-1 
∆G° = -10.3 kcal•mol-1 
∆H° =-9.1 kcal•mol-1 






T = 298 K 
Ka =2.8 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-9.1 kcal•mol-1 







T = 288 K 
Ka =5.1 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-6.8 kcal•mol-1 
–T∆S° = –3.4 kcal•mol-1 
 
T = 298 K 
Ka =6.0 x 107 M-1 
∆G° = -10.6 kcal•mol-1 
∆H° =-9.6 kcal•mol-1 
–T∆S° = –1.2 kcal•mol-
1 
 
T = 308 K 
Ka =2.6 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-11.2 kcal•mol-1 






T = 298 K 
Ka =1.7 x 107 M-1 
∆G° = –9.8 kcal•mol-1 
∆H° =-7.8 kcal•mol-1 







T = 298 K 
Ka =1.7 x 107 M-1 
∆G° = –9.8 kcal•mol-1 
∆H° =-7.8 kcal•mol-1 




T = 298 K 
Ka =4.1 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-5.5 kcal•mol-1 
–T∆S° = –4.7 kcal•mol-1 
 
T = 298 K 
Ka =2.8 x 107 M-1 
∆G° = -9.8 kcal•mol-1 
∆H° =-8.0 kcal•mol-1 
–T∆S° = –1.9 kcal•mol-1 
 
 
T = 208 K 
Ka =2.8 x 107 M-1 
∆G° = -10.2 kcal•mol-1 
∆H° =-8.7 kcal•mol-1 





T = 298 K 
Ka =4.7 x 107 M-1 
∆G° = –10.3 kcal•mol-1 
∆H° =-9.2 kcal•mol-1 






T = 298 K 
Ka =3.0 x 107 M-1 
∆G° = –10.1 kcal•mol-1 
∆H° =-8.4 kcal•mol-1 






T = 298 K 
Ka =4.7 x 107 M-1 
∆G° = –10.3 kcal•mol-1 
∆H° = –8.4 kcal•mol-1 






T = 298 K 
Ka =5.1 x 107 M-1 
∆G° = –10.5 kcal•mol-1 
∆H° =-9.5 kcal•mol-1 






T = 298 K 
Ka =2.8 x 106 M-1 
∆G° = –8.8 kcal•mol-1 
∆H° =-14.0 kcal•mol-1 









T = 298 K 
Ka =1.6 x 106 M-1 
∆G° = –8.4 kcal•mol-1 
∆H° =-12.2 kcal•mol-1 







T = 298 K 
Ka < 1 x 103 M-1 
∆G° = na 
∆H° =na 











T = 298 K 
Ka =3.4 x 106 M-1 
∆G° = –8.9 kcal•mol-1 
∆H° =-15.3 kcal•mol-1 









T = 298 K 
Ka =8.8 x 105 M-1 
∆G° = –8.2 kcal•mol-1 
∆H° =-13.7 kcal•mol-1 








T = 298 K 
Ka =1.6 x 106 M-1 
∆G° = –8.2 kcal•mol-1 
∆H° = –11.4 kcal•mol-1 










T = 298 K 
Ka < 1 x 103 M-1 
∆G° = na 
∆H° =na 
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